Copy of ISGR Case Study
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

View only
 
 
ABCDEFGJLMNQRSTUVWXYZAAABACADAEAFAGAHAIAJAKALAM
1
ISRG
2
1/20/2020
Review this page to learn the history of key announcements by the company and see how the price and multiples responded after the announcement.
Note: stock price data per Google Finance; announcement data and financial statements per Capital IQ. Market cap data is estimated using most recent quarterly shares reported; any holes in the data are related to Google Finance price availability. www.huntervalue.com
3
(date of report)
4
Market Multiples as of date:TEV/LTM Total RevenueTEV/LTM EBITDATEV/LTM EBITP/LTM Normalized EPSTEV/LTM Unlevered FCFMarket Cap $MM30 day price change after announcementPrice as of Announce DateReturn from Announce Date to todayDateTypeHeadlineOther PartiesSituation
6
1/17/202015.67x44.92x50.86x79.90x73.77x$69,671$602.69-0.73%Jan-14-2020Company Conference PresentationIntuitive Surgical, Inc. Presents at 38th Annual J.P Morgan Healthcare Conference, Jan-14-2020 10:30 AM-Intuitive Surgical, Inc. Presents at 38th Annual J.P Morgan Healthcare Conference, Jan-14-2020 10:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Gary S. Guthart, CEO & Director.
7
1/17/202015.67x44.92x50.86x79.90x73.77x$69,721$603.12Jan-13-2020ConferenceJPMorgan Chase & Co., 38th Annual J.P Morgan Healthcare Conference, Jan 13, 2020 through Jan 16, 2020Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Repligen Corporation (NasdaqGS:RGEN), Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL), Seattle Genetics, Inc. (NasdaqGS:SGEN), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), United Therapeutics Corporation (NasdaqGS:UTHR), Walgreens Boots Alliance, Inc. (NasdaqGS:WBA), Biogen Inc. (NasdaqGS:BIIB), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Nektar Therapeutics (NasdaqGS:NKTR), Insmed Incorporated (NasdaqGS:INSM), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Natus Medical Incorporated (NasdaqGS:NTUS), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), NVIDIA Corporation (NasdaqGS:NVDA), Omnicell, Inc. (NasdaqGS:OMCL), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), ICON Public Limited Company (NasdaqGS:ICLR), Amedisys, Inc. (NasdaqGS:AMED), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Enanta Pharmaceuticals, Inc. (NasdaqGS:ENTA), Endologix, Inc. (NasdaqGS:ELGX), Novavax, Inc. (NasdaqGS:NVAX), ICU Medical, Inc. (NasdaqGS:ICUI), Patterson Companies, Inc. (NasdaqGS:PDCO), Incyte Corporation (NasdaqGS:INCY), Henry Schein, Inc. (NasdaqGS:HSIC), Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Mylan N.V. (NasdaqGS:MYL), Quidel Corporation (NasdaqGS:QDEL), Mirati Therapeutics, Inc. (NasdaqGS:MRTX), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Cerner Corporation (NasdaqGS:CERN), CONMED Corporation (NasdaqGS:CNMD), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Bio-Techne Corporation (NasdaqGS:TECH), Accuray Incorporated (NasdaqGS:ARAY), Premier, Inc. (NasdaqGS:PINC), OraSure Technologies, Inc. (NasdaqGS:OSUR), Bruker Corporation (NasdaqGS:BRKR), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), ChemoCentryx, Inc. (NasdaqGS:CCXI), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Mersana Therapeutics, Inc. (NasdaqGS:MRSN), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), HealthEquity, Inc. (NasdaqGS:HQY), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), Conformis, Inc. (NasdaqGS:CFMS), Intrexon Corporation (NasdaqGS:XON), Athenex, Inc. (NasdaqGS:ATNX), R1 RCM Inc. (NasdaqGS:RCM), Natera, Inc. (NasdaqGS:NTRA), Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Inogen, Inc. (NasdaqGS:INGN), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), AngioDynamics, Inc. (NasdaqGS:ANGO), LHC Group, Inc. (NasdaqGS:LHCG), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), Alphabet Inc. (NasdaqGS:GOOG.L), HMS Holdings Corp. (NasdaqGS:HMSY), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Endo International plc (NasdaqGS:ENDP), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Amgen Inc. (NasdaqGS:AMGN), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Alkermes plc (NasdaqGS:ALKS), Tivity Health, Inc. (NasdaqGS:TVTY), Almirall, S.A. (BME:ALM), Pharma Mar, S.A. (BME:PHM), DLA Piper LLP (US), Clayton, Dubilier & Rice, LLC, Domain Associates, L.L.C., Ancestry.com LLC, NxStage Medical, Inc., Sirona Dental Systems Inc., Intas Pharmaceuticals Limited, CommonSpirit Health, Kaiser Permanente Inc., University of California, Netsmart Technologies, Inc., ClearDATA Networks, Inc., Baylor Scott & White Health LLC, NorthShore University HealthSystem, Bon Secours Mercy Health, ProMedica Health System, Inc., National Institutes of Health, Silicon Valley Bank, Inc., The California Endowment, SEQENS SAS, Partners HealthCare System, Inc., Henry Ford Health System, Intermountain Healthcare, Inc., SSM Health Care Corporation, Mayo Clinic, City Of Hope, The Children's Hospital of Philadelphia, Pharmaceutical Research and Manufacturers of America, UC Health, LLC, Enterprise Community Partners, Cotiviti, Inc., Deerfield Management Company, L.P., Providence St. Joseph Health, Oregon Health & Science University, Northwestern Memorial Healthcare Corporation, Cottage Health System, Inc., Seattle Cancer Care Alliance, Duke University Medical Center, Hospital for Special Surgery, NYU Langone Hospitals, Jefferson Healthcare, U.S. Food and Drug Administration, Waystar, Inc, Centers for Medicare & Medicaid Services, OSF Healthcare System, Availity, LLC, GenScript Corporation, Christiana Care Health System, Inc., Pfizer Venture Investments, Cardiva Medical, Inc., Asklepios BioPharmaceutical, Inc., EUSA Pharma, Inc., Rafael Pharmaceuticals, Inc., Siemens Healthineers, Inc., Biomarck Pharmaceuticals, Ltd., SYNLAB International GmbH, Blau Farmacêutica S.A., Seattle Children's Home Inc., Broad Institute, TraceLink, Inc., RxSight, Inc., Welltok, Inc., Health Carousel, LLC, Sera Prognostics, Inc., Privia Health, LLC, SHINE Medical Technologies, Inc., Ginkgo Bioworks, Inc., Geisinger Health System, Social Finance, Inc., Foghorn Capital, LLC, Proaxis Therapy, LLC, Ascension Health Alliance, Adagene (Suzhou) Limited, Bioventus LLC, Grand Rounds, Inc., Oak Street Health, LLC, GE Healthcare Inc., GenapSys, Inc., Vohra Wound Physicians Mgnt Llc, Evidation Health, Inc., Oscar Insurance Corporation, ArcherDx, Inc., American Gene Technologies International Inc., Genomics England Limited, MedAvail Technologies Inc., Avidity Biosciences LLC, Maravai Life Sciences Inc., Benchling, Inc., LINK Document Services Group LLC, Recursion Pharmaceuticals, Inc., Compass Therapeutics LLC, ZyVersa Therapeutics, Inc., Wellington Management Company LLP, Rakuten Medical, Inc., Eargo, Inc., Outset Medical, Inc., Caris Life Sciences, Inc., China Pharmaceutical Innovation and Research Development Association, Ark Biosciences Inc., Checkmate Pharmaceuticals, Inc., Color Genomics, Inc., VillageMD, Berkeley Lights, Inc., Companion Medical, Inc., Evolve Biosystems, Inc., Butterfly Network, Inc., NantCell, Inc., PHC Holdings Corporation, ORIC Pharmaceuticals, Inc., QuVa Pharma, Inc., Immatics US Inc., Adicet Bio, Inc., E-Scape Bio, Inc., Ping An Health Cloud Company Limited, Akeso Biopharma, Inc., Savonix, Inc., Verily Life Sciences LLC, Tmunity Therapeutics, Inc., Freeline Therapeutics Limited, WuXi Nextcode Genomics, Inc., Roivant Sciences, Inc., 91streets Media Technologies Private Limited, Corvidia Therapeutics, Inc., Fox Business Network, CardioNXT, Inc., Relay Therapeutics, Inc., Insightec, Inc, Goldfinch Bio, Inc., Macrophage Pharma Limited, Landos Biopharma, Inc., Sigilon Therapeutics, Inc., Repare Therapeutics Inc., Medically Home Group, Inc., Antengene Corporation, Senti Biosciences, Inc., Nkarta, Inc., Precigen, Inc., Dizal Pharmaceutical, RemeGen LTD, Ada Digital Health Ltd, Fusion Pharmaceuticals Inc., Generation Bio Co., Legend Biotech Corporation, Spring Discovery, Inc, Seqster, Theragnostics Inc., Tempus, Kronos Bio, Inc., Advocate Aurora Health, Ocumension Therapeutics, Hypera Pharma, AllerGenis, Inc, Sana Biotechnology, Inc., WeDoctor Group (Zhejiang) Co., Ltd., BioAge Group, LLC, Trialspark, Inc., Lg Chem Life Sciences India Private Limited, Gracell Biotechnologies Co., Ltd., Aligos Therapeutics, IONTAS Limited, Medlife International Private Limited, Transcenta Holding Ltd., Nurix Therapeutics, Inc, Concerto HealthAI Solutions LLC, Carbon, Inc., Immutep Limited (ASX:IMM), CSL Limited (ASX:CSL), Immunicum AB (publ) (OM:IMMU), Immunovia AB (publ) (OM:IMMNOV), Diamyd Medical AB (publ) (OM:DMYD B), PledPharma AB (OM:PLED), Moberg Pharma AB (publ) (OM:MOB), Orexo AB (publ) (OM:ORX), Hansa Biopharma AB (publ) (OM:HNSA), Oncopeptides AB (publ) (OM:ONCO), Elekta AB (publ) (OM:EKTA B), BioInvent International AB (publ) (OM:BINV), Novartis AG (SWX:NOVN), Vifor Pharma AG (SWX:VIFN), Roche Holding AG (SWX:ROG), Alcon, Inc. (SWX:ALC), Lonza Group Ltd (SWX:LONN), Basilea Pharmaceutica AG (SWX:BSLN), Santhera Pharmaceuticals Holding AG (SWX:SANN), Molecular Partners AG (SWX:MOLN), Medacta Group SA (SWX:MOVE), Galapagos NV (ENXTAM:GLPG), Pharming Group N.V. (ENXTAM:PHARM), Koninklijke Philips N.V. (ENXTAM:PHIA), Signify N.V. (ENXTAM:LIGHT), IHH Healthcare Berhad (KLSE:IHH), Hanmi Pharm. Co., Ltd. (KOSE:A128940), Samsung Biologics Co.,Ltd. (KOSE:A207940), Celltrion, Inc. (KOSE:A068270), Daewoong Pharmaceutical Co., Ltd. (KOSE:A069620), Hikma Pharmaceuticals PLC (LSE:HIK), GlaxoSmithKline plc (LSE:GSK), Vectura Group plc (LSE:VEC), ScinoPharm Taiwan, Ltd. (TSEC:1789), Hutchison China MediTech Limited (AIM:HCM), Abcam plc (AIM:ABC), Mereo BioPharma Group plc (AIM:MPH), Horizon Discovery Group plc (AIM:HZD), Tiziana Life Sciences PLC (AIM:TILS), Intersect ENT, Inc. (NasdaqGM:XENT), Akebia Therapeutics, Inc. (NasdaqGM:AKBA), Sutro Biopharma, Inc. (NasdaqGM:STRO), Quanterix Corporation (NasdaqGM:QTRX), Silk Road Medical, Inc (NasdaqGM:SILK), Axcella Health Inc. (NasdaqGM:AXLA), Sesen Bio, Inc. (NasdaqGM:SESN), Zai Lab Limited (NasdaqGM:ZLAB), Aeglea BioTherapeutics, Inc. (NasdaqGM:AGLE), UroGen Pharma Ltd. (NasdaqGM:URGN), Theravance Biopharma, Inc. (NasdaqGM:TBPH), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Adverum Biotechnologies, Inc. (NasdaqGM:ADVM), Clearside Biomedical, Inc. (NasdaqGM:CLSD), Karuna Therapeutics, Inc. (NasdaqGM:KRTX), Sage Therapeutics, Inc. (NasdaqGM:SAGE), RAPT Therapeutics, Inc. (NasdaqGM:RAPT), Magenta Therapeutics, Inc. (NasdaqGM:MGTA), Morphic Holding, Inc. (NasdaqGM:MORF), Kodiak Sciences Inc. (NasdaqGM:KOD), Valneva SE (ENXTPA:VLA), Innate Pharma S.A. (ENXTPA:IPH), Sanofi (ENXTPA:SAN), Quantum Genomics Société Anonyme (ENXTPA:ALQGC), Sensorion SA (ENXTPA:ALSEN), Inventiva S.A. (ENXTPA:IVA), Transgene SA (ENXTPA:TNG), Ipsen S.A. (ENXTPA:IPN), Novo Nordisk A/S (CPSE:NOVO B), WuXi AppTec Co., Ltd. (SHSE:603259), GN Store Nord A/S (CPSE:GN), Genmab A/S (CPSE:GMAB), H. Lundbeck A/S (CPSE:LUN), Bavarian Nordic A/S (CPSE:BAVA), HealthCare Global Enterprises Limited (BSE:539787), Kamada Ltd. (TASE:KMDA), Ribomic Inc. (TSE:4591), Otsuka Holdings Co., Ltd. (TSE:4578), Healios K.K. (TSE:4593), SanBio Company Limited (TSE:4592), Daiichi Sankyo Company, Limited (TSE:4568), Sosei Group Corporation (TSE:4565), Santen Pharmaceutical Co., Ltd. (TSE:4536), Takeda Pharmaceutical Company Limited (TSE:4502), Achilles Corporation (TSE:5142), Olympus Corporation (TSE:7733), Innovent Biologics, Inc. (SEHK:1801), Viva Biotech Holdings (SEHK:1873), Hong Kong Exchanges and Clearing Limited (SEHK:388), 3SBio Inc. (SEHK:1530), Sino Biopharmaceutical Limited (SEHK:1177), Lupin Limited (BSE:500257), Dr. Reddy's Laboratories Limited (BSE:500124), Hangzhou Tigermed Consulting Co.,Ltd (SZSE:300347), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SZSE:300760), Raia Drogasil S.A. (BOVESPA:RADL3), Fleury S.A. (BOVESPA:FLRY3), IMV Inc. (TSX:IMV), Qualicorp Consultoria e Corretora de Seguros S.A. (BOVESPA:QUAL3), Biotoscana Investments S.A. (BOVESPA:GBIO33), Oxurion NV (ENXTBR:OXUR), UCB SA (ENXTBR:UCB), Mithra Pharmaceuticals S.A. (ENXTBR:MITRA), Biocartis Group NV (ENXTBR:BCART), argenx SE (ENXTBR:ARGX), Siemens Healthineers AG (XTRA:SHL), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), Evotec SE (XTRA:EVT), Fresenius SE & Co. KGaA (XTRA:FRE), Bayer Aktiengesellschaft (XTRA:BAYN), MorphoSys AG (XTRA:MOR), 4SC AG (XTRA:VSC), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), AVRA Medical Robotics, Inc. (OTCPK:AVMR), STADA Arzneimittel Aktiengesellschaft (MUN:SAZ), Apollo Hospitals Enterprise Limited (NSEI:APOLLOHOSP), Hugel, Inc. (KOSDAQ:A145020), Genexine, Inc. (KOSDAQ:A095700), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Community Health Systems, Inc. (NYSE:CYH), Hill-Rom Holdings, Inc. (NYSE:HRC), AmerisourceBergen Corporation (NYSE:ABC), AMN Healthcare Services, Inc. (NYSE:AMN), Waters Corporation (NYSE:WAT), Charles River Laboratories International, Inc. (NYSE:CRL), STERIS plc (NYSE:STE), Universal Health Services, Inc. (NYSE:UHS), QIAGEN N.V. (NYSE:QGEN), Encompass Health Corporation (NYSE:EHC), Laboratory Corporation of America Holdings (NYSE:LH), Humana Inc. (NYSE:HUM), Medtronic plc (NYSE:MDT), Mettler-Toledo International Inc. (NYSE:MTD), ResMed Inc. (NYSE:RMD), Bausch Health Companies Inc. (NYSE:BHC), Quest Diagnostics Incorporated (NYSE:DGX), Welltower Inc. (NYSE:WELL), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), Abbott Laboratories (NYSE:ABT), The Cooper Companies, Inc. (NYSE:COO), Danaher Corporation (NYSE:DHR), PerkinElmer, Inc. (NYSE:PKI), Boston Scientific Corporation (NYSE:BSX), Perrigo Company plc (NYSE:PRGO), Owens & Minor, Inc. (NYSE:OMI), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Varian Medical Systems, Inc. (NYSE:VAR), West Pharmaceutical Services, Inc. (NYSE:WST), Tenet Healthcare Corporation (NYSE:THC), CVS Health Corporation (NYSE:CVS), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), UnitedHealth Group Incorporated (NYSE:UNH), Baxter International Inc. (NYSE:BAX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Cantel Medical Corp. (NYSE:CMD), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Agilent Technologies, Inc. (NYSE:A), salesforce.com, inc. (NYSE:CRM), Johnson & Johnson (NYSE:JNJ), Edwards Lifesciences Corporation (NYSE:EW), JPMorgan Chase & Co. (NYSE:JPM), JPMorgan Chase & Co. (NYSE:JPM), Glaukos Corporation (NYSE:GKOS), Molina Healthcare, Inc. (NYSE:MOH), Teladoc Health, Inc. (NYSE:TDOC), Emergent BioSolutions Inc. (NYSE:EBS), Avantor, Inc. (NYSE:AVTR), Myovant Sciences Ltd. (NYSE:MYOV), AbbVie Inc. (NYSE:ABBV), Zoetis Inc. (NYSE:ZTS), Invitae Corporation (NYSE:NVTA), Mallinckrodt plc (NYSE:MNK), Evolent Health, Inc. (NYSE:EVH), Avanos Medical, Inc. (NYSE:AVNS), Inspire Medical Systems, Inc. (NYSE:INSP), Catalent, Inc. (NYSE:CTLT), Veeva Systems Inc. (NYSE:VEEV), Penumbra, Inc. (NYSE:PEN), Nevro Corp. (NYSE:NVRO), Phreesia, Inc. (NYSE:PHR), Zymeworks Inc. (NYSE:ZYME), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Elanco Animal Health Incorporated (NYSE:ELAN), New Frontier Health Corporation (NYSE:NFH), Envista Holdings Corporation (NYSE:NVST), TransEnterix, Inc. (AMEX:TRXC), Radius Health, Inc. (NasdaqGM:RDUS), Acceleron Pharma Inc. (NasdaqGM:XLRN), Revance Therapeutics, Inc. (NasdaqGM:RVNC), NanoString Technologies, Inc. (NasdaqGM:NSTG), Cara Therapeutics, Inc. (NasdaqGM:CARA), GW Pharmaceuticals plc (NasdaqGM:GWPH), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Marinus Pharmaceuticals, Inc. (NasdaqGM:MRNS), Oxford Immunotec Global PLC (NasdaqGM:OXFD), AtriCure, Inc. (NasdaqGM:ATRC), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), TransMedics Group, Inc. (NasdaqGM:TMDX), Amarin Corporation plc (NasdaqGM:AMRN), Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), Misonix, Inc. (NasdaqGM:MSON), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), 111, Inc. (NasdaqGM:YI), Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT), AxoGen, Inc. (NasdaqCM:AXGN), ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP), Stemline Therapeutics, Inc. (NasdaqCM:STML), Applied DNA Sciences, Inc. (NasdaqCM:APDN), Agile Therapeutics, Inc. (NasdaqCM:AGRX), Accelerate Diagnostics, Inc. (NasdaqCM:AXDX), Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), Heska Corporation (NasdaqCM:HSKA), Exact Sciences Corporation (NasdaqCM:EXAS), Salarius Pharmaceuticals, Inc. (NasdaqCM:SLRX), Cue Biopharma, Inc. (NasdaqCM:CUE), TFF Pharmaceuticals, Inc. (NasdaqCM:TFFP), AdaptHealth Corp. (NasdaqCM:AHCO), TG Therapeutics, Inc. (NasdaqCM:TGTX), CohBar, Inc. (NasdaqCM:CWBR), Option Care Health, Inc. (NasdaqCM:BIOS), Taiwan Liposome Company, Ltd. (GTSM:4152), OBI Pharma, Inc. (GTSM:4174), Oneness Biotech Co., Ltd. (GTSM:4743), PharmaEssentia Corporation (GTSM:6446), Scandion Oncology A/S (NGM:SCOL), RhoVac AB (NGM:RHOVAC), Kura Oncology, Inc. (NasdaqGS:KURA), NextCure, Inc. (NasdaqGS:NXTC), TCR2 Therapeutics Inc. (NasdaqGS:TCRR), Kaleido BioSciences, Inc. (NasdaqGS:KLDO), Rubius Therapeutics, Inc. (NasdaqGS:RUBY), Gritstone Oncology, Inc. (NasdaqGS:GRTS), Crinetics Pharmaceuticals, Inc. (NasdaqGS:CRNX), SmileDirectClub, Inc. (NasdaqGS:SDC), Denali Therapeutics Inc. (NasdaqGS:DNLI), Change Healthcare Inc. (NasdaqGS:CHNG), Vir Biotechnology, Inc. (NasdaqGS:VIR), Frequency Therapeutics, Inc. (NasdaqGS:FREQ), Oyster Point Pharma, Inc. (NasdaqGS:OYST), IDEAYA Biosciences, Inc. (NasdaqGS:IDYA), Orchard Therapeutics plc (NasdaqGS:ORTX), Aptinyx Inc. (NasdaqGS:APTX), Y-mAbs Therapeutics, Inc. (NasdaqGS:YMAB), BridgeBio Pharma, Inc. (NasdaqGS:BBIO), Afya Limited (NasdaqGS:AFYA), Covetrus, Inc. (NasdaqGS:CVET), SpringWorks Therapeutics, Inc. (NasdaqGS:SWTX), Allogene Therapeutics, Inc. (NasdaqGS:ALLO), Kiniksa Pharmaceuticals, Ltd. (NasdaqGS:KNSA), Cyclerion Therapeutics, Inc. (NasdaqGS:CYCN), Autolus Therapeutics plc (NasdaqGS:AUTL), Replimune Group, Inc. (NasdaqGS:REPL), Akero Therapeutics, Inc. (NasdaqGS:AKRO), Urovant Sciences Ltd. (NasdaqGS:UROV), BioNTech SE (NasdaqGS:BNTX), Kala Pharmaceuticals, Inc. (NasdaqGS:KALA), NovoCure Limited (NasdaqGS:NVCR), Clovis Oncology, Inc. (NasdaqGS:CLVS), Adaptive Biotechnologies Corporation (NasdaqGS:ADPT), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), Apellis Pharmaceuticals, Inc. (NasdaqGS:APLS), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Progyny, Inc. (NasdaqGS:PGNY), BeiGene, Ltd. (NasdaqGS:BGNE), Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Puma Biotechnology, Inc. (NasdaqGS:PBYI), Moderna, Inc. (NasdaqGS:MRNA), Health Catalyst, Inc. (NasdaqGS:HCAT), Surgery Partners, Inc. (NasdaqGS:SGRY), IVERIC bio, Inc. (NasdaqGS:ISEE), iRhythm Technologies, Inc. (NasdaqGS:IRTC), OPKO Health, Inc. (NasdaqGS:OPK), AnaptysBio, Inc. (NasdaqGS:ANAB), Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST), Ascendis Pharma A/S (NasdaqGS:ASND), Precision BioSciences, Inc. (NasdaqGS:DTIL), InflaRx N.V. (NasdaqGS:IFRX), Inovalon Holdings, Inc. (NasdaqGS:INOV), G1 Therapeutics, Inc. (NasdaqGS:GTHX), Jounce Therapeutics, Inc. (NasdaqGS:JNCE), 10x Genomics, Inc. (NasdaqGS:TXG), MyoKardia, Inc. (NasdaqGS:MYOK), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), Stoke Therapeutics, Inc. (NasdaqGS:STOK), Editas Medicine, Inc. (NasdaqGS:EDIT), Turning Point Therapeutics, Inc. (NasdaqGS:TPTX), Tricida, Inc. (NasdaqGS:TCDA), Alector, Inc. (NasdaqGS:ALEC), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Twist Bioscience Corporation (NasdaqGS:TWST), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), ObsEva SA (NasdaqGS:OBSV), Livongo Health, Inc. (NasdaqGS:LVGO), Syneos Health, Inc. (NasdaqGS:SYNH), NantKwest, Inc. (NasdaqGS:NK), Guardant Health, Inc. (NasdaqGS:GH), Aprea Therapeutics, Inc. (NasdaqGS:APRE)JPMorgan Chase & Co., 38th Annual J.P Morgan Healthcare Conference, Jan 13, 2020 through Jan 16, 2020. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States.
8
1/17/202015.67x44.92x50.86x79.90x73.77x$67,717$585.792.13%Jan-09-2020Corporate Guidance - New/ConfirmedIntuitive Announces Unaudited Preliminary Unaudited Revenue Results Fourth Quarter and Full Year of 2019-Intuitive announced unaudited preliminary unaudited revenue results fourth quarter and full year of 2019. The company expects fourth quarter 2019 revenue of approximately $1.278 billion, an increase of 22% compared with $1.047 billion in the fourth quarter of 2018.

The company expects 2019 revenue of approximately $4.479 billion, an increase of 20% compared with $3.724 billion in 2018.
9
12/31/201915.43x44.23x50.07x78.71x72.63x$67,317$582.332.74%Dec-04-2019Company Conference PresentationIntuitive Surgical, Inc. Presents at Piper Jaffray 31st Annual Healthcare Conference, Dec-04-2019 08:00 AM-Intuitive Surgical, Inc. Presents at Piper Jaffray 31st Annual Healthcare Conference, Dec-04-2019 08:00 AM. Venue: The Lotte New York Palace, 455 Madison Avenue, New York, New York, United States.
10
12/31/201915.43x44.23x50.07x78.71x72.63x$66,959$579.233.29%Dec-3-2019ConferencePiper Jaffray Companies, Piper Jaffray 31st Annual Healthcare Conference, Dec 03, 2019 through Dec 05, 2019Progyny, Inc. (NasdaqGS:PGNY), BeiGene, Ltd. (NasdaqGS:BGNE), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Health Catalyst, Inc. (NasdaqGS:HCAT), Moderna, Inc. (NasdaqGS:MRNA), Milestone Pharmaceuticals Inc. (NasdaqGS:MIST), Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST), Chiasma, Inc. (NasdaqGS:CHMA), Dermira, Inc. (NasdaqGS:DERM), Menlo Therapeutics Inc. (NasdaqGS:MNLO), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), uniQure N.V. (NasdaqGS:QURE), Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Arvinas, Inc. (NasdaqGS:ARVN), scPharmaceuticals Inc. (NasdaqGS:SCPH), Stoke Therapeutics, Inc. (NasdaqGS:STOK), OptiNose, Inc. (NasdaqGS:OPTN), Turning Point Therapeutics, Inc. (NasdaqGS:TPTX), Axonics Modulation Technologies, Inc. (NasdaqGS:AXNX), Livongo Health, Inc. (NasdaqGS:LVGO), Unum Therapeutics Inc. (NasdaqGS:UMRX), SeaSpine Holdings Corporation (NasdaqGS:SPNE), Crinetics Pharmaceuticals, Inc. (NasdaqGS:CRNX), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Luminex Corporation (NasdaqGS:LMNX), Merit Medical Systems, Inc. (NasdaqGS:MMSI), PDL BioPharma, Inc. (NasdaqGS:PDLI), Incyte Corporation (NasdaqGS:INCY), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR), Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Apyx Medical Corporation (NasdaqGS:APYX), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), ChemoCentryx, Inc. (NasdaqGS:CCXI), Fluidigm Corporation (NasdaqGS:FLDM), OraSure Technologies, Inc. (NasdaqGS:OSUR), Insulet Corporation (NasdaqGS:PODD), Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Collegium Pharmaceutical, Inc. (NasdaqGS:COLL), Alphatec Holdings, Inc. (NasdaqGS:ATEC), Athenex, Inc. (NasdaqGS:ATNX), Nabriva Therapeutics plc (NasdaqGS:NBRV), OPKO Health, Inc. (NasdaqGS:OPK), Trulieve Cannabis Corp. (CNSX:TRUL), CB2 Insights Inc. (CNSX:CBII), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), LivaNova PLC (NasdaqGS:LIVN), Cytokinetics, Incorporated (NasdaqGS:CYTK), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Exelixis, Inc. (NasdaqGS:EXEL), Inovio Pharmaceuticals, Inc. (NasdaqGS:INO), Gossamer Bio, Inc. (NasdaqGS:GOSS), HOOKIPA Pharma Inc. (NasdaqGS:HOOK), Replimune Group, Inc. (NasdaqGS:REPL), Bicycle Therapeutics plc (NasdaqGS:BCYC), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), Apellis Pharmaceuticals, Inc. (NasdaqGS:APLS), CytomX Therapeutics, Inc. (NasdaqGS:CTMX), Otonomy, Inc. (NasdaqGS:OTIC), Aravive, Inc. (NasdaqGS:ARAV), MeiraGTx Holdings plc (NasdaqGS:MGTX), Aptinyx Inc. (NasdaqGS:APTX), Oyster Point Pharma, Inc. (NasdaqGS:OYST), Harpoon Therapeutics, Inc. (NasdaqGS:HARP), Change Healthcare Inc. (NasdaqGS:CHNG), resTORbio, Inc. (NasdaqGS:TORC), Gritstone Oncology, Inc. (NasdaqGS:GRTS), IGM Biosciences, Inc. (NasdaqGS:IGMS), Ovid Therapeutics Inc. (NasdaqGS:OVID), NextCure, Inc. (NasdaqGS:NXTC), Kezar Life Sciences, Inc. (NasdaqGS:KZR), Akcea Therapeutics, Inc. (NasdaqGS:AKCA), Kura Oncology, Inc. (NasdaqGS:KURA), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Masimo Corporation (NasdaqGS:MASI), NuVasive, Inc. (NasdaqGS:NUVA), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), VIVUS, Inc. (NasdaqGS:VVUS), RTI Surgical Holdings, Inc. (NasdaqGS:RTIX), Quidel Corporation (NasdaqGS:QDEL), Cutera, Inc. (NasdaqGS:CUTR), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Vermillion, Inc. (NasdaqCM:VRML), Heska Corporation (NasdaqCM:HSKA), Molecular Templates, Inc. (NasdaqCM:MTEM), AxoGen, Inc. (NasdaqCM:AXGN), Stemline Therapeutics, Inc. (NasdaqCM:STML), AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO), Accelerate Diagnostics, Inc. (NasdaqCM:AXDX), Cytosorbents Corporation (NasdaqCM:CTSO), PolarityTE, Inc. (NasdaqCM:PTE), iCAD, Inc. (NasdaqCM:ICAD), Spring Bank Pharmaceuticals, Inc. (NasdaqCM:SBPH), OncoSec Medical Incorporated (NasdaqCM:ONCS), ContraFect Corporation (NasdaqCM:CFRX), Novus Therapeutics, Inc. (NasdaqCM:NVUS), Motus GI Holdings, Inc. (NasdaqCM:MOTS), BioXcel Therapeutics, Inc. (NasdaqCM:BTAI), Baudax Bio, Inc. (NasdaqCM:BXRX), NeuBase Therapeutics, Inc. (NasdaqCM:NBSE), vTv Therapeutics Inc. (NasdaqCM:VTVT), Edesa Biotech, Inc. (NasdaqCM:EDSA), Oncternal Therapeutics, Inc. (NasdaqCM:ONCT), Immunic, Inc. (NasdaqCM:IMUX), Sensei Biotherapeutics, Inc., CureVac AG, EarlySense Ltd., Diasome Pharmaceuticals, Inc., ArunA Biomedical, Inc., FORMA Therapeutics, Inc., Luc Therapeutics, Inc., Knopp Biosciences LLC, Sonendo, Inc., Sight Sciences, Inc., NexImmune, Inc., Alcyone Lifesciences, Inc., Iteos Therapeutics S.A., Audentes Therapeutics, Inc., Progenity, Inc., Compass Therapeutics LLC, ORIC Pharmaceuticals, Inc., Caris Life Sciences, Inc., StemoniX Inc., Teewinot Life Sciences Corp., Oncorus, Inc., Kleo Pharmaceuticals, Inc., Axial Biotherapeutics, Inc., Cerevance LLC, Landos Biopharma, Inc., CARISMA Therapeutics Inc., KSQ Therapeutics, Inc., Akoya Biosciences, Inc., Orchestra BioMed, Inc., Passage Bio, Inc., Cellibre, Inc., Nurix Therapeutics, Inc, Boundless Bio, Inc., Hutchison China MediTech Limited (AIM:HCM), Avadel Pharmaceuticals plc (NasdaqGM:AVDL), Curis, Inc. (NasdaqGM:CRIS), Pfenex Inc. (AMEX:PFNX), Matinas BioPharma Holdings, Inc. (AMEX:MTNB), Kiadis Pharma N.V. (ENXTAM:KDS), Itamar Medical Ltd. (TASE:ITMR), Cellectis S.A. (ENXTPA:ALCLS), argenx SE (ENXTBR:ARGX), Hamilton Thorne Ltd. (TSXV:HTL), Aptose Biosciences Inc. (TSX:APS), Titan Medical Inc. (TSX:TMD), IMV Inc. (TSX:IMV), Theratechnologies Inc. (TSX:TH), Liminal BioSciences Inc. (TSX:LMNL), Correvio Pharma Corp. (TSX:CORV), Greenbrook TMS Inc. (TSX:GTMS), Viemed Healthcare, Inc. (TSX:VMD), Theravance Biopharma, Inc. (NasdaqGM:TBPH), Synlogic, Inc. (NasdaqGM:SYBX), Eloxx Pharmaceuticals, Inc. (NasdaqGM:ELOX), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Adverum Biotechnologies, Inc. (NasdaqGM:ADVM), Personalis, Inc. (NasdaqGM:PSNL), Protagonist Therapeutics, Inc. (NasdaqGM:PTGX), Karuna Therapeutics, Inc. (NasdaqGM:KRTX), Ardelyx, Inc. (NasdaqGM:ARDX), Castle Biosciences, Inc. (NasdaqGM:CSTL), SI-BONE, Inc. (NasdaqGM:SIBN), Sensus Healthcare, Inc. (NasdaqGM:SRTS), Proteostasis Therapeutics, Inc. (NasdaqGM:PTI), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), Adamas Pharmaceuticals, Inc. (NasdaqGM:ADMS), Neoleukin Therapeutics, Inc. (NasdaqGM:NLTX), Akebia Therapeutics, Inc. (NasdaqGM:AKBA), OrthoPediatrics Corp. (NasdaqGM:KIDS), Intersect ENT, Inc. (NasdaqGM:XENT), Apollo Endosurgery, Inc. (NasdaqGM:APEN), Sutro Biopharma, Inc. (NasdaqGM:STRO), Fate Therapeutics, Inc. (NasdaqGM:FATE), Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA), Ocular Therapeutix, Inc. (NasdaqGM:OCUL), ViewRay, Inc. (NasdaqGM:VRAY), Zogenix, Inc. (NasdaqGM:ZGNX), Oxford Immunotec Global PLC (NasdaqGM:OXFD), Lantheus Holdings, Inc. (NasdaqGM:LNTH), Exagen Inc. (NasdaqGM:XGN), MannKind Corporation (NasdaqGM:MNKD), CareDx, Inc (NasdaqGM:CDNA), Marker Therapeutics, Inc. (NasdaqGM:MRKR), Xencor, Inc. (NasdaqGM:XNCR), Neuronetics, Inc. (NasdaqGM:STIM), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), GlycoMimetics, Inc. (NasdaqGM:GLYC), GW Pharmaceuticals plc (NasdaqGM:GWPH), Tactile Systems Technology, Inc. (NasdaqGM:TCMD), Foamix Pharmaceuticals Ltd. (NasdaqGM:FOMX), AtriCure, Inc. (NasdaqGM:ATRC), Gamida Cell Ltd. (NasdaqGM:GMDA), Xenon Pharmaceuticals Inc. (NasdaqGM:XENE), Rockwell Medical, Inc. (NasdaqGM:RMTI), Misonix, Inc. (NasdaqGM:MSON), Immunomedics, Inc. (NasdaqGM:IMMU), Fulcrum Therapeutics, Inc. (NasdaqGM:FULC), Krystal Biotech, Inc. (NasdaqGM:KRYS), Alpine Immune Sciences, Inc. (NasdaqGM:ALPN), Fulgent Genetics, Inc. (NasdaqGM:FLGT), Aeglea BioTherapeutics, Inc. (NasdaqGM:AGLE), CRISPR Therapeutics AG (NasdaqGM:CRSP), Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC), Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT), Integer Holdings Corporation (NYSE:ITGR), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Bausch Health Companies Inc. (NYSE:BHC), Agilent Technologies, Inc. (NYSE:A), Teleflex Incorporated (NYSE:TFX), Varian Medical Systems, Inc. (NYSE:VAR), Boston Scientific Corporation (NYSE:BSX), Piper Sandler Companies (NYSE:PIPR), Piper Sandler Companies (NYSE:PIPR), Glaukos Corporation (NYSE:GKOS), Teladoc Health, Inc. (NYSE:TDOC), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Inspire Medical Systems, Inc. (NYSE:INSP), Invitae Corporation (NYSE:NVTA), Evolent Health, Inc. (NYSE:EVH), Mallinckrodt plc (NYSE:MNK), GTX Corp (OTCPK:GTXO), MorphoSys AG (XTRA:MOR)Piper Jaffray Companies, Piper Jaffray 31st Annual Healthcare Conference, Dec 03, 2019 through Dec 05, 2019. Venue: The Lotte New York Palace, 455 Madison Avenue, New York, New York, United States.
11
12/31/201915.43x44.23x50.07x78.71x72.63x$67,742$586.002.10%Nov-26-2019Product-Related AnnouncementIntuitive Announces U.S. Food and Drug Administration Clearance of Two Innovative Technologies-Intuitive announced U.S. Food and Drug Administration clearance of two innovative technologies for two of the company’s da Vinci® surgical systems to help improve procedures that require sealing. The company's E-100 generator is its first internally developed robotic generator to power two key instruments on the da Vinci X® and Xi™ systems. Vessel Sealer Extend is the instrument in the da Vinci energy sealing portfolio today, and the new SynchroSeal instrument offers enhanced capabilities in general surgery. The E-100 is Intuitive’s first generator and is offered as an upgrade to power Vessel Sealer Extend and SynchroSeal. SynchroSeal will enable a surgeon to perform rapid one-step sealing and transection with a single pedal press. SynchroSeal uses advanced bipolar energy from its raised cut electrode to transect tissue then cool down quickly, and will allow surgeons to move on to the next step. With its wristed articulation, its rapid sealing cycle, and refined curved jaw, SynchroSeal offers enhanced versatility to the da Vinci Energy portfolio.
12
12/31/201915.43x44.23x50.07x78.71x72.63x$64,311$556.327.54%Oct-30-2019Company Conference PresentationIntuitive Surgical, Inc. Presents at The Future is now: How Digital Workers & AI are Reshaping Life Sciences, Oct-30-2019 11:00 AM-Intuitive Surgical, Inc. Presents at The Future is now: How Digital Workers & AI are Reshaping Life Sciences, Oct-30-2019 11:00 AM. Speakers: Sivakumar Narayanan, Center of Excellence Lead.
13
12/31/201915.43x44.23x50.07x78.71x72.63x$64,311$556.327.54%Oct-30-2019ConferenceInforma plc, the Future is now: How Digital Workers & AI are Reshaping Life Sciences, Oct 30, 2019Informa plc (LSE:INF), Informa plc (LSE:INF), Automation Anywhere, Inc.Informa plc, The Future is now: How Digital Workers & AI are Reshaping Life Sciences, Oct 30, 2019.
14
12/31/201915.43x44.23x50.07x78.71x72.63x$64,293$556.177.57%Oct-29-2019Client AnnouncementIntuitive Surgical Limited Wins GBP 397 258.90 Contract-Intuitive Surgical Ltd. won a GBP397 258.90 contract award from University Hospitals of North Midlands NHS Trust for Provision of Instrumentation for Da Vinci Robot (Contract Award Notice No.: 2019/S 206-501751).
15
12/31/201915.43x44.23x50.07x78.71x72.63x$65,459$566.255.66%Oct-18-2019Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From July 1, 2019 to September 30, 2019, the company has repurchased 141,081 shares, representing 0.12% for $69.54 million. With this, the company has completed the repurchase of 9,196,189 shares, representing 7.95% for $2,495.79 million under the buyback announced on February 2, 2015.
16
12/31/201915.43x44.23x50.07x78.71x72.63x$61,199$529.4013.01%Oct-17-2019Earnings CallIntuitive Surgical, Inc., Q3 2019 Earnings Call, Oct 17, 2019-Intuitive Surgical, Inc., Q3 2019 Earnings Call, Oct 17, 2019
17
12/31/201915.43x44.23x50.07x78.71x72.63x$61,199$529.4013.01%Oct-17-2019Announcement of EarningsIntuitive Surgical, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019-Intuitive Surgical, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced total revenue was USD 1,128.2 million compared to USD 920.9 million a year ago. Operating income was USD 365.7 million compared to USD 313.3 million a year ago. Net income was USD 396.8 million compared to USD 292.5 million a year ago. Basic earnings per share was USD 3.44 compared to USD 2.57 a year ago. Diluted earnings per share was USD 3.33 compared to USD 2.45 a year ago. For the nine months, total revenue was USD 3,200.8 million compared to USD 2,677.7 million a year ago. Operating income was USD 976.9 million compared to USD 867.4 million a year ago. Net income was USD 1,021.6 million compared to USD 835.4 million a year ago. Basic earnings per share was USD 8.86 compared to USD 7.37 a year ago. Diluted earnings per share was USD 8.56 compared to USD 7.04 a year ago.
18
9/30/201914.75x42.36x47.53x75.09x75.98x$57,417$496.6920.46%Sep-9-2019Company Conference PresentationIntuitive Surgical, Inc. Presents at Morgan Stanley 17th Annual Global Healthcare Conference, Sep-09-2019 03:40 PM-Intuitive Surgical, Inc. Presents at Morgan Stanley 17th Annual Global Healthcare Conference, Sep-09-2019 03:40 PM. Venue: Grand Hyatt New York, 109 E.42nd St., New York, New York, United States. Speakers: Jamie E. Samath, VP, Corporate Controller & Principal Accounting Officer.
19
9/30/201914.75x42.36x47.53x75.09x75.98x$57,417$496.6920.46%Sep-09-2019ConferenceMorgan Stanley, Morgan Stanley 17th Annual Global Healthcare Conference, Sep 09, 2019 through Sep 11, 2019Scholar Rock Holding Corporation (NasdaqGS:SRRK), Allogene Therapeutics, Inc. (NasdaqGS:ALLO), Autolus Therapeutics plc (NasdaqGS:AUTL), Akero Therapeutics, Inc. (NasdaqGS:AKRO), Change Healthcare Inc. (NasdaqGS:CHNG), Unity Biotechnology, Inc. (NasdaqGS:UBX), AVROBIO, Inc. (NasdaqGS:AVRO), Forty Seven, Inc. (NasdaqGS:FTSV), Evelo Biosciences, Inc. (NasdaqGS:EVLO), Orchard Therapeutics plc (NasdaqGS:ORTX), Kaleido BioSciences, Inc. (NasdaqGS:KLDO), Rubius Therapeutics, Inc. (NasdaqGS:RUBY), NextCure, Inc. (NasdaqGS:NXTC), Alector, Inc. (NasdaqGS:ALEC), Twist Bioscience Corporation (NasdaqGS:TWST), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Editas Medicine, Inc. (NasdaqGS:EDIT), ShockWave Medical, Inc. (NasdaqGS:SWAV), Denali Therapeutics Inc. (NasdaqGS:DNLI), Voyager Therapeutics, Inc. (NasdaqGS:VYGR), Axonics Modulation Technologies, Inc. (NasdaqGS:AXNX), Livongo Health, Inc. (NasdaqGS:LVGO), Unum Therapeutics Inc. (NasdaqGS:UMRX), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), MyoKardia, Inc. (NasdaqGS:MYOK), Allena Pharmaceuticals, Inc. (NasdaqGS:ALNA), uniQure N.V. (NasdaqGS:QURE), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), Xeris Pharmaceuticals, Inc. (NasdaqGS:XERS), Apellis Pharmaceuticals, Inc. (NasdaqGS:APLS), BeiGene, Ltd. (NasdaqGS:BGNE), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Moderna, Inc. (NasdaqGS:MRNA), Blueprint Medicines Corporation (NasdaqGS:BPMC), REGENXBIO Inc. (NasdaqGS:RGNX), Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX), Natera, Inc. (NasdaqGS:NTRA), Nabriva Therapeutics plc (NasdaqGS:NBRV), Athenex, Inc. (NasdaqGS:ATNX), iRhythm Technologies, Inc. (NasdaqGS:IRTC), Ascendis Pharma A/S (NasdaqGS:ASND), NuCana plc (NasdaqGS:NCNA), Epizyme, Inc. (NasdaqGS:EPZM), Inovalon Holdings, Inc. (NasdaqGS:INOV), ICU Medical, Inc. (NasdaqGS:ICUI), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Anika Therapeutics, Inc. (NasdaqGS:ANIK), Incyte Corporation (NasdaqGS:INCY), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), CONMED Corporation (NasdaqGS:CNMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Inogen, Inc. (NasdaqGS:INGN), Portola Pharmaceuticals, Inc. (NasdaqGS:PTLA), Cardiovascular Systems, Inc. (NasdaqGS:CSII), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Fluidigm Corporation (NasdaqGS:FLDM), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), Amgen Inc. (NasdaqGS:AMGN), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Cytokinetics, Incorporated (NasdaqGS:CYTK), Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), Biogen Inc. (NasdaqGS:BIIB), Insmed Incorporated (NasdaqGS:INSM), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Masimo Corporation (NasdaqGS:MASI), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), NxStage Medical, Inc., Alder BioPharmaceuticals, Inc., Luc Therapeutics, Inc., Audentes Therapeutics, Inc., Caris Life Sciences, Inc., Passage Bio, Inc., Greenwich Biosciences, Inc, Gilmartin Group LLC, Koninklijke Philips N.V. (ENXTAM:PHIA), Vifor Pharma AG (SWX:VIFN), Roche Holding AG (SWX:ROG), Alcon, Inc. (SWX:ALC), Lonza Group Ltd (SWX:LONN), Hansa Biopharma AB (publ) (OM:HNSA), Hutchison China MediTech Limited (AIM:HCM), AstraZeneca PLC (LSE:AZN), Takeda Pharmaceutical Company Limited (TSE:4502), Dr. Reddy's Laboratories Limited (BSE:500124), Sanofi (ENXTPA:SAN), ERYTECH Pharma S.A. (ENXTPA:ERYP), Coloplast A/S (CPSE:COLO B), Zealand Pharma A/S (CPSE:ZEAL), ALK-Abelló A/S (CPSE:ALK B), Odontoprev S.A. (BOVESPA:ODPV3), argenx SE (ENXTBR:ARGX), CryoLife, Inc. (NYSE:CRY), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Fresenius SE & Co. KGaA (XTRA:FRE), Sartorius Aktiengesellschaft (XTRA:SRT), Hill-Rom Holdings, Inc. (NYSE:HRC), AmerisourceBergen Corporation (NYSE:ABC), Bristol-Myers Squibb Company (NYSE:BMY), Laboratory Corporation of America Holdings (NYSE:LH), Medtronic plc (NYSE:MDT), Waters Corporation (NYSE:WAT), Charles River Laboratories International, Inc. (NYSE:CRL), CVS Health Corporation (NYSE:CVS), Haemonetics Corporation (NYSE:HAE), Stryker Corporation (NYSE:SYK), Becton, Dickinson and Company (NYSE:BDX), Tenet Healthcare Corporation (NYSE:THC), Emergent BioSolutions Inc. (NYSE:EBS), Morgan Stanley (NYSE:MS), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), Teleflex Incorporated (NYSE:TFX), West Pharmaceutical Services, Inc. (NYSE:WST), Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), QIAGEN N.V. (NYSE:QGEN), STERIS plc (NYSE:STE), ResMed Inc. (NYSE:RMD), Bausch Health Companies Inc. (NYSE:BHC), Baxter International Inc. (NYSE:BAX), Quest Diagnostics Incorporated (NYSE:DGX), Perrigo Company plc (NYSE:PRGO), Penumbra, Inc. (NYSE:PEN), Avantor, Inc. (NYSE:AVTR), Quorum Health Corporation (NYSE:QHC), Arcus Biosciences, Inc. (NYSE:RCUS), Evolent Health, Inc. (NYSE:EVH), Mallinckrodt plc (NYSE:MNK), Avanos Medical, Inc. (NYSE:AVNS), AbbVie Inc. (NYSE:ABBV), Zoetis Inc. (NYSE:ZTS), Catalent, Inc. (NYSE:CTLT), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Nevro Corp. (NYSE:NVRO), Vocera Communications, Inc. (NYSE:VCRA), Elanco Animal Health Incorporated (NYSE:ELAN), Immunomedics, Inc. (NasdaqGM:IMMU), Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), TransMedics Group, Inc. (NasdaqGM:TMDX), Phibro Animal Health Corporation (NasdaqGM:PAHC), NanoString Technologies, Inc. (NasdaqGM:NSTG), Radius Health, Inc. (NasdaqGM:RDUS), Revance Therapeutics, Inc. (NasdaqGM:RVNC), AtriCure, Inc. (NasdaqGM:ATRC), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), GlycoMimetics, Inc. (NasdaqGM:GLYC), GW Pharmaceuticals plc (NasdaqGM:GWPH), Tactile Systems Technology, Inc. (NasdaqGM:TCMD), Cerus Corporation (NasdaqGM:CERS), ViewRay, Inc. (NasdaqGM:VRAY), Akebia Therapeutics, Inc. (NasdaqGM:AKBA), Veracyte, Inc. (NasdaqGM:VCYT), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), SI-BONE, Inc. (NasdaqGM:SIBN), Personalis, Inc. (NasdaqGM:PSNL), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Wave Life Sciences Ltd. (NasdaqGM:WVE), Axsome Therapeutics, Inc. (NasdaqGM:AXSM), Theravance Biopharma, Inc. (NasdaqGM:TBPH), Rhythm Pharmaceuticals, Inc. (NasdaqGM:RYTM), Fulcrum Therapeutics, Inc. (NasdaqGM:FULC), Kodiak Sciences Inc. (NasdaqGM:KOD), Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT), Prevail Therapeutics Inc. (NasdaqGM:PRVL), Vericel Corporation (NasdaqCM:VCEL), IRadimed Corporation (NasdaqCM:IRMD), ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP), NeoGenomics, Inc. (NasdaqCM:NEO), Corcept Therapeutics Incorporated (NasdaqCM:CORT), Veru Inc. (NasdaqCM:VERU), Option Care Health, Inc. (NasdaqCM:BIOS), Viking Therapeutics, Inc. (NasdaqCM:VKTX), Establishment Labs Holdings Inc. (NasdaqCM:ESTA)Morgan Stanley, Morgan Stanley 17th Annual Global Healthcare Conference, Sep 09, 2019 through Sep 11, 2019. Venue: Grand Hyatt New York, 109 E.42nd St., New York, New York, United States.
20
9/30/201914.75x42.36x47.53x75.09x75.98x$57,363$496.2220.57%Sep-04-2019Company Conference PresentationIntuitive Surgical, Inc. Presents at 14th Annual Wells Fargo Securities Healthcare Conference, Sep-04-2019 08:30 AM-Intuitive Surgical, Inc. Presents at 14th Annual Wells Fargo Securities Healthcare Conference, Sep-04-2019 08:30 AM. Venue: Westin Copley Place, 10 Huntington Ave., Boston, Massachusetts, United States. Speakers: Calvin Darling, Senior Director of IR, Marshall L. Mohr, Executive VP & CFO.
21
9/30/201914.75x42.36x47.53x75.09x75.98x$57,363$496.2220.57%Sep-04-2019ConferenceWells Fargo Securities, LLC, 14th Annual Wells Fargo Securities Healthcare Conference, Sep 04, 2019 through Sep 05, 2019Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), Merit Medical Systems, Inc. (NasdaqGS:MMSI), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Premier, Inc. (NasdaqGS:PINC), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Wright Medical Group N.V. (NasdaqGS:WMGI), Cerner Corporation (NasdaqGS:CERN), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Natus Medical Incorporated (NasdaqGS:NTUS), NuVasive, Inc. (NasdaqGS:NUVA), Omnicell, Inc. (NasdaqGS:OMCL), HMS Holdings Corp. (NasdaqGS:HMSY), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Kezar Life Sciences, Inc. (NasdaqGS:KZR), AVROBIO, Inc. (NasdaqGS:AVRO), SeaSpine Holdings Corporation (NasdaqGS:SPNE), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Autolus Therapeutics plc (NasdaqGS:AUTL), HOOKIPA Pharma Inc. (NasdaqGS:HOOK), Osmotica Pharmaceuticals plc (NasdaqGS:OSMT), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Conformis, Inc. (NasdaqGS:CFMS), HealthEquity, Inc. (NasdaqGS:HQY), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), BioDelivery Sciences International, Inc. (NasdaqGS:BDSI), Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH), Computer Programs and Systems, Inc. (NasdaqGS:CPSI), Ascendis Pharma A/S (NasdaqGS:ASND), Precision BioSciences, Inc. (NasdaqGS:DTIL), Clovis Oncology, Inc. (NasdaqGS:CLVS), NovoCure Limited (NasdaqGS:NVCR), Kala Pharmaceuticals, Inc. (NasdaqGS:KALA), Xeris Pharmaceuticals, Inc. (NasdaqGS:XERS), Calithera Biosciences, Inc. (NasdaqGS:CALA), ShockWave Medical, Inc. (NasdaqGS:SWAV), Voyager Therapeutics, Inc. (NasdaqGS:VYGR), Axonics Modulation Technologies, Inc. (NasdaqGS:AXNX), Jounce Therapeutics, Inc. (NasdaqGS:JNCE), Principia Biopharma Inc. (NasdaqGS:PRNB), Moderna, Inc. (NasdaqGS:MRNA), uniQure N.V. (NasdaqGS:QURE), MyoKardia, Inc. (NasdaqGS:MYOK), Teladoc Health, Inc. (NYSE:TDOC), Select Medical Holdings Corporation (NYSE:SEM), Emergent BioSolutions Inc. (NYSE:EBS), Globus Medical, Inc. (NYSE:GMED), Triple-S Management Corporation (NYSE:GTS), Glaukos Corporation (NYSE:GKOS), Inspire Medical Systems, Inc. (NYSE:INSP), Mallinckrodt plc (NYSE:MNK), Evolent Health, Inc. (NYSE:EVH), Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), Zymeworks Inc. (NYSE:ZYME), Penumbra, Inc. (NYSE:PEN), Encompass Health Corporation (NYSE:EHC), Humana Inc. (NYSE:HUM), Centene Corporation (NYSE:CNC), Hanger, Inc. (NYSE:HNGR), Medtronic plc (NYSE:MDT), Baxter International Inc. (NYSE:BAX), Universal Health Services, Inc. (NYSE:UHS), Becton, Dickinson and Company (NYSE:BDX), UnitedHealth Group Incorporated (NYSE:UNH), Johnson & Johnson (NYSE:JNJ), Anthem, Inc. (NYSE:ANTM), Cigna Corporation (NYSE:CI), MAXIMUS, Inc. (NYSE:MMS), Abbott Laboratories (NYSE:ABT), HCA Healthcare, Inc. (NYSE:HCA), The Cooper Companies, Inc. (NYSE:COO), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Service Corporation International (NYSE:SCI), Teleflex Incorporated (NYSE:TFX), Boston Scientific Corporation (NYSE:BSX), Vocera Communications, Inc. (NYSE:VCRA), Edwards Lifesciences Corporation (NYSE:EW), Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), Affimed N.V. (NasdaqGM:AFMD), Immunomedics, Inc. (NasdaqGM:IMMU), SIGA Technologies, Inc. (NasdaqGM:SIGA), IRIDEX Corporation (NasdaqGM:IRIX), Fate Therapeutics, Inc. (NasdaqGM:FATE), TRACON Pharmaceuticals, Inc. (NasdaqGM:TCON), Ocular Therapeutix, Inc. (NasdaqGM:OCUL), Veracyte, Inc. (NasdaqGM:VCYT), Evolus, Inc. (NasdaqGM:EOLS), Flexion Therapeutics, Inc. (NasdaqGM:FLXN), Karuna Therapeutics, Inc. (NasdaqGM:KRTX), Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA), MediWound Ltd. (NasdaqGM:MDWD), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), Neos Therapeutics, Inc. (NasdaqGM:NEOS), Applied Genetic Technologies Corporation (NasdaqGM:AGTC), Benefitfocus, Inc. (NasdaqGM:BNFT), Lantheus Holdings, Inc. (NasdaqGM:LNTH), Revance Therapeutics, Inc. (NasdaqGM:RVNC), Oxford Immunotec Global PLC (NasdaqGM:OXFD), Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM), Theravance Biopharma, Inc. (NasdaqGM:TBPH), CRISPR Therapeutics AG (NasdaqGM:CRSP), Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC), Mustang Bio, Inc. (NasdaqGM:MBIO), Morphic Holding, Inc. (NasdaqGM:MORF), C. R. Bard, Inc., Wells Fargo Securities, LLC, Wells Fargo Securities, LLC, OMNI life science, Inc., Alder BioPharmaceuticals, Inc., RxSight, Inc., Impulse Dynamics LLC, Optum, Inc., Rodin Therapeutics Inc., Akouos, Inc., Aveta Biomics, Inc, Relay Therapeutics, Inc., InterWest Partners LLC, Titan Medical Inc. (TSX:TMD), IMV Inc. (TSX:IMV), Ellex Medical Lasers Limited (ASX:ELX), Celyad SA (ENXTBR:CYAD), Novartis AG (SWX:NOVN), Alcon, Inc. (SWX:ALC), TransEnterix, Inc. (AMEX:TRXC), Cellectis S.A. (ENXTPA:ALCLS), Sunesis Pharmaceuticals, Inc. (NasdaqCM:SNSS), Regulus Therapeutics Inc. (NasdaqCM:RGLS), MEI Pharma, Inc. (NasdaqCM:MEIP), Second Sight Medical Products, Inc. (NasdaqCM:EYES), Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT), Evofem Biosciences, Inc. (NasdaqCM:EVFM)Wells Fargo Securities, LLC, 14th Annual Wells Fargo Securities Healthcare Conference, Sep 04, 2019 through Sep 05, 2019. Venue: Westin Copley Place, 10 Huntington Ave., Boston, Massachusetts, United States.
22
9/30/201914.75x42.36x47.53x75.09x75.98x$0Aug-31-2019M&A Transaction ClosingIntuitive Surgical, Inc. (NasdaqGS:ISRG) completed the acquisition of robotic endoscope business from Schölly Fiberoptic GmbH for approximately $110 million.Schölly Fiberoptic GmbH, Robotic Endoscope Business of Schölly Fiberoptic GmbHIntuitive Surgical, Inc. (NasdaqGS:ISRG) entered into agreement to acquire robotic endoscope business from Schölly Fiberoptic GmbH on July 15, 2019. This acquisition will integrate Schölly’s robotic endoscope manufacturing line, and two Schölly sites into Intuitive operations: the robotic-related manufacturing line from Denzlingen, Germany; the manufacturing site in Biebertal, Germany; and the repair site in Worcester, Mass., USA. Intuitive will welcome and integrate into its team approximately 200 staff from these three sites over the next 18 months. The closing of the Schölly Acquisition is subject to certain substantive closing conditions.

Elisabeth Rotheaicher, Andreas Thun, Tim Joppich and Falk Loose of Hogan Lovells acted as a legal advisors to Intuitive Surgical, Inc.


Intuitive Surgical, Inc. (NasdaqGS:ISRG) completed the acquisition of robotic endoscope business from Schölly Fiberoptic GmbH for approximately $110 million on August 31, 2019.
23
9/30/201914.75x42.36x47.53x75.09x75.98x$61,223$529.6112.97%Jul-29-2019Executive/Board Change - OtherIntuitive Surgical, Inc. Appoints Amy L. Ladd to Board of Directors, Effective August 1, 2019-Intuitive Surgical, Inc. announced the appointment of Amy L. Ladd, M.D., from Stanford University Medical Center to its board of directors, effective August 1, 2019. Dr. Ladd has spent nearly three decades practicing orthopaedic surgery at Stanford University, specializing in hand surgery and research focused on deciphering the progression and treatment of common basilar thumb arthritis. She currently serves as the Elsbach-Richards Professor of Surgery, and by courtesy, Professor of Medicine (Immunology & Rheumatology) at the Stanford University Medical Center. She holds ten patents and trademarks for innovation that include treatment for wrist fractures, thumb arthritis and that promote musculoskeletal health awareness. Dr. Ladd also served as the chair of the American Academy of Orthopaedic Surgeons (AAOS) Board of Specialties Society and is a past member of the AAOS board of directors. She previously served as president of the Ruth Jackson Orthopaedic Society.
24
9/30/201914.75x42.36x47.53x75.09x75.98x$61,463$531.6912.53%Jul-25-2019Shelf Registration FilingIntuitive Surgical, Inc. has filed a Shelf Registration in the amount of $2.17216 billion.-Intuitive Surgical, Inc. has filed a Shelf Registration in the amount of $2.17216 billion.

Security Name: Common Stock
Securities Offered: 4,000,000
Transaction Features: ESOP Related Offering
25
9/30/201914.75x42.36x47.53x75.09x75.98x$62,034$536.6311.49%Jul-18-2019Earnings CallIntuitive Surgical, Inc., Q2 2019 Earnings Call, Jul 18, 2019-Intuitive Surgical, Inc., Q2 2019 Earnings Call, Jul 18, 2019
26
9/30/201914.75x42.36x47.53x75.09x75.98x$62,034$536.6311.49%Jul-18-2019Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From April 1, 2019 to June 30, 2019, the company has repurchased 418,918 shares, representing 0.36% for $200 million. With this, the company has completed the repurchase of 9,055,108 shares, representing 7.83% for $2,426.25 million under the buyback announced on February 2, 2015.
27
9/30/201914.75x42.36x47.53x75.09x75.98x$62,034$536.6311.49%Jul-18-2019Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2019-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2019. For the quarter, the company reported total revenue of $1,098.9 million against $909.3 million a year ago. Income from operations was $359.0 million against $277.4 million a year ago. Net income was $316.4 million against $254.6 million a year ago. Basic net income per share attributable to the company was $2.76 against $2.25 per share a year ago. Diluted net income per share attributable to the company was $2.67 against $2.15 per share a year ago.

For the six months, the company reported total revenue of $2,072.6 million against $1,756.8 million a year ago. Income from operations was $611.2 million against $554.1 million a year ago. Net income was $620.4 million against $541.9 million a year ago. Basic net income per share attributable to the company was $5.42 against $4.80 per share a year ago. Diluted net income per share attributable to the company was $5.23 against $4.59 per share a year ago.
28
9/30/201914.75x42.36x47.53x75.09x75.98x$61,008$527.7513.37%Jul-15-2019M&A Transaction AnnouncementIntuitive Surgical, Inc. (NasdaqGS:ISRG) entered into agreement to acquire robotic endoscope business from Schölly Fiberoptic GmbH.Schölly Fiberoptic GmbH, Robotic Endoscope Business of Schölly Fiberoptic GmbHIntuitive Surgical, Inc. (NasdaqGS:ISRG) entered into agreement to acquire robotic endoscope business from Schölly Fiberoptic GmbH on July 15, 2019. This acquisition will integrate Schölly’s robotic endoscope manufacturing line, and two Schölly sites into Intuitive operations: the robotic-related manufacturing line from Denzlingen, Germany; the manufacturing site in Biebertal, Germany; and the repair site in Worcester, Mass., USA. Intuitive will welcome and integrate into its team approximately 200 staff from these three sites over the next 18 months. The closing of the Schölly Acquisition is subject to certain substantive closing conditions.

Elisabeth Rotheaicher, Andreas Thun, Tim Joppich and Falk Loose of Hogan Lovells acted as a legal advisors to Intuitive Surgical, Inc.
29
9/30/201914.75x42.36x47.53x75.09x75.98x$61,962$536.0011.62%Jul-11-2019Executive/Board Change - OtherIntuitive Surgical, Inc. Announces Transition of Salvatore J. Brogna from Executive Vice President and Chief Operating Officer to Serve as Consultant and Advisor-On July 11, 2019, Intuitive Surgical, Inc. announced that Salvatore J. Brogna will transition from his role as Executive Vice President and Chief Operating Officer in 2019 and plans to serve as a consultant and advisor to the Company starting in 2020 on terms and conditions to be agreed between the Company and Mr. Brogna. Brogna joined Intuitive in October 1999 and held a number of key roles in the organization over the course of his career, including Executive Vice President of Product Operations, Senior Vice President of Product Development and Vice President of Engineering. Prior to joining Intuitive, Brogna led design and development of complex robotic systems for commercial and industrial use. Business unit general managers will report to Intuitive's CEO as part of Brogna's transition.
30
6/30/201915.02x42.84x47.61x75.94x79.60x$59,591$517.2815.66%Jun-18-2019Company Conference PresentationIntuitive Surgical, Inc. Presents at Gartner Supply Chain Executive Conferences, Jun-18-2019 12:45 PM-Intuitive Surgical, Inc. Presents at Gartner Supply Chain Executive Conferences, Jun-18-2019 12:45 PM. Venue: Palau de Congressos de Catalunya, Avinguda Diagonal, 661-671, Barcelona, Spain. Speakers: Ana Maia, Business Development Manager.
31
6/30/201915.02x42.84x47.61x75.94x79.60x$0Jun-16-2019ConferenceGartner, Inc., Gartner Supply Chain Executive Conferences, Jun 17, 2019 through Jun 19, 2019Cisco Systems, Inc. (NasdaqGS:CSCO), Intel Corporation (NasdaqGS:INTC), Manhattan Associates, Inc. (NasdaqGS:MANH), Domo, Inc. (NasdaqGM:DOMO), Gartner, Inc. (NYSE:IT), Gartner, Inc. (NYSE:IT), HP Inc. (NYSE:HPQ), International Business Machines Corporation (NYSE:IBM), Johnson & Johnson (NYSE:JNJ), Colgate-Palmolive Company (NYSE:CL), The Procter & Gamble Company (NYSE:PG), Oracle Corporation (NYSE:ORCL), SAP SE (XTRA:SAP), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), Henkel AG & Co. KGaA (XTRA:HEN3), Bayer Aktiengesellschaft (XTRA:BAYN), Lenzing Aktiengesellschaft (WBAG:LNZ), Loblaw Companies Limited (TSX:L), Kinaxis Inc. (TSX:KXS), A.P. Møller - Mærsk A/S (CPSE:MAERSK B), Danone S.A. (ENXTPA:BN), Airbus SE (ENXTPA:AIR), Schneider Electric S.E. (ENXTPA:SU), Sanofi (ENXTPA:SAN), L'Oréal S.A. (ENXTPA:OR), Diageo plc (LSE:DGE), Husqvarna AB (publ) (OM:HUSQ B), AB Electrolux (publ) (OM:ELUX B), JDA Software Group, Inc., Ernst & Young LLP, E2open, LLC, Robert Bosch GmbH, Data Systems International, Inc., CargoSmart Limited, IKEA AB, Barilla G. e R. Fratelli S.p.A., Magna Steyr Fahrzeugtechnik AG & Co. KG, MANN + HUMMEL Holding GmbH, Instituto de Empresa, Natural Factors Nutritional Products Ltd., BOARD International S.A., HealthSmart Holdings, Inc., Air France Industries and KLM Engineering & Maintenance, Transalis Ltd., Aera Technology, Inc., TRANSPOREON GmbH, Oliver Wight EAME LLP, Orchestr8 Ltd., Logistyx Technologies, LLC, Avetta, LLC, Blume Global Inc., IBM Europe, Circle K Stores Inc., Shippeo SAS, Project44, Inc., The Linde Group, Inc., GE Renewable Energy, The WOW Factor, Inc., SupplyStack, Bluecrux CVBA, Sixfold GmbH, BluJay Solutions Ltd, Amber Road, Inc., Infor (US), Inc., Bacardi LimitedGartner, Inc., Gartner Supply Chain Executive Conferences, Jun 17, 2019 through Jun 19, 2019. Venue: Palau de Congressos de Catalunya, Avinguda Diagonal, 661-671, Barcelona, Spain.
32
6/30/201915.02x42.84x47.61x75.94x79.60x$56,143$487.3522.76%May-14-2019Company Conference PresentationIntuitive Surgical, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-14-2019 01:00 PM-Intuitive Surgical, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-14-2019 01:00 PM. Venue: Encore Hotel, Wynn, Las Vegas, Nevada, United States. Speakers: Marshall L. Mohr, Executive VP & CFO.
33
6/30/201915.02x42.84x47.61x75.94x79.60x$56,143$487.3522.76%May-14-2019ConferenceBank of America Corporation, Bank of America Merrill Lynch 2019 Healthcare Conference, May 14, 2019 through May 16, 2019Eidos Therapeutics, Inc. (NasdaqGS:EIDX), Gossamer Bio, Inc. (NasdaqGS:GOSS), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Illumina, Inc. (NasdaqGS:ILMN), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Wright Medical Group N.V. (NasdaqGS:WMGI), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), LHC Group, Inc. (NasdaqGS:LHCG), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Intrexon Corporation (NasdaqGS:XON), Nabriva Therapeutics plc (NasdaqGS:NBRV), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), R1 RCM Inc. (NasdaqGS:RCM), AnaptysBio, Inc. (NasdaqGS:ANAB), Ascendis Pharma A/S (NasdaqGS:ASND), Surgery Partners, Inc. (NasdaqGS:SGRY), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Principia Biopharma Inc. (NasdaqGS:PRNB), Moderna, Inc. (NasdaqGS:MRNA), Puma Biotechnology, Inc. (NasdaqGS:PBYI), Blueprint Medicines Corporation (NasdaqGS:BPMC), REGENXBIO Inc. (NasdaqGS:RGNX), CytomX Therapeutics, Inc. (NasdaqGS:CTMX), Clovis Oncology, Inc. (NasdaqGS:CLVS), Kala Pharmaceuticals, Inc. (NasdaqGS:KALA), MyoKardia, Inc. (NasdaqGS:MYOK), Spero Therapeutics, Inc. (NasdaqGS:SPRO), CONMED Corporation (NasdaqGS:CNMD), Hologic, Inc. (NasdaqGS:HOLX), Quidel Corporation (NasdaqGS:QDEL), Bio-Techne Corporation (NasdaqGS:TECH), Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR), Merit Medical Systems, Inc. (NasdaqGS:MMSI), Incyte Corporation (NasdaqGS:INCY), Brooks Automation, Inc. (NasdaqGS:BRKS), Henry Schein, Inc. (NasdaqGS:HSIC), Nuance Communications, Inc. (NasdaqGS:NUAN), Amedisys, Inc. (NasdaqGS:AMED), Mylan N.V. (NasdaqGS:MYL), Align Technology, Inc. (NasdaqGS:ALGN), Amgen Inc. (NasdaqGS:AMGN), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Neon Therapeutics, Inc. (NasdaqGS:NTGN), Alector, Inc. (NasdaqGS:ALEC), ShockWave Medical, Inc. (NasdaqGS:SWAV), Guardant Health, Inc. (NasdaqGS:GH), Axonics Modulation Technologies, Inc. (NasdaqGS:AXNX), NantKwest, Inc. (NasdaqGS:NK), Y-mAbs Therapeutics, Inc. (NasdaqGS:YMAB), MeiraGTx Holdings plc (NasdaqGS:MGTX), resTORbio, Inc. (NasdaqGS:TORC), Homology Medicines, Inc. (NasdaqGS:FIXX), Kura Oncology, Inc. (NasdaqGS:KURA), Array BioPharma Inc., The Medicines Company, Schrödinger, Inc., Avedro, Inc., SetPoint Medical Corporation, Audentes Therapeutics, Inc., Caris Life Sciences, Inc., Roche Holding AG (SWX:ROG), Alcon, Inc. (SWX:ALC), Vifor Pharma AG (SWX:VIFN), Hutchison China MediTech Limited (AIM:HCM), DBV Technologies S.A. (ENXTPA:DBV), Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Core Laboratories N.V. (NYSE:CLB), Bausch Health Companies Inc. (NYSE:BHC), Service Corporation International (NYSE:SCI), Teleflex Incorporated (NYSE:TFX), West Pharmaceutical Services, Inc. (NYSE:WST), Boston Scientific Corporation (NYSE:BSX), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), Tenet Healthcare Corporation (NYSE:THC), MEDNAX, Inc. (NYSE:MD), Baxter International Inc. (NYSE:BAX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Chemed Corporation (NYSE:CHE), Hanger, Inc. (NYSE:HNGR), Encompass Health Corporation (NYSE:EHC), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Danaher Corporation (NYSE:DHR), Bank of America Corporation (NYSE:BAC), Hill-Rom Holdings, Inc. (NYSE:HRC), Universal Health Services, Inc. (NYSE:UHS), Allergan plc (NYSE:AGN), Mettler-Toledo International Inc. (NYSE:MTD), Centene Corporation (NYSE:CNC), Humana Inc. (NYSE:HUM), Vapotherm, Inc. (NYSE:VAPO), Capital Senior Living Corporation (NYSE:CSU), Edwards Lifesciences Corporation (NYSE:EW), Vocera Communications, Inc. (NYSE:VCRA), Charles River Laboratories International, Inc. (NYSE:CRL), Glaukos Corporation (NYSE:GKOS), Penumbra, Inc. (NYSE:PEN), Physicians Realty Trust (NYSE:DOC), Invitae Corporation (NYSE:NVTA), Evolent Health, Inc. (NYSE:EVH), AbbVie Inc. (NYSE:ABBV), Catalent, Inc. (NYSE:CTLT), Inspire Medical Systems, Inc. (NYSE:INSP), Nevro Corp. (NYSE:NVRO), Quorum Health Corporation (NYSE:QHC), ArQule, Inc. (NasdaqGM:ARQL), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Immunomedics, Inc. (NasdaqGM:IMMU), Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT), Rhythm Pharmaceuticals, Inc. (NasdaqGM:RYTM), CRISPR Therapeutics AG (NasdaqGM:CRSP), Zai Lab Limited (NasdaqGM:ZLAB), Verrica Pharmaceuticals Inc. (NasdaqGM:VRCA), Kodiak Sciences Inc. (NasdaqGM:KOD), Zogenix, Inc. (NasdaqGM:ZGNX), Silk Road Medical, Inc (NasdaqGM:SILK), Intersect ENT, Inc. (NasdaqGM:XENT), SI-BONE, Inc. (NasdaqGM:SIBN), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), Adamas Pharmaceuticals, Inc. (NasdaqGM:ADMS), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Evolus, Inc. (NasdaqGM:EOLS), Xencor, Inc. (NasdaqGM:XNCR), Phibro Animal Health Corporation (NasdaqGM:PAHC), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Marker Therapeutics, Inc. (NasdaqGM:MRKR), GW Pharmaceuticals plc (NasdaqGM:GWPH), Foamix Pharmaceuticals Ltd. (NasdaqGM:FOMX), Cara Therapeutics, Inc. (NasdaqGM:CARA), NewLink Genetics Corporation (NasdaqGM:NLNK), Radius Health, Inc. (NasdaqGM:RDUS), Corcept Therapeutics Incorporated (NasdaqCM:CORT), Exact Sciences Corporation (NasdaqCM:EXAS), Heron Therapeutics, Inc. (NasdaqCM:HRTX), Heska Corporation (NasdaqCM:HSKA)Bank of America Corporation, Bank of America Merrill Lynch 2019 Healthcare Conference, May 14, 2019 through May 16, 2019. Venue: Encore Hotel, Wynn, Las Vegas, Nevada, United States.
34
6/30/201915.02x42.84x47.61x75.94x79.60x$57,260$497.0520.37%May-1-2019Business ExpansionIntuitive Surgical Widens Expansion Footprint with New Sunnyvale Deal-Intuitive Surgical has bought three low-slung buildings on Commercial Street on sites that are a short distance from the company's headquarters in Sunnyvale. Intuitive Surgical has bought some old research and office buildings in Sunnyvale, a deal that took place in area where the company has been busy lately attempting to expand its footprint. Intuitive Surgical paid $15.1 million for the buildings, which are located at 164 Commercial St. through 174 Commercial St. in Sunnyvale and are on the south side of Central Expressway, according to Santa Clara County property records that were filed on April 30, 2019. The property currently contains three buildings that together total 36,000 square feet.
35
6/30/201915.02x42.84x47.61x75.94x79.60x$59,648$517.7815.55%Apr-25-2019Annual General MeetingIntuitive Surgical, Inc., Annual General Meeting, Apr 25, 2019-Intuitive Surgical, Inc., Annual General Meeting, Apr 25, 2019, at 15:00 Pacific Daylight. Location: 1020 Kifer Road Sunnyvale California United States Agenda: To elect nine members to the board of directors of the company to serve until the 2020 annual meeting of stockholders; to consider and approve, on an advisory basis, the compensation of the company's Named Executive Officers as disclosed in the Proxy Statement; to ratify the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2019; to approve the amendment and restatement of the 2010 incentive award plan; to consider and vote upon a stockholder proposal regarding elimination of supermajority voting provisions, if properly presented at the annual meeting; and to transact any other business which is properly brought before the Annual Meeting or adjournments or postponements thereof.
36
6/30/201915.02x42.84x47.61x75.94x79.60x$0April-19-2019Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From January 1, 2019 to March 31, 2019, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 8,636,190 shares, representing 7.47% for $2,226.25 million under the buyback announced on February 2, 2015.
37
6/30/201915.02x42.84x47.61x75.94x79.60x$60,833$528.0613.30%Apr-18-2019Earnings CallIntuitive Surgical, Inc., Q1 2019 Earnings Call, Apr 18, 2019-Intuitive Surgical, Inc., Q1 2019 Earnings Call, Apr 18, 2019
38
6/30/201915.02x42.84x47.61x75.94x79.60x$60,833$528.0613.30%Apr-18-2019Announcement of Earnings, Impairments/Write OffIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2019; Provides Impairment Charges for the First Quarter Ended March 31, 2019-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2019. For the quarter, the company reported total revenue of $973.7 million against $847.5 million a year ago. Income from operations was $252.2 million against $276.7 million a year ago. Net income was $304.0 million against $287.3 million a year ago. Basic net income per share attributable to the company was $2.67 against $2.55 per share a year ago. Diluted net income per share attributable to the company was $2.56 against $2.44 per share a year ago.

For the first quarter ended March 31, 2019, the company reported impairment charges of $1.5 million.
39
3/31/201916.85x45.99x50.43x81.59x87.21x$64,417$558.217.18%Mar-15-2019Product-Related AnnouncementIntuitive Receives Clearance for the da Vinci SP® Surgical System-Intuitive announced it has received clearance for the da Vinci SP® surgical system for use in certain transoral otolaryngology procedures in adults. The FDA cleared the single port approach for lateral oropharyngectomy procedures (commonly referred to as radical tonsillectomy) and tongue base resection. The da Vinci SP system provides surgeons with robotic-assisted technology designed for deep and narrow access to tissue in the body. The ability to enter the body through a single, small incision or through a natural orifice can provide a minimally invasive experience for complex procedures.
40
3/31/201916.85x45.99x50.43x81.59x87.21x$64,457$558.557.11%Mar-1-2019Company Conference PresentationIntuitive Surgical, Inc. Presents at 8th Annual SVB Leerink Global Healthcare Conference, Mar-01-2019 10:00 AM-Intuitive Surgical, Inc. Presents at 8th Annual SVB Leerink Global Healthcare Conference, Mar-01-2019 10:00 AM. Venue: Lotte New York Palace Hotel, New York, New York, United States.
41
3/31/201916.85x45.99x50.43x81.59x87.21x$63,402$549.418.90%Feb-27-2019ConferenceLeerink Partners LLC, 8th Annual SVB Leerink Global Healthcare Conference, Feb 27, 2019 through Mar 01, 2019Bruker Corporation (NasdaqGS:BRKR), MacroGenics, Inc. (NasdaqGS:MGNX), Henry Schein, Inc. (NasdaqGS:HSIC), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), CONMED Corporation (NasdaqGS:CNMD), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Bio-Techne Corporation (NasdaqGS:TECH), Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Achillion Pharmaceuticals, Inc. (NasdaqGS:ACHN), Teligent, Inc. (NasdaqGS:TLGT), Walgreens Boots Alliance, Inc. (NasdaqGS:WBA), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), Aclaris Therapeutics, Inc. (NasdaqGS:ACRS), Dermira, Inc. (NasdaqGS:DERM), Translate Bio, Inc. (NasdaqGS:TBIO), uniQure N.V. (NasdaqGS:QURE), Adaptimmune Therapeutics plc (NasdaqGS:ADAP), BeiGene, Ltd. (NasdaqGS:BGNE), Blueprint Medicines Corporation (NasdaqGS:BPMC), Principia Biopharma Inc. (NasdaqGS:PRNB), ObsEva SA (NasdaqGS:OBSV), scPharmaceuticals Inc. (NasdaqGS:SCPH), Cellular Biomedicine Group, Inc. (NasdaqGS:CBMG), Crinetics Pharmaceuticals, Inc. (NasdaqGS:CRNX), Kura Oncology, Inc. (NasdaqGS:KURA), Voyager Therapeutics, Inc. (NasdaqGS:VYGR), Guardant Health, Inc. (NasdaqGS:GH), Aptinyx Inc. (NasdaqGS:APTX), Rubius Therapeutics, Inc. (NasdaqGS:RUBY), Akcea Therapeutics, Inc. (NasdaqGS:AKCA), NantKwest, Inc. (NasdaqGS:NK), Synthorx, Inc. (NasdaqGS:THOR), Axovant Gene Therapies Ltd. (NasdaqGS:AXGT), Neon Therapeutics, Inc. (NasdaqGS:NTGN), Gritstone Oncology, Inc. (NasdaqGS:GRTS), IGM Biosciences, Inc. (NasdaqGS:IGMS), TCR2 Therapeutics Inc. (NasdaqGS:TCRR), Eidos Therapeutics, Inc. (NasdaqGS:EIDX), Oyster Point Pharma, Inc. (NasdaqGS:OYST), Provention Bio, Inc. (NasdaqGS:PRVB), Gossamer Bio, Inc. (NasdaqGS:GOSS), resTORbio, Inc. (NasdaqGS:TORC), BridgeBio Pharma, Inc. (NasdaqGS:BBIO), Harpoon Therapeutics, Inc. (NasdaqGS:HARP), Mersana Therapeutics, Inc. (NasdaqGS:MRSN), Computer Programs and Systems, Inc. (NasdaqGS:CPSI), ChemoCentryx, Inc. (NasdaqGS:CCXI), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Premier, Inc. (NasdaqGS:PINC), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Aduro BioTech, Inc. (NasdaqGS:ADRO), Inogen, Inc. (NasdaqGS:INGN), Cardiovascular Systems, Inc. (NasdaqGS:CSII), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), Clovis Oncology, Inc. (NasdaqGS:CLVS), Xeris Pharmaceuticals, Inc. (NasdaqGS:XERS), Calithera Biosciences, Inc. (NasdaqGS:CALA), InflaRx N.V. (NasdaqGS:IFRX), Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST), Epizyme, Inc. (NasdaqGS:EPZM), Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), Tocagen Inc. (NasdaqGS:TOCA), Intrexon Corporation (NasdaqGS:XON), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Dicerna Pharmaceuticals, Inc. (NasdaqGS:DRNA), Ascendis Pharma A/S (NasdaqGS:ASND), Sientra, Inc. (NasdaqGS:SIEN), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Alkermes plc (NasdaqGS:ALKS), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), HMS Holdings Corp. (NasdaqGS:HMSY), ImmunoGen, Inc. (NasdaqGS:IMGN), Insmed Incorporated (NasdaqGS:INSM), CymaBay Therapeutics, Inc. (NasdaqGS:CBAY), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), NuVasive, Inc. (NasdaqGS:NUVA), Repligen Corporation (NasdaqGS:RGEN), Seattle Genetics, Inc. (NasdaqGS:SGEN), Replimune Group, Inc. (NasdaqGS:REPL), Vericel Corporation (NasdaqCM:VCEL), AxoGen, Inc. (NasdaqCM:AXGN), Cryoport, Inc. (NasdaqCM:CYRX), Sorrento Therapeutics, Inc. (NasdaqCM:SRNE), Dyadic International, Inc. (NasdaqCM:DYAI), Cytosorbents Corporation (NasdaqCM:CTSO), AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO), NeoGenomics, Inc. (NasdaqCM:NEO), HTG Molecular Diagnostics, Inc. (NasdaqCM:HTGM), Millendo Therapeutics, Inc. (NasdaqCM:MLND), Abeona Therapeutics Inc. (NasdaqCM:ABEO), CTI BioPharma Corp. (NasdaqCM:CTIC), Heron Therapeutics, Inc. (NasdaqCM:HRTX), DBV Technologies S.A. (ENXTPA:DBV), Genfit SA (ENXTPA:GNFT), Innate Pharma S.A. (ENXTPA:IPH), Novo Nordisk A/S (CPSE:NOVO B), H. Lundbeck A/S (CPSE:LUN), Zealand Pharma A/S (CPSE:ZEAL), RedHill Biopharma Ltd. (TASE:RDHL), GlaxoSmithKline plc (LSE:GSK), PureTech Health plc (LSE:PRTC), Newron Pharmaceuticals S.p.A. (SWX:NWRN), Cassiopea S.p.A. (SWX:SKIN), Novartis AG (SWX:NOVN), Galapagos NV (ENXTAM:GLPG), Celyad SA (ENXTBR:CYAD), Aptose Biosciences Inc. (TSX:APS), Correvio Pharma Corp. (TSX:CORV), Aurinia Pharmaceuticals Inc. (TSX:AUP), Neovasc Inc. (TSX:NVCN), HLS Therapeutics Inc. (TSX:HLS), Array BioPharma Inc., The Medicines Company, SVB Leerink LLC, Medidata Solutions, Inc., Inotek Pharmaceuticals Corporation, CureVac AG, Alder BioPharmaceuticals, Inc., Immune Design Corp., PsiOxus Therapeutics Limited, Apexigen Inc., Angion Biomedica Corp., Navitor Pharmaceuticals, Inc., Audentes Therapeutics, Inc., Clementia Pharmaceuticals Inc., Revolution Medicines, Inc., Torque Therapeutics Inc., ORIC Pharmaceuticals, Inc., Pliant Therapeutics, Inc., Imara, Inc., Relay Therapeutics, Inc., Dova Pharmaceuticals, Inc., Precigen, Inc., Everest Medicines Limited, Dermavant Sciences Ltd., Rainier Therapeutics, Inc, MannKind Corporation (NasdaqGM:MNKD), Marinus Pharmaceuticals, Inc. (NasdaqGM:MRNS), Acceleron Pharma Inc. (NasdaqGM:XLRN), Paratek Pharmaceuticals, Inc. (NasdaqGM:PRTK), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), GW Pharmaceuticals plc (NasdaqGM:GWPH), Reata Pharmaceuticals, Inc. (NasdaqGM:RETA), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Xencor, Inc. (NasdaqGM:XNCR), Affimed N.V. (NasdaqGM:AFMD), Ra Pharmaceuticals, Inc. (NasdaqGM:RARX), Ardelyx, Inc. (NasdaqGM:ARDX), Veracyte, Inc. (NasdaqGM:VCYT), Quanterix Corporation (NasdaqGM:QTRX), Adamas Pharmaceuticals, Inc. (NasdaqGM:ADMS), Radius Health, Inc. (NasdaqGM:RDUS), Zogenix, Inc. (NasdaqGM:ZGNX), T2 Biosystems, Inc. (NasdaqGM:TTOO), Intersect ENT, Inc. (NasdaqGM:XENT), Fate Therapeutics, Inc. (NasdaqGM:FATE), Iterum Therapeutics plc (NasdaqGM:ITRM), LogicBio Therapeutics, Inc. (NasdaqGM:LOGC), Quotient Limited (NasdaqGM:QTNT), Fulcrum Therapeutics, Inc. (NasdaqGM:FULC), Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA), Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT), Eton Pharmaceuticals, Inc. (NasdaqGM:ETON), Krystal Biotech, Inc. (NasdaqGM:KRYS), Wave Life Sciences Ltd. (NasdaqGM:WVE), Synlogic, Inc. (NasdaqGM:SYBX), Zai Lab Limited (NasdaqGM:ZLAB), Intellia Therapeutics, Inc. (NasdaqGM:NTLA), Eloxx Pharmaceuticals, Inc. (NasdaqGM:ELOX), Arcturus Therapeutics Holdings Inc. (NasdaqGM:ARCT), Theravance Biopharma, Inc. (NasdaqGM:TBPH), Protagonist Therapeutics, Inc. (NasdaqGM:PTGX), Proteostasis Therapeutics, Inc. (NasdaqGM:PTI), Verastem, Inc. (NasdaqGM:VSTM), Retrophin, Inc. (NasdaqGM:RTRX), Adverum Biotechnologies, Inc. (NasdaqGM:ADVM), ArQule, Inc. (NasdaqGM:ARQL), STAAR Surgical Company (NasdaqGM:STAA), Amarin Corporation plc (NasdaqGM:AMRN), SIGA Technologies, Inc. (NasdaqGM:SIGA), Misonix, Inc. (NasdaqGM:MSON), Equillium, Inc. (NasdaqGM:EQ), Invitae Corporation (NYSE:NVTA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), Arcus Biosciences, Inc. (NYSE:RCUS), Diplomat Pharmacy, Inc. (NYSE:DPLO), Inspire Medical Systems, Inc. (NYSE:INSP), Vocera Communications, Inc. (NYSE:VCRA), Globus Medical, Inc. (NYSE:GMED), Medtronic plc (NYSE:MDT), Boston Scientific Corporation (NYSE:BSX), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Baxter International Inc. (NYSE:BAX), Johnson & Johnson (NYSE:JNJ), Agilent Technologies, Inc. (NYSE:A), Universal Health Services, Inc. (NYSE:UHS), Allergan plc (NYSE:AGN), CVS Health Corporation (NYSE:CVS), Stryker Corporation (NYSE:SYK), Becton, Dickinson and Company (NYSE:BDX), MorphoSys AG (XTRA:MOR), Achaogen, Inc. (OTCPK:AKAO.Q)Leerink Partners LLC, 8th Annual SVB Leerink Global Healthcare Conference, Feb 27, 2019 through Mar 01, 2019. Venue: Lotte New York Palace Hotel, New York, New York, United States.
42
3/31/201916.85x45.99x50.43x81.59x87.21x$63,259$548.179.14%Feb-19-2019Product-Related AnnouncementIntuitive Surgical, Inc. Announces U.S. Food and Drug Administration Cleared the Ion™ endoluminal System to Enable Minimally Invasive Biopsy in the Peripheral Lung-Intuitive Surgical, Inc. announced that the U.S. Food and Drug Administration (FDA) cleared the Ion™ endoluminal system to enable minimally invasive biopsy in the peripheral lung.
Lung cancer is the world’s leading cause of cancer deaths. Many suspicious lesions found in the lung may be small and difficult to access, which can make obtaining a diagnosis challenging.
The Ion system uses an ultra-thin articulating robotic catheter that can move 180 degrees in all directions. The outer diameter of the catheter is 3.5 mm, which physicians can navigate through small and tortuous airways to reach nodules in any airway segment within the lung. The Ion system’s flexible biopsy needle (called the Flexision Biopsy Needle) can also pass through very tight bends via Ion’s catheter to collect tissue in the peripheral lung. The catheter’s 2mm working channel can also accommodate other biopsy tools, such as biopsy forceps or cytology brushes, if necessary. Intuitive developed the system’s fiber optic shape sensor technology to provide the physician with the precise location and shape information of the catheter throughout the navigation and biopsy process. Intuitive designed the Ion system to easily integrate into existing lung nodule biopsy workflows, as well as existing imaging technology, including fluoroscopy, radial-endobronchial ultrasound, and cone-beam CT.
43
3/31/201916.85x45.99x50.43x81.59x87.21x$60,233$521.9514.63%Feb-06-2019Company Conference PresentationIntuitive Surgical, Inc. Presents at West Pack 2019, Feb-06-2019 02:30 PM-Intuitive Surgical, Inc. Presents at West Pack 2019, Feb-06-2019 02:30 PM. Venue: Anaheim, United States. Speakers: Kyle Miller.
44
3/31/201916.85x45.99x50.43x81.59x87.21x$60,342$522.8914.42%Feb-05-2019ConferenceUBM plc, West Pack 2019, Feb 05, 2019 through Feb 07, 2019Insulet Corporation (NasdaqGS:PODD), Altair Engineering Inc. (NasdaqGS:ALTR), Autodesk, Inc. (NasdaqGS:ADSK), Cardiovascular Systems, Inc. (NasdaqGS:CSII), PolyOne Corporation (NYSE:POL), HP Inc. (NYSE:HPQ), Eastman Chemical Company (NYSE:EMN), International Business Machines Corporation (NYSE:IBM), Merck & Co., Inc. (NYSE:MRK), Owens Corning (NYSE:OC), Boston Scientific Corporation (NYSE:BSX), Celanese Corporation (NYSE:CE), Proto Labs, Inc. (NYSE:PRLB), Inspire Medical Systems, Inc. (NYSE:INSP), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), Mitsubishi Chemical Holdings Corporation (TSE:4188), Nestlé S.A. (SWX:NESN), Koninklijke DSM N.V. (ENXTAM:DSM), SRI International, Inc., Sotera Health LLC, Tekni-Plex, Inc., Pharmaceutical Product Development, LLC, Branson Corporation, United Technologies Research Center, Battelle Memorial Institute, Inc., Dow Silicones Corporation, MicroVention, Inc., Medtronic MiniMed, Inc., E. I. du Pont de Nemours and Company, Sparton Corporation, UBM plc, Yaskawa America, Inc., University of Southern California, BASF Corporation, Latham & Watkins LLP, NSF International Inc., Solvay Specialty Polymers USA, L.L.C., L.E.K. Consulting LLC, British Standards Institution, Terumo Cardiovascular Systems Corporation, FANUC America Corporation, The University of California, San Francisco, Mayo Clinic, Edwards Lifesciences LLC, Ogilvy CommonHealth Worldwide LLC, Carl Zeiss Industrial Metrology LLC, Whitford Corporation, Banner Engineering Corp., Teel Plastics, Inc., California Manufacturing Technology Consulting, Inc., North American Science Associates, Inc., Arburg Inc, Toxikon Corp., Johnson & Johnson, Inc., Replenish, Inc., Eos Of North America, Inc., StarFish Product Engineering Inc., Ximedica, LLC, Metaphase Design Group, Inc, Hogan Lovells US LLP, Electro-Core, Inc., Kinsale Holdings, Inc., DiabetesMine.com, Back Bay Life Science Advisors, Cactus Semiconductor, Inc., Mueller Prost PC, Children's Hospital of Orange County, Applied Medical Inc., W.S. Badger Company, Inc., Dollar Shave Club, Inc., Novatec Inc, Innovize, Inc., Kc Pharmaceuticals Inc., OPS Solutions,LLC, CorInnova, Inc, GE Healthcare Inc., Kablooe Design, Prescient Surgical, Inc., Neural Analytics, Inc., Advanced Molding Technology, Inc., Procept Biorobotics Corp., Packsize LLC, Design Concepts Inc, Fathom, LLC, Product Creation Studio Ltd., Medtronic, Inc., Thrive Market, Inc., Fast Radius, Inc., Element22 LLC, Qure Medical, Carbon, Inc., Bigfoot Biomedical, Inc., Nalu Medical, Inc., Scope Technologies US Inc., Acknowledge - Regulatory Strategies, Elemental Machines, Inc., R. D. Abbott Co., Inc., inVia Robotics, LLC, Beta Bionics, Inc., natals, Inc., Universal Robots (USA), Inc., PostProcess Technologies Inc., Mcr Integrated Design Systems, Inc., Valeritas, Inc., Birlasoft Inc., 3DEO, Inc., Praxair, Inc., Vascular Sciences, Rramac Connected Systems, Bex Brands, LLC, 3Diligent Corporation, Ultimaker USA Inc., H&M Consulting Group, LLC, Dogtown Media, LLC, GE Additive, The Advanced Robotics for Manufacturing (ARM) Institute, Marquee Staffing, Waypoint Robotics, Inc., The Cedars-Sinai Accelerator, Oden Technologies Inc., MED Institute Inc, Farmgirl Flowers Inc., Essentium, Inc., ParaMatters Inc., OSKA, Inc., Packaging Digest, VYTAL Group, TransAutomation Technologies Inc., Tera Engineering Co., Springborne Life Sciences, Research Collective, LLC, Precys, Nectar Product Development, Kim Walker Consulting, Isometric Micro Molding, Inc., Inductive Intelligence LLC, Healthcare Evolution, Inc., Phasium, Formalloy, Betten Systems Solutions LLC, UpStart Product Development LLC, University of Southern California Liquid Propulsion Laboratory, Smartest Systems, Singer Instruments & Control, Ltd., HirLan, Inc., Fracture Labs, LLC, ElectroFab Sales, Eisner Safety Consultants, DesignAbly, Centaur Sports Medicine LLC, Centennial Software Solutions LLC, Additive Manufacturing Technologies Limited, Sterigenics U.S., LLC, Siemens Product Lifecycle Management Software Inc., California State University, Northridge, The Alfred E Mann Foundation For Scientific Research, Lapp USA, Inc., Clariant Produkte (Deutschland) GmbH, Choc Health Alliance, Nihon Kohden America, Inc., Nelson Laboratories, Inc., CeloNova Biosciences, Inc., Jet Propulsion Laboratory, The U.S. Small Business Administration, Accenture LLP, M3 Design Inc., Instrumental, Inc., Greenleaf Ventures, Inc., Lux Research Inc., Samtec, Inc., ZPower, Inc., Lawrence Berkeley National Laboratory, LLC, Sotera Wireless, Inc., Johnson Matthey Inc., DyAnsys Inc., AirXpanders, Inc., IBM Thomas J. Watson Research Center, Evolve Manufacturing Technologies, Inc., Applied Manufacturing Technologies, Inc., SetPoint Medical Corporation, Hantel Technologies, Inc., Devicix, LLC, EtherCAT Technology Group, HungaroTrial Ltd., RJG, Inc., Eag Laboratories, Cirtec Medical Corp., Delve LLC, FUTEK Advanced Sensor Technology, Inc., EH Publishing Inc.UBM plc, West Pack 2019, Feb 05, 2019 through Feb 07, 2019. Venue: Anaheim, United States.
45
3/31/201916.85x45.99x50.43x81.59x87.21x$60,428$523.6414.26%Jan-31-2019Buyback - Change in Plan TermsIntuitive Surgical, Inc. announces an Increase in Equity Buyback.-On January 31, 2019, the company announced an increase in its equity buyback plan. The company increased its remaining authorization to $2,000 million.
46
3/31/201916.85x45.99x50.43x81.59x87.21x$61,868$536.1211.60%Jan-24-2019Earnings CallIntuitive Surgical, Inc., Q4 2018 Earnings Call, Jan 24, 2019-Intuitive Surgical, Inc., Q4 2018 Earnings Call, Jan 24, 2019
47
3/31/201916.85x45.99x50.43x81.59x87.21x$61,868$536.1211.60%Jan-24-2019Announcement of EarningsIntuitive Surgical, Inc. Announces Earnings Results of Fourth Quarter and Year Ended December 31, 2018-Intuitive Surgical, Inc. announced earnings results of fourth quarter and year ended December 31, 2018. For the quarter, the company reported revenue of $1,046.5 million against $892.0 million a year ago. Income from operations was $332.0 million against $329.0 million a year ago. Net income was $291.3 million against loss $31.5 million a year ago. Earnings per basic share was $2.56 against loss of $0.28 and earnings per diluted share was $2.45 against loss $0.28 a year ago.


For the year, the company reported revenue of $3,724.2 million against $3,138.2 million a year ago. Income from operations was $1,199.4 million against $1,062.9 million a year ago. Net income was $1,125.0 million against $670.9 million a year ago. Earnings per basic share was $9.92 against $6.01 and earnings per diluted share was $9.49 against $5.77 a year ago.
48
3/31/201916.85x45.99x50.43x81.59x87.21x$61,868$536.1211.60%Jan-24-2019Earnings Release DateIntuitive Surgical, Inc. to Report Q4, 2018 Results on Jan 24, 2019-Intuitive Surgical, Inc. announced that they will report Q4, 2018 results at 7:05 PM, GMT Standard Time on Jan 24, 2019
49
3/31/201916.85x45.99x50.43x81.59x87.21x$61,868$536.1211.60%Jan-24-2019Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From October 1, 2018 to December 31, 2018, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 8,636,190 shares, representing 7.47% for $2,226.25 million under the buyback announced on February 2, 2015.
50
3/31/201916.85x45.99x50.43x81.59x87.21x$59,785$518.0715.48%Jan-10-2019Company Conference PresentationIntuitive Surgical, Inc. Presents at JP Morgan 37th Annual Healthcare conference, Jan-10-2019 09:00 AM-Intuitive Surgical, Inc. Presents at JP Morgan 37th Annual Healthcare conference, Jan-10-2019 09:00 AM. Venue: Westin St. Francis Hotel, Union Square, 335 Powell St., San Francisco, California, United States. Speakers: Gary S. Guthart, CEO, President & Director.
51
3/31/201916.85x45.99x50.43x81.59x87.21x$59,674$517.1115.70%Jan-09-2019Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2018-Intuitive Surgical, Inc. provided revenue guidance for the fourth quarter and full year of 2018. The company expects revenue for the fourth quarter of 2018 of approximately $1.047 billion, an increase of approximately 17% compared with $0.892 billion for the fourth quarter of 2017.

The company expects 2018 revenue of approximately $3.724 billion, an increase of approximately 19% compared with $3.138 billion for 2017.
52
3/31/201916.85x45.99x50.43x81.59x87.21x$55,212$478.4425.05%Jan-07-2019ConferenceJPMorgan Chase & Co., JP Morgan 37th Annual Healthcare conference, Jan 07, 2019 through Jan 10, 2019Quidel Corporation (NasdaqGS:QDEL), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Mirati Therapeutics, Inc. (NasdaqGS:MRTX), Walgreens Boots Alliance, Inc. (NasdaqGS:WBA), CymaBay Therapeutics, Inc. (NasdaqGS:CBAY), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Repligen Corporation (NasdaqGS:RGEN), Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL), Seattle Genetics, Inc. (NasdaqGS:SGEN), Wright Medical Group N.V. (NasdaqGS:WMGI), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), United Therapeutics Corporation (NasdaqGS:UTHR), Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Bio-Techne Corporation (NasdaqGS:TECH), Cerner Corporation (NasdaqGS:CERN), CONMED Corporation (NasdaqGS:CNMD), ICU Medical, Inc. (NasdaqGS:ICUI), Meridian Bioscience, Inc. (NasdaqGS:VIVO), Crinetics Pharmaceuticals, Inc. (NasdaqGS:CRNX), Syneos Health, Inc. (NasdaqGS:SYNH), Axovant Gene Therapies Ltd. (NasdaqGS:AXGT), Denali Therapeutics Inc. (NasdaqGS:DNLI), Gritstone Oncology, Inc. (NasdaqGS:GRTS), Solid Biosciences Inc. (NasdaqGS:SLDB), Kura Oncology, Inc. (NasdaqGS:KURA), IDEAYA Biosciences, Inc. (NasdaqGS:IDYA), Orchard Therapeutics plc (NasdaqGS:ORTX), Aptinyx Inc. (NasdaqGS:APTX), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Twist Bioscience Corporation (NasdaqGS:TWST), Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS), Spero Therapeutics, Inc. (NasdaqGS:SPRO), Jounce Therapeutics, Inc. (NasdaqGS:JNCE), 10x Genomics, Inc. (NasdaqGS:TXG), Aclaris Therapeutics, Inc. (NasdaqGS:ACRS), MyoKardia, Inc. (NasdaqGS:MYOK), Stoke Therapeutics, Inc. (NasdaqGS:STOK), Editas Medicine, Inc. (NasdaqGS:EDIT), Tricida, Inc. (NasdaqGS:TCDA), Guardant Health, Inc. (NasdaqGS:GH), ObsEva SA (NasdaqGS:OBSV), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), Livongo Health, Inc. (NasdaqGS:LVGO), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), HMS Holdings Corp. (NasdaqGS:HMSY), Biogen Inc. (NasdaqGS:BIIB), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Nektar Therapeutics (NasdaqGS:NKTR), Insmed Incorporated (NasdaqGS:INSM), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Masimo Corporation (NasdaqGS:MASI), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), NVIDIA Corporation (NasdaqGS:NVDA), Omnicell, Inc. (NasdaqGS:OMCL), Orthofix Medical Inc. (NasdaqGS:OFIX), Alkermes plc (NasdaqGS:ALKS), Tivity Health, Inc. (NasdaqGS:TVTY), Amgen Inc. (NasdaqGS:AMGN), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Cross Country Healthcare, Inc. (NasdaqGS:CCRN), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Endo International plc (NasdaqGS:ENDP), R1 RCM Inc. (NasdaqGS:RCM), Natera, Inc. (NasdaqGS:NTRA), AnaptysBio, Inc. (NasdaqGS:ANAB), IVERIC bio, Inc. (NasdaqGS:ISEE), iRhythm Technologies, Inc. (NasdaqGS:IRTC), HealthEquity, Inc. (NasdaqGS:HQY), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Intrexon Corporation (NasdaqGS:XON), Conformis, Inc. (NasdaqGS:CFMS), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH), Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), BioNTech SE (NasdaqGS:BNTX), Otonomy, Inc. (NasdaqGS:OTIC), Clovis Oncology, Inc. (NasdaqGS:CLVS), Ascendis Pharma A/S (NasdaqGS:ASND), InflaRx N.V. (NasdaqGS:IFRX), Inovalon Holdings, Inc. (NasdaqGS:INOV), Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST), Kala Pharmaceuticals, Inc. (NasdaqGS:KALA), Adaptive Biotechnologies Corporation (NasdaqGS:ADPT), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), NovoCure Limited (NasdaqGS:NVCR), Apellis Pharmaceuticals, Inc. (NasdaqGS:APLS), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), Chiasma, Inc. (NasdaqGS:CHMA), Puma Biotechnology, Inc. (NasdaqGS:PBYI), Blueprint Medicines Corporation (NasdaqGS:BPMC), Moderna, Inc. (NasdaqGS:MRNA), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Health Catalyst, Inc. (NasdaqGS:HCAT), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), REGENXBIO Inc. (NasdaqGS:RGNX), G1 Therapeutics, Inc. (NasdaqGS:GTHX), Atreca, Inc. (NasdaqGS:BCEL), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Nuance Communications, Inc. (NasdaqGS:NUAN), Amedisys, Inc. (NasdaqGS:AMED), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Endologix, Inc. (NasdaqGS:ELGX), Novavax, Inc. (NasdaqGS:NVAX), Enanta Pharmaceuticals, Inc. (NasdaqGS:ENTA), Mylan N.V. (NasdaqGS:MYL), Patterson Companies, Inc. (NasdaqGS:PDCO), PDL BioPharma, Inc. (NasdaqGS:PDLI), Incyte Corporation (NasdaqGS:INCY), Brooks Automation, Inc. (NasdaqGS:BRKS), Henry Schein, Inc. (NasdaqGS:HSIC), ICON Public Limited Company (NasdaqGS:ICLR), Bruker Corporation (NasdaqGS:BRKR), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Accuray Incorporated (NasdaqGS:ARAY), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), OraSure Technologies, Inc. (NasdaqGS:OSUR), Premier, Inc. (NasdaqGS:PINC), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Inogen, Inc. (NasdaqGS:INGN), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), AngioDynamics, Inc. (NasdaqGS:ANGO), LHC Group, Inc. (NasdaqGS:LHCG), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), Mersana Therapeutics, Inc. (NasdaqGS:MRSN), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), Aduro BioTech, Inc. (NasdaqGS:ADRO), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), ChemoCentryx, Inc. (NasdaqGS:CCXI), Frequency Therapeutics, Inc. (NasdaqGS:FREQ), Vir Biotechnology, Inc. (NasdaqGS:VIR), Scholar Rock Holding Corporation (NasdaqGS:SRRK), Eidos Therapeutics, Inc. (NasdaqGS:EIDX), Oyster Point Pharma, Inc. (NasdaqGS:OYST), MeiraGTx Holdings plc (NasdaqGS:MGTX), BridgeBio Pharma, Inc. (NasdaqGS:BBIO), Rubius Therapeutics, Inc. (NasdaqGS:RUBY), Y-mAbs Therapeutics, Inc. (NasdaqGS:YMAB), Varex Imaging Corporation (NasdaqGS:VREX), Allogene Therapeutics, Inc. (NasdaqGS:ALLO), Kiniksa Pharmaceuticals, Ltd. (NasdaqGS:KNSA), Replimune Group, Inc. (NasdaqGS:REPL), Akero Therapeutics, Inc. (NasdaqGS:AKRO), Urovant Sciences Ltd. (NasdaqGS:UROV), Cabaletta Bio, Inc. (NasdaqGS:CABA), Almirall, S.A. (BME:ALM), New Enterprise Associates, Inc., Array BioPharma Inc., Acelity L.P. Inc., Intas Pharmaceuticals Limited, Ascension Health, Inc., CommonSpirit Health, Kaiser Permanente Inc., BioScrip, Inc., Celgene Corporation, Albany Molecular Research, Inc., GE Healthcare Limited, EndPoints Inc., Novacap, Inc., The Cleveland Clinic Foundation, SomaLogic, Inc., The General Hospital Corporation, AdventHealth, NorthShore University HealthSystem, University of Pittsburgh Medical Center, Bon Secours Mercy Health, Baylor Scott & White Health LLC, Medidata Solutions, Inc., InTouch Technologies, Inc., Genomic Health, Inc., National Institutes of Health, Henry Ford Health System, Intermountain Healthcare, Inc., SSM Health Care Corporation, Mayo Clinic, Northwell Health, Inc., Spectrum Health Systems, Inc., Hartford HealthCare Corporation, Medical College Of Wisconsin, Vizient, Inc., FOX News Network, LLC, Daiichi Sankyo, Inc., Biotechnology Innovation Organization, Lilly USA, LLC, Providence St. Joseph Health, Oregon Health & Science University, Sofinnova SA, Memorial Sloan Kettering Cancer Center, Northwestern Memorial Healthcare Corporation, Borsa Italiana S.p.A., Beacon Health Options, Hospital for Special Surgery, Jefferson Healthcare, U.S. Food and Drug Administration, Proteus Digital Health, Inc., immatics biotechnologies GmbH, Waystar, Inc, GenScript Corporation, Novant Health, Inc., Selexis SA, Aprea Therapeutics AB, Harvard School of Public Health, The Children's Hospital Corporation, BioCentury Publications, Inc., Alder BioPharmaceuticals, Inc., Mevion Medical Systems, Inc., EUSA Pharma, Inc., Rafael Pharmaceuticals, Inc., Cell Medica Limited, Advantagene, Inc., Hapvida Assistência Médica Ltda., PegBio Co., Ltd., TraceLink, Inc., Sharecare Inc., Minerva Surgical Inc., Mitra Biotech Pvt Ltd, Ob Hospitalist Group, Inc., Arrail Dental International Group Co. Ltd., Humacyte, Inc., Welltok, Inc., Quartet, Inc., Vohra Wound Physicians, LLC, Privia Health, LLC, Direct Vet Marketing, Inc., Fountain Biopharma Inc., One Medical Group, Inc., Ginkgo Bioworks, Inc., JLabs, LLC, Peloton Therapeutics, Inc., Geisinger Health System, Columbia Asia Group, Bioventus LLC, GoodRx, Inc., PT Soho Global Healthcare, HitGen Inc., Formation Biologics Inc., GenapSys, Inc., Cohealo Inc., MedAvail Technologies Inc., Spark Therapeutics, Inc., Audentes Therapeutics, Inc., Zymergen, Inc., Maravai Life Sciences Inc., Pear Therapeutics, Inc., Notre Dame Intermédica Saúde S.A., Companion Medical, Inc., Compass Therapeutics LLC, Revolution Medicines, Inc., Outset Medical, Inc., Caris Life Sciences, Inc., Carbon, Inc., China Pharmaceutical Innovation and Research Development Association, Ark Biosciences Inc., Color Genomics, Inc., NantCell, Inc., PHC Holdings Corporation, ORIC Pharmaceuticals, Inc., QuVa Pharma, Inc., Adicet Bio, Inc., Ping An Health Cloud Company Limited, Aerami Therapeutics, Codiak BioSciences, Inc., WuXi Nextcode Genomics, Inc., Roivant Sciences, Inc., CollectiveHealth, Inc., Tmunity Therapeutics, Inc., Freeline Therapeutics Limited, Corvidia Therapeutics, Inc., Pliant Therapeutics, Inc., Biosim Pharmaceuticals, LLC, AiVita Biomedical, Inc., Relay Therapeutics, Inc., Dova Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., BlueRock Therapeutics LP, Tempus Labs, Inc., Mindstrong, Inc., Aetion, Inc., Insight Rx, Inc., SpringWorks Therapeutics, LLC, Foghorn Therapeutics Inc., BenevolentAI Limited, Precigen, Inc., Generation Bio Co., Grace Therapeutics, LLC, Sinovant Sciences Ltd, Legend Biotech Corporation, Softhale NV, WuXi Biologics USA, LLC., We Doctor Holdings Limited, Systems Oncology, LLC, Hypera Pharma, MGI Tech Co., Ltd., Human Technopole Foundation, Concerto HealthAI Solutions LLC, Advocate Aurora Health, Wellforce, Inc., Reprieve Cardiovascular, Inc., EpiVario Inc., Ipsen S.A. (ENXTPA:IPN), NOXXON Pharma N.V. (ENXTPA:ALNOX), Onxeo SA (ENXTPA:ONXEO), Herantis Pharma Oyj (HLSE:HRTIS), Inventiva S.A. (ENXTPA:IVA), Valbiotis SA (ENXTPA:ALVAL), Sanofi (ENXTPA:SAN), Innate Pharma S.A. (ENXTPA:IPH), Transgene SA (ENXTPA:TNG), Valneva SE (ENXTPA:VLA), Adocia SA (ENXTPA:ADOC), GN Store Nord A/S (CPSE:GN), Zealand Pharma A/S (CPSE:ZEAL), Ambu A/S (CPSE:AMBU B), Genmab A/S (CPSE:GMAB), H. Lundbeck A/S (CPSE:LUN), Kamada Ltd. (TASE:KMDA), Daiichi Sankyo Company, Limited (TSE:4568), Otsuka Holdings Co., Ltd. (TSE:4578), Sosei Group Corporation (TSE:4565), NanoCarrier Co., Ltd. (TSE:4571), Eisai Co., Ltd. (TSE:4523), Santen Pharmaceutical Co., Ltd. (TSE:4536), Konica Minolta, Inc. (TSE:4902), Takeda Pharmaceutical Company Limited (TSE:4502), Astellas Pharma Inc. (TSE:4503), SanBio Company Limited (TSE:4592), Healios K.K. (TSE:4593), Dr. Reddy's Laboratories Limited (BSE:500124), Lupin Limited (BSE:500257), Innovent Biologics, Inc. (SEHK:1801), 3SBio Inc. (SEHK:1530), Lee's Pharmaceutical Holdings Limited (SEHK:950), Luye Pharma Group Ltd. (SEHK:2186), Sino Biopharmaceutical Limited (SEHK:1177), Hong Kong Exchanges and Clearing Limited (SEHK:388), WuXi Biologics (Cayman) Inc. (SEHK:2269), Alphamab Oncology (SEHK:9966), TransEnterix, Inc. (AMEX:TRXC), Lineage Cell Therapeutics, Inc. (AMEX:LCTX), Hutchison China MediTech Limited (AIM:HCM), Abcam plc (AIM:ABC), Silence Therapeutics plc (AIM:SLN), Vectura Group plc (LSE:VEC), Smith & Nephew plc (LSE:SN.), GlaxoSmithKline plc (LSE:GSK), Aksa Akrilik Kimya Sanayii A.S. (IBSE:AKSA), Hikma Pharmaceuticals PLC (LSE:HIK), Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B), Galapagos NV (ENXTAM:GLPG), Koninklijke Philips N.V. (ENXTAM:PHIA), Pharming Group N.V. (ENXTAM:PHARM), Celltrion, Inc. (KOSE:A068270), Hanmi Science Co., Ltd. (KOSE:A008930), LG Chem, Ltd. (KOSE:A051910), Samsung Biologics Co.,Ltd. (KOSE:A207940), Kancera AB (publ) (OM:KAN), Moberg Pharma AB (publ) (OM:MOB), Elekta AB (publ) (OM:EKTA B), Vifor Pharma AG (SWX:VIFN), Lonza Group Ltd (SWX:LONN), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), Tecan Group Ltd. (SWX:TECN), Basilea Pharmaceutica AG (SWX:BSLN), Molecular Partners AG (SWX:MOLN), Santhera Pharmaceuticals Holding AG (SWX:SANN), ASIT Biotech S.A. (ENXTBR:ASIT), UCB SA (ENXTBR:UCB), Biocartis Group NV (ENXTBR:BCART), argenx SE (ENXTBR:ARGX), Acrux Limited (ASX:ACR), Immutep Limited (ASX:IMM), CSL Limited (ASX:CSL), Spectral Medical Inc. (TSX:EDT), Aurinia Pharmaceuticals Inc. (TSX:AUP), Profound Medical Corp. (TSX:PRN), ImmunoPrecise Antibodies Ltd. (TSXV:IPA), Instituto Hermes Pardini S.A. (BOVESPA:PARD3), Fleury S.A. (BOVESPA:FLRY3), Raia Drogasil S.A. (BOVESPA:RADL3), Biotoscana Investments S.A. (BOVESPA:GBIO33), Ouro Fino Saúde Animal Participações S.A. (BOVESPA:OFSA3), Vocera Communications, Inc. (NYSE:VCRA), JPMorgan Chase & Co. (NYSE:JPM), JPMorgan Chase & Co. (NYSE:JPM), Edwards Lifesciences Corporation (NYSE:EW), Boston Scientific Corporation (NYSE:BSX), Perrigo Company plc (NYSE:PRGO), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), ResMed Inc. (NYSE:RMD), Bausch Health Companies Inc. (NYSE:BHC), Quest Diagnostics Incorporated (NYSE:DGX), Alexandria Real Estate Equities, Inc. (NYSE:ARE), Molina Healthcare, Inc. (NYSE:MOH), Glaukos Corporation (NYSE:GKOS), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Diplomat Pharmacy, Inc. (NYSE:DPLO), Veeva Systems Inc. (NYSE:VEEV), Nevro Corp. (NYSE:NVRO), Phreesia, Inc. (NYSE:PHR), Penumbra, Inc. (NYSE:PEN), Teladoc Health, Inc. (NYSE:TDOC), Select Medical Holdings Corporation (NYSE:SEM), WellCare Health Plans, Inc. (NYSE:WCG), Emergent BioSolutions Inc. (NYSE:EBS), AbbVie Inc. (NYSE:ABBV), Inspire Medical Systems, Inc. (NYSE:INSP), Catalent, Inc. (NYSE:CTLT), Rite Aid Corporation (NYSE:RAD), CVS Health Corporation (NYSE:CVS), Haemonetics Corporation (NYSE:HAE), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), Tenet Healthcare Corporation (NYSE:THC), Charles River Laboratories International, Inc. (NYSE:CRL), Johnson & Johnson (NYSE:JNJ), QIAGEN N.V. (NYSE:QGEN), Hill-Rom Holdings, Inc. (NYSE:HRC), Medtronic plc (NYSE:MDT), STERIS plc (NYSE:STE), DaVita Inc. (NYSE:DVA), Universal Health Services, Inc. (NYSE:UHS), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Eli Lilly and Company (NYSE:LLY), Welltower Inc. (NYSE:WELL), Owens & Minor, Inc. (NYSE:OMI), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Varian Medical Systems, Inc. (NYSE:VAR), West Pharmaceutical Services, Inc. (NYSE:WST), Baxter International Inc. (NYSE:BAX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Cantel Medical Corp. (NYSE:CMD), The Cooper Companies, Inc. (NYSE:COO), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Danaher Corporation (NYSE:DHR), PerkinElmer, Inc. (NYSE:PKI), Abbott Laboratories (NYSE:ABT), Agilent Technologies, Inc. (NYSE:A), Model N, Inc. (NYSE:MODN), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Humana Inc. (NYSE:HUM), Laboratory Corporation of America Holdings (NYSE:LH), AMN Healthcare Services, Inc. (NYSE:AMN), Encompass Health Corporation (NYSE:EHC), Mettler-Toledo International Inc. (NYSE:MTD), AmerisourceBergen Corporation (NYSE:ABC), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Community Health Systems, Inc. (NYSE:CYH), Veracyte, Inc. (NasdaqGM:VCYT), Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA), Sutro Biopharma, Inc. (NasdaqGM:STRO), Quanterix Corporation (NasdaqGM:QTRX), Verastem, Inc. (NasdaqGM:VSTM), SI-BONE, Inc. (NasdaqGM:SIBN), Retrophin, Inc. (NasdaqGM:RTRX), Axcella Health Inc. (NasdaqGM:AXLA), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Adverum Biotechnologies, Inc. (NasdaqGM:ADVM), Sage Therapeutics, Inc. (NasdaqGM:SAGE), GW Pharmaceuticals plc (NasdaqGM:GWPH), Acceleron Pharma Inc. (NasdaqGM:XLRN), NanoString Technologies, Inc. (NasdaqGM:NSTG), Radius Health, Inc. (NasdaqGM:RDUS), MediciNova, Inc. (NasdaqGM:MNOV), ViewRay, Inc. (NasdaqGM:VRAY), Intersect ENT, Inc. (NasdaqGM:XENT), Akebia Therapeutics, Inc. (NasdaqGM:AKBA), AtriCure, Inc. (NasdaqGM:ATRC), Chimerix, Inc. (NasdaqGM:CMRX), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), Oxford Immunotec Global PLC (NasdaqGM:OXFD), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Rockwell Medical, Inc. (NasdaqGM:RMTI), Amarin Corporation plc (NasdaqGM:AMRN), Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), Affimed N.V. (NasdaqGM:AFMD), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), Immunomedics, Inc. (NasdaqGM:IMMU), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), UroGen Pharma Ltd. (NasdaqGM:URGN), Clearside Biomedical, Inc. (NasdaqGM:CLSD), Zai Lab Limited (NasdaqGM:ZLAB), RAPT Therapeutics, Inc. (NasdaqGM:RAPT), Rhythm Pharmaceuticals, Inc. (NasdaqGM:RYTM), 111, Inc. (NasdaqGM:YI), Morphic Holding, Inc. (NasdaqGM:MORF), Magenta Therapeutics, Inc. (NasdaqGM:MGTA), Avantor, Inc. (NYSE:AVTR), Myovant Sciences Ltd. (NYSE:MYOV), Elanco Animal Health Incorporated (NYSE:ELAN), Avanos Medical, Inc. (NYSE:AVNS), Zoetis Inc. (NYSE:ZTS), Invitae Corporation (NYSE:NVTA), Evolent Health, Inc. (NYSE:EVH), Mallinckrodt plc (NYSE:MNK), Cannabics Pharmaceuticals Inc. (OTCPK:CNBX), Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q), Generex Biotechnology Corporation (OTCPK:GNBT), INSYS Therapeutics, Inc. (OTCPK:INSY.Q), Apollo Hospitals Enterprise Limited (NSEI:APOLLOHOSP), Cadila Healthcare Limited (NSEI:CADILAHC), Glenmark Pharmaceuticals Limited (NSEI:GLENMARK), Aurobindo Pharma Limited (NSEI:AUROPHARMA), Cipla Limited (NSEI:CIPLA), Medigene AG (XTRA:MDG1), MorphoSys AG (XTRA:MOR), Biofrontera AG (XTRA:B8F), Heidelberg Pharma AG (XTRA:WL6), Siemens Healthineers AG (XTRA:SHL), Kolon TissueGene, Inc. (KOSDAQ:A950160), Helixmith Co., Ltd (KOSDAQ:A084990), Medy-Tox Inc. (KOSDAQ:A086900), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Evotec SE (XTRA:EVT), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), Fresenius SE & Co. KGaA (XTRA:FRE), Heron Therapeutics, Inc. (NasdaqCM:HRTX), Heska Corporation (NasdaqCM:HSKA), La Jolla Pharmaceutical Company (NasdaqCM:LJPC), Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), Exact Sciences Corporation (NasdaqCM:EXAS), Athersys, Inc. (NasdaqCM:ATHX), MRI Interventions, Inc. (NasdaqCM:MRIC), AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO), VistaGen Therapeutics, Inc. (NasdaqCM:VTGN), Onconova Therapeutics, Inc. (NasdaqCM:ONTX), Dynavax Technologies Corporation (NasdaqCM:DVAX), Accelerate Diagnostics, Inc. (NasdaqCM:AXDX), Diffusion Pharmaceuticals Inc. (NasdaqCM:DFFN), Brainstorm Cell Therapeutics Inc. (NasdaqCM:BCLI), Stemline Therapeutics, Inc. (NasdaqCM:STML), ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP), TG Therapeutics, Inc. (NasdaqCM:TGTX), CohBar, Inc. (NasdaqCM:CWBR), vTv Therapeutics Inc. (NasdaqCM:VTVT), BioXcel Therapeutics, Inc. (NasdaqCM:BTAI), Taiwan Liposome Company, Ltd. (GTSM:4152), OBI Pharma, Inc. (GTSM:4174), PharmaEngine, Inc. (GTSM:4162)JPMorgan Chase & Co., JP Morgan 37th Annual Healthcare conference, Jan 07, 2019 through Jan 10, 2019. Venue: Westin St. Francis Hotel, Union Square, 335 Powell St., San Francisco, California, United States.
53
12/31/201814.48x38.40x41.83x69.69x71.79x$58,173$508.0617.76%Dec-11-2018M&A Transaction ClosingIntuitive Surgical Medical Device Taiwan Ltd. completed the acquisition of Unison Surgicals Company from individual sellers.Unison Surgicals CompanyIntuitive Surgical Medical Device Taiwan Ltd. agreed to acquire Unison Surgicals Company from individual sellers on October 19, 2018. Alan Mendelson from Latham & Watkins LLP acted as the legal advisor for Intuitive Surgical, Inc.


Intuitive Surgical Medical Device Taiwan Ltd. completed the acquisition of Unison Surgicals Company from individual sellers on December 11, 2018.
54
12/31/201814.48x38.40x41.83x69.69x71.79x$60,785$530.8712.70%Nov-30-2018M&A Transaction AnnouncementIntuitive Surgical Medical Device Taiwan Ltd. agreed to acquire an unknown stake Unison Surgicals Company from individual sellers.Unison Surgicals CompanyIntuitive Surgical Medical Device Taiwan Ltd. agreed to acquire Unison Surgicals Company from individual sellers on October 19, 2018. Alan Mendelson from Latham & Watkins LLP acted as the legal advisor for Intuitive Surgical, Inc.
55
12/31/201814.48x38.40x41.83x69.69x71.79x$60,978$532.5612.34%Nov-09-2018Executive/Board Change - OtherIntuitive Surgical, Inc. Names Austin Kim as Vice President and General Manager in Korea-Intuitive Surgical, Inc. has named Austin Kim as Vice President and General Manager in Korea, where he will direct business strategy and operations for the company. Intuitive pioneered the field of robotic-assisted, minimally invasive surgery with the creation of its da Vinci Surgical System. Now on its fourth-generation system, the Silicon Valley-based company has seen more than five million robotic-assisted surgical procedures performed worldwide, and more than 43,000 physicians worldwide trained on da Vinci systems. Kim brings more than 25 years of experience in the life sciences industry, including healthcare, government, and academia, and has developed extensive knowledge and expertise working in diverse markets, including the Asia Pacific region, India, China, Brazil, and the Americas. Kim has led successful teams in the delivery of enterprise solutions. Most recently, he was the general manager in Korea for Agilent Technology, where he oversaw all aspects of the business from sales, marketing, service, finance, and regulatory affairs.
56
12/31/201814.48x38.40x41.83x69.69x71.79x$58,556$511.4116.99%Oct-22-2018Lawsuits & Legal IssueLabaton Sucharow LLP Announces Proposed Class Action Settlement with Intuitive Surgical, Inc-Labaton Sucharow LLP announced pursuant to an Order of the United States District Court for the Northern District of California, that Class Representatives Employees' Retirement System of the State of Hawaii and Greater Pennsylvania Carpenters' Pension Fund, on behalf of themselves and the certified Class, and Intuitive Surgical, Inc., Gary S. Guthart, Marshall L. Mohr, and Lonnie M. Smith (collectively, the ‘Defendants’), have reached a settlement in the amount of $42,500,000 in cash that, if approved by the Court, will resolve all claims in the Action. A hearing will be held before the Honorable Edward J. Davila of the United States District Court for the Northern District of California in Courtroom 4, 5th Floor, Robert F. Peckham Federal Building & United States Courthouse, 280 South 1st Street, San Jose, CA 95113 at 10:00 a.m. on December 20, 2018 to, among other things, determine whether (1) the Settlement should be approved by the Court as fair, reasonable, and adequate; (2) the Plan of Allocation for distribution of the Settlement Amount, and any interest thereon, less Court-awarded attorneys' fees, Notice and Administration Expenses, Taxes, and any other costs, fees, or expenses approved by the Court should be approved as fair, reasonable, and adequate; and (3) to approve the application of Class Counsel for an award of attorneys' fees of no more than 19% of the Settlement Fund (or up to $8,075,000) and payment of expenses of no more than $2,500,000 from the Settlement Fund, which will include the expenses of Class Representatives pursuant to the Private Securities Litigation Reform Act of 1995.
57
12/31/201814.48x38.40x41.83x69.69x71.79x$59,802$522.2914.55%Oct-18-2018Earnings CallIntuitive Surgical, Inc., Q3 2018 Earnings Call, Oct 18, 2018-Intuitive Surgical, Inc., Q3 2018 Earnings Call, Oct 18, 2018
58
12/31/201814.48x38.40x41.83x69.69x71.79x$59,802$522.2914.55%Oct-18-2018Corporate Guidance - New/Confirmed, Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018; Provides Earnings Guidance for the Year 2018-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2018. For the quarter, the company’s total revenue was $920.9 million compared with $807.8 million a year ago. Income from operations was $313.3 million compared with $280.6 million a year ago. Income before taxes was $335.2 million compared with $291.4 million a year ago. Net income was $291.8 million compared with $298.6 million a year ago. Diluted net income per share was $2.45 compared with $2.56 a year ago. Non-GAAP income from operations was $390.6 million compared with $349.1 million a year ago. Non-GAAP net income was $337.0 million compared with $324.9 million a year ago. Diluted non-GAAP net income per share was $2.83 compared with $2.78 a year ago. Net income attributable to company was $292.5 million compared with $298.6 million a year ago. Capital placement performance in the third quarter was strong with growth in total placements over third quarter of 2017 rising 37% from 169 to 231 this quarter. Total recurring revenue in the quarter was $660 million.


For the nine months, the company reported total revenue was $2,677.7 million compared with $2,246.2 million a year ago. Income from operations was $867.4 million compared with $733.9 million a year ago. Income before taxes was $920.7 million compared with $763.5 million a year ago. Net income was $833.7 million compared with $702.4 million a year ago. Diluted net income per share was $7.04 compared with $6.06 a year ago. Non-GAAP income from operations was $1,125.6 million compared with $929.8 million a year ago. Non-GAAP net income was $951.9 million compared with $751.8 million a year ago. Diluted non-GAAP net income per share was $8.03 compared with $6.49 a year ago. Net income attributable to company was $835.4 million compared with $702.4 million a year ago.

The company forecast 2018 pro forma gross profit margin to be within a range of between 70% and 71.5% of net revenue. The company now retiring the lower end of the range and expect pro forma gross profit margin to be between 70.5% and 71.5% of net revenue. The company previous forecasts 2018 pro forma income tax rates to be between 19.5% and 20.5% of pretax income. The company now shifting estimates slightly lowers to a range between 19% and 20% of pretax income.
59
12/31/201814.48x38.40x41.83x69.69x71.79x$59,802$522.2914.55%Oct-18-2018Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From July 1, 2018 to September 30, 2018, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 8,636,190 shares, representing 7.47% for $2,226.25 million under the buyback announced on February 2, 2015.
60
12/31/201814.48x38.40x41.83x69.69x71.79x$62,163$542.9110.20%Oct-16-2018Company Conference PresentationIntuitive Surgical, Inc. Presents at Technology Services World Las Vegas 2018, Oct-16-2018 01:30 PM-Intuitive Surgical, Inc. Presents at Technology Services World Las Vegas 2018, Oct-16-2018 01:30 PM. Venue: ARIA Resort & Casino, Las Vegas, United States. Speakers: Suzanne Davison, Sr. Director, Customer Engagement.
61
12/31/201814.48x38.40x41.83x69.69x71.79x$59,459$519.2915.21%Oct-15-2018ConferenceTechnology Services Industry Association, Technology Services World Las Vegas 2018, Oct 15, 2018 through Oct 18, 2018Cisco Systems, Inc. (NasdaqGS:CSCO), Microsoft Corporation (NasdaqGS:MSFT), Microsoft Corporation (NasdaqGS:MSFT), Workday, Inc. (NasdaqGS:WDAY), Workday, Inc. (NasdaqGS:WDAY), Mimecast Limited (NasdaqGS:MIME), Zscaler, Inc. (NasdaqGS:ZS), NetScout Systems, Inc. (NasdaqGS:NTCT), PTC Inc. (NasdaqGS:PTC), Zebra Technologies Corporation (NasdaqGS:ZBRA), Citrix Systems, Inc. (NasdaqGS:CTXS), LogMeIn, Inc. (NasdaqGS:LOGM), Blackboard Inc., Ellucian Company L.P., Informatica LLC, The Ultimate Software Group, Inc., Changepoint Corporation, Changepoint Corporation, Deltek, Inc., FinancialForce.com, inc., FinancialForce.com, inc., Technology Services Industry Association, Technology Services Industry Association, Rtm Consulting LLC, ANCILE Solutions, Inc., Tricentis GmbH, Mavenlink, LLC, Mavenlink, LLC, DB Kay & Associates, Inc., Pretium Partners, Inc., Value and Pricing Partners, LLC, KeyedIn Solutions, Inc., KeyedIn Solutions, Inc., Gainsight, Inc., Gainsight, Inc., Gigamon Inc., nCino, Inc., iasset.com, Inc, YourPeople, Inc., Skilljar Inc., ImageNet Consulting, LLC, Kimble Applications Limited, Kimble Applications Limited, Rubrik, Inc., Miller Heiman Group, Inc., Answer 1 Communications, inc., Compugen USA, Inc, Emerson Automation Solutions, Totango, INC, Totango, INC, Konica Minolta Healthcare Americas, Inc., CSM Practice, Inc, TOP Step Consulting Inc., Grazitti Interactive, Grazitti Interactive, VMI Collective, nVision Consulting Group Inc, LIFTinnovate LLC, Klever Insight, PS Principles LLC, Tangoe, Inc., Ivanti Software, Inc., Riverbed Technology, Inc., Dimension Data North America, Inc., W.S. Emerson Company, Inc., Foss North America, Inc., ServiceSource, Inc., ServiceSource, Inc., JDA Software, Inc., Service 800, Inc., EnBW Energy Solutions GmbH, SumTotal Systems, LLC, Tableau Software, Inc., Sutherland Lumber Company, LP, Hitachi Vantara Corporation, Imprivata, Inc., TransLogic Corporation, Coveo Solutions Inc., Clarizen, Inc., Clarizen, Inc., CSS Corp., Aha!, Acquia Inc., Phase2 Technology, Inc., Waterstone Management Group, LLC, Oracle Corporation (NYSE:ORCL), Palo Alto Networks, Inc. (NYSE:PANW), ServiceNow, Inc. (NYSE:NOW), ServiceNow, Inc. (NYSE:NOW), Guidewire Software, Inc. (NYSE:GWRE), Juniper Networks, Inc. (NYSE:JNPR), NCR Corporation (NYSE:NCR), General Electric Company (NYSE:GE), Emerson Electric Co. (NYSE:EMR), Pitney Bowes Inc. (NYSE:PBI), Rockwell Automation, Inc. (NYSE:ROK), Motorola Solutions, Inc. (NYSE:MSI), HP Inc. (NYSE:HPQ), HP Inc. (NYSE:HPQ), FedEx Corporation (NYSE:FDX), VMware, Inc. (NYSE:VMW), Ciena Corporation (NYSE:CIEN), SAP SE (XTRA:SAP)Technology Services Industry Association, Technology Services World Las Vegas 2018, Oct 15, 2018 through Oct 18, 2018. Venue: ARIA Resort & Casino, Las Vegas, United States.
62
9/30/201818.09x47.41x51.48x85.27x82.21x$64,087$561.186.61%Sep-20-2018Client AnnouncementInTouch Health Signs Multi-Year Licensing Service Agreement with Intuitive Surgical, IncInTouch Technologies, Inc.InTouch Health announced it has signed a multi-year licensing service agreement with Intuitive Surgical, Inc. Under the agreement, the two companies will collaborate to deepen Intuitive's Internet of Medical Things (IoMT) network to connect into thousands of da Vinci surgical systems in medical institutions around the world on a single global network. InTouch Health's proprietary IoMT network will enable healthcare companies like Intuitive, to connect directly to their surgical systems worldwide to exchange real-time data for enhanced clinical insights, proactive service and maintenance monitoring, surgical collaboration between disparate locations, and the ability to extract data for data analytics and machine learning.
63
9/30/201818.09x47.41x51.48x85.27x82.21x$63,817$558.827.06%Sep-13-2018Company Conference PresentationIntuitive Surgical, Inc. Presents at Morgan Stanley 16th Annual Global Healthcare Conference, Sep-13-2018 08:00 AM-Intuitive Surgical, Inc. Presents at Morgan Stanley 16th Annual Global Healthcare Conference, Sep-13-2018 08:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Calvin Darling, Senior Director of IR.
64
9/30/201818.09x47.41x51.48x85.27x82.21x$62,399$546.409.50%Sep-11-2018ConferenceMedtechWomen, MedtechVision 2018: the Impact of AI on Medicine, Sep 11, 2018Livongo Health, Inc. (NasdaqGS:LVGO), iRhythm Technologies, Inc. (NasdaqGS:IRTC), Abbott Laboratories (NYSE:ABT), Edwards Lifesciences Corporation (NYSE:EW), Kilpatrick Townsend & Stockton LLP, Venable LLP, Fish & Richardson P.C., Proteus Digital Health, Inc., Lazar Partners Ltd., BioQuest, Inc., HeartFlow, Inc., Experien Group, LLC, Ginger.io, Inc., Arterys Inc., Procept Biorobotics Corp., HealthReveal, Inc., Google LLC, GRAIL, Inc., KenSci Inc., MedtechWomen, MedTech ColorMedtechWomen, MedtechVision 2018: The Impact of AI on Medicine, Sep 11, 2018. Venue: Rosewood Hotel, 2825 Sand Hill Rd, Menlo Park, California, United States.
65
9/30/201818.09x47.41x51.48x85.27x82.21x$62,399$546.409.50%Sep-11-2018Company Conference PresentationIntuitive Surgical, Inc. Presents at MedtechVision 2018: The Impact of AI on Medicine, Sep-11-2018-Intuitive Surgical, Inc. Presents at MedtechVision 2018: The Impact of AI on Medicine, Sep-11-2018 . Venue: Rosewood Hotel, 2825 Sand Hill Rd, Menlo Park, California, United States.
66
9/30/201818.09x47.41x51.48x85.27x82.21x$61,883$541.8810.41%Sep-10-2018ConferenceMorgan Stanley, Morgan Stanley 16th Annual Global Healthcare Conference, Sep 10, 2018 through Sep 14, 2018Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Natus Medical Incorporated (NasdaqGS:NTUS), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Biogen Inc. (NasdaqGS:BIIB), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Masimo Corporation (NasdaqGS:MASI), LivaNova PLC (NasdaqGS:LIVN), Cytokinetics, Incorporated (NasdaqGS:CYTK), Endo International plc (NasdaqGS:ENDP), Amgen Inc. (NasdaqGS:AMGN), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Autolus Therapeutics plc (NasdaqGS:AUTL), AVROBIO, Inc. (NasdaqGS:AVRO), Forty Seven, Inc. (NasdaqGS:FTSV), Evelo Biosciences, Inc. (NasdaqGS:EVLO), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Syndax Pharmaceuticals, Inc. (NasdaqGS:SNDX), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Inogen, Inc. (NasdaqGS:INGN), Portola Pharmaceuticals, Inc. (NasdaqGS:PTLA), AngioDynamics, Inc. (NasdaqGS:ANGO), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Blueprint Medicines Corporation (NasdaqGS:BPMC), REGENXBIO Inc. (NasdaqGS:RGNX), Epizyme, Inc. (NasdaqGS:EPZM), Clovis Oncology, Inc. (NasdaqGS:CLVS), Kala Pharmaceuticals, Inc. (NasdaqGS:KALA), Assembly Biosciences, Inc. (NasdaqGS:ASMB), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), Adaptimmune Therapeutics plc (NasdaqGS:ADAP), BeiGene, Ltd. (NasdaqGS:BGNE), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), iRhythm Technologies, Inc. (NasdaqGS:IRTC), Ascendis Pharma A/S (NasdaqGS:ASND), Neon Therapeutics, Inc. (NasdaqGS:NTGN), Rubius Therapeutics, Inc. (NasdaqGS:RUBY), Unity Biotechnology, Inc. (NasdaqGS:UBX), Voyager Therapeutics, Inc. (NasdaqGS:VYGR), Unum Therapeutics Inc. (NasdaqGS:UMRX), Denali Therapeutics Inc. (NasdaqGS:DNLI), Editas Medicine, Inc. (NasdaqGS:EDIT), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), MyoKardia, Inc. (NasdaqGS:MYOK), Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS), Fluidigm Corporation (NasdaqGS:FLDM), Bruker Corporation (NasdaqGS:BRKR), Luminex Corporation (NasdaqGS:LMNX), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), CONMED Corporation (NasdaqGS:CNMD), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Assertio Therapeutics, Inc. (NasdaqGS:ASRT), Nuance Communications, Inc. (NasdaqGS:NUAN), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Enanta Pharmaceuticals, Inc. (NasdaqGS:ENTA), Anika Therapeutics, Inc. (NasdaqGS:ANIK), Incyte Corporation (NasdaqGS:INCY), DexCom, Inc. (NasdaqGS:DXCM), Bio-Techne Corporation (NasdaqGS:TECH), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), ICU Medical, Inc. (NasdaqGS:ICUI), Hologic, Inc. (NasdaqGS:HOLX), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Agiliti Health, Inc., Cambrex Corporation, Celgene Corporation, Alder BioPharmaceuticals, Inc., Loxo Oncology, Inc., Audentes Therapeutics, Inc., Clementia Pharmaceuticals Inc., Grace Therapeutics, LLC, Knight Therapeutics Inc. (TSX:GUD), Celyad SA (ENXTBR:CYAD), UCB SA (ENXTBR:UCB), Elekta AB (publ) (OM:EKTA B), Recipharm AB (publ) (OM:RECI B), Koninklijke Philips N.V. (ENXTAM:PHIA), Mediclinic International plc (LSE:MDC), Vifor Pharma AG (SWX:VIFN), Basilea Pharmaceutica AG (SWX:BSLN), Molecular Partners AG (SWX:MOLN), Hutchison China MediTech Limited (AIM:HCM), Zealand Pharma A/S (CPSE:ZEAL), ALK-Abelló A/S (CPSE:ALK B), Genmab A/S (CPSE:GMAB), Novo Nordisk A/S (CPSE:NOVO B), Sanofi (ENXTPA:SAN), DBV Technologies S.A. (ENXTPA:DBV), Cellectis S.A. (ENXTPA:ALCLS), ERYTECH Pharma S.A. (ENXTPA:ERYP), Genfit SA (ENXTPA:GNFT), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Fresenius SE & Co. KGaA (XTRA:FRE), Sartorius Aktiengesellschaft (XTRA:SRT), Siemens Healthineers AG (XTRA:SHL), Melinta Therapeutics, Inc. (OTCPK:MLNT.Q), Nuvectra Corporation (OTCPK:NVTR.Q), Arcus Biosciences, Inc. (NYSE:RCUS), Omeros Corporation (NasdaqGM:OMER), Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT), ViewRay, Inc. (NasdaqGM:VRAY), Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA), Radius Health, Inc. (NasdaqGM:RDUS), Acceleron Pharma Inc. (NasdaqGM:XLRN), MediciNova, Inc. (NasdaqGM:MNOV), NanoString Technologies, Inc. (NasdaqGM:NSTG), AtriCure, Inc. (NasdaqGM:ATRC), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), Chimerix, Inc. (NasdaqGM:CMRX), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), Akebia Therapeutics, Inc. (NasdaqGM:AKBA), OrthoPediatrics Corp. (NasdaqGM:KIDS), Fate Therapeutics, Inc. (NasdaqGM:FATE), Veracyte, Inc. (NasdaqGM:VCYT), Rhythm Pharmaceuticals, Inc. (NasdaqGM:RYTM), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Phibro Animal Health Corporation (NasdaqGM:PAHC), Immunomedics, Inc. (NasdaqGM:IMMU), Boston Scientific Corporation (NYSE:BSX), AbbVie Inc. (NYSE:ABBV), Avanos Medical, Inc. (NYSE:AVNS), Quorum Health Corporation (NYSE:QHC), Catalent, Inc. (NYSE:CTLT), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Diplomat Pharmacy, Inc. (NYSE:DPLO), Globus Medical, Inc. (NYSE:GMED), WellCare Health Plans, Inc. (NYSE:WCG), Emergent BioSolutions Inc. (NYSE:EBS), Penumbra, Inc. (NYSE:PEN), Nevro Corp. (NYSE:NVRO), Hill-Rom Holdings, Inc. (NYSE:HRC), AmerisourceBergen Corporation (NYSE:ABC), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Humana Inc. (NYSE:HUM), Medtronic plc (NYSE:MDT), QIAGEN N.V. (NYSE:QGEN), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Charles River Laboratories International, Inc. (NYSE:CRL), CVS Health Corporation (NYSE:CVS), Haemonetics Corporation (NYSE:HAE), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Becton, Dickinson and Company (NYSE:BDX), Ingersoll-Rand Plc (NYSE:IR), Invacare Corporation (NYSE:IVC), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), West Pharmaceutical Services, Inc. (NYSE:WST), International Business Machines Corporation (NYSE:IBM), Johnson & Johnson (NYSE:JNJ), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), Edwards Lifesciences Corporation (NYSE:EW), Morgan Stanley (NYSE:MS), Vocera Communications, Inc. (NYSE:VCRA), ResMed Inc. (NYSE:RMD), Bausch Health Companies Inc. (NYSE:BHC), Quest Diagnostics Incorporated (NYSE:DGX), Baxter International Inc. (NYSE:BAX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Danaher Corporation (NYSE:DHR), PerkinElmer, Inc. (NYSE:PKI), Exact Sciences Corporation (NasdaqCM:EXAS), PolarityTE, Inc. (NasdaqCM:PTE), AxoGen, Inc. (NasdaqCM:AXGN), Brainstorm Cell Therapeutics Inc. (NasdaqCM:BCLI)Morgan Stanley, Morgan Stanley 16th Annual Global Healthcare Conference, Sep 10, 2018 through Sep 14, 2018. Venue: Grand Hyatt, New York, New York, United States.
67
9/30/201818.09x47.41x51.48x85.27x82.21x$61,880$541.8610.41%Sep-06-2018Product-Related AnnouncementIntuitive Surgical, Inc. Submits New Robotic-Assisted Platform to FDA for Obtaining Lung Biopsies-Intuitive Surgical, Inc. announced it has submitted a premarket notification to the U.S. Food and Drug Administration (FDA) for the company’s new flexible robotic-assisted, catheter-based platform, designed to navigate through very small lung airways to reach peripheral nodules for biopsies. Lung cancer is the world’s leading cause of cancer deaths. The majority of suspicious lesions found in the lung are small and difficult to access, which can make obtaining a diagnosis challenging.
68
9/30/201818.09x47.41x51.48x85.27x82.21x$61,293$536.7211.47%Sep-05-2018Company Conference PresentationIntuitive Surgical, Inc. Presents at 2018 Wells Fargo Securities Healthcare Conference, Sep-05-2018 through Sep-06-2018-Intuitive Surgical, Inc. Presents at 2018 Wells Fargo Securities Healthcare Conference, Sep-05-2018 through Sep-06-2018. Venue: The Westin Copley Place, 10 Huntington Ave, Boston, Massachusetts, United States. Presentation Date & Speakers: Sep-05-2018, Calvin Darling, Senior Director of IR, Marshall L. Mohr, Senior VP & CFO. Sep-06-2018, Salvatore J. Brogna, Executive VP & COO.
69
9/30/201818.09x47.41x51.48x85.27x82.21x$61,293$536.7211.47%Sep-05-2018ConferenceWells Fargo Securities, LLC, 2018 Wells Fargo Securities Healthcare Conference, Sep 05, 2018 through Sep 06, 2018Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), bluebird bio, Inc. (NasdaqGS:BLUE), NextGen Healthcare, Inc. (NasdaqGS:NXGN), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Omnicell, Inc. (NasdaqGS:OMCL), HMS Holdings Corp. (NasdaqGS:HMSY), BioTelemetry, Inc. (NasdaqGS:BEAT), resTORbio, Inc. (NasdaqGS:TORC), Kiniksa Pharmaceuticals, Ltd. (NasdaqGS:KNSA), Autolus Therapeutics plc (NasdaqGS:AUTL), Kezar Life Sciences, Inc. (NasdaqGS:KZR), Akcea Therapeutics, Inc. (NasdaqGS:AKCA), AVROBIO, Inc. (NasdaqGS:AVRO), Ascendis Pharma A/S (NasdaqGS:ASND), NovoCure Limited (NasdaqGS:NVCR), Kala Pharmaceuticals, Inc. (NasdaqGS:KALA), Xeris Pharmaceuticals, Inc. (NasdaqGS:XERS), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Calithera Biosciences, Inc. (NasdaqGS:CALA), Adaptimmune Therapeutics plc (NasdaqGS:ADAP), Jounce Therapeutics, Inc. (NasdaqGS:JNCE), MyoKardia, Inc. (NasdaqGS:MYOK), NantHealth, Inc. (NasdaqGS:NH), uniQure N.V. (NasdaqGS:QURE), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Voyager Therapeutics, Inc. (NasdaqGS:VYGR), Unum Therapeutics Inc. (NasdaqGS:UMRX), SeaSpine Holdings Corporation (NasdaqGS:SPNE), OPKO Health, Inc. (NasdaqGS:OPK), Surgery Partners, Inc. (NasdaqGS:SGRY), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), HealthEquity, Inc. (NasdaqGS:HQY), Conformis, Inc. (NasdaqGS:CFMS), Strongbridge Biopharma plc (NasdaqGS:SBBP), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH), Computer Programs and Systems, Inc. (NasdaqGS:CPSI), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), AngioDynamics, Inc. (NasdaqGS:ANGO), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Merit Medical Systems, Inc. (NasdaqGS:MMSI), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Premier, Inc. (NasdaqGS:PINC), MEI Pharma, Inc. (NasdaqCM:MEIP), PolarityTE, Inc. (NasdaqCM:PTE), Regulus Therapeutics Inc. (NasdaqCM:RGLS), Avid Bioservices, Inc. (NasdaqCM:CDMO), Sunesis Pharmaceuticals, Inc. (NasdaqCM:SNSS), Globus Medical, Inc. (NYSE:GMED), Teladoc Health, Inc. (NYSE:TDOC), Emergent BioSolutions Inc. (NYSE:EBS), Penumbra, Inc. (NYSE:PEN), Select Medical Holdings Corporation (NYSE:SEM), Diplomat Pharmacy, Inc. (NYSE:DPLO), Glaukos Corporation (NYSE:GKOS), Triple-S Management Corporation (NYSE:GTS), Owens & Minor, Inc. (NYSE:OMI), Service Corporation International (NYSE:SCI), Teleflex Incorporated (NYSE:TFX), Boston Scientific Corporation (NYSE:BSX), HCA Healthcare, Inc. (NYSE:HCA), The Cooper Companies, Inc. (NYSE:COO), Edwards Lifesciences Corporation (NYSE:EW), Baxter International Inc. (NYSE:BAX), Vocera Communications, Inc. (NYSE:VCRA), Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), American Renal Associates Holdings, Inc. (NYSE:ARA), Evolent Health, Inc. (NYSE:EVH), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Inspire Medical Systems, Inc. (NYSE:INSP), Zymeworks Inc. (NYSE:ZYME), Centene Corporation (NYSE:CNC), Community Health Systems, Inc. (NYSE:CYH), Encompass Health Corporation (NYSE:EHC), Humana Inc. (NYSE:HUM), Allergan plc (NYSE:AGN), Charles River Laboratories International, Inc. (NYSE:CRL), Stryker Corporation (NYSE:SYK), Becton, Dickinson and Company (NYSE:BDX), Tenet Healthcare Corporation (NYSE:THC), Hanger, Inc. (NYSE:HNGR), Medtronic plc (NYSE:MDT), Mallinckrodt plc (NYSE:MNK), Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), Universal Health Services, Inc. (NYSE:UHS), Abbott Laboratories (NYSE:ABT), Quanterix Corporation (NasdaqGM:QTRX), Fate Therapeutics, Inc. (NasdaqGM:FATE), Iovance Biotherapeutics, Inc. (NasdaqGM:IOVA), Flexion Therapeutics, Inc. (NasdaqGM:FLXN), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Aeglea BioTherapeutics, Inc. (NasdaqGM:AGLE), Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), Immunomedics, Inc. (NasdaqGM:IMMU), Affimed N.V. (NasdaqGM:AFMD), MediWound Ltd. (NasdaqGM:MDWD), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), TRACON Pharmaceuticals, Inc. (NasdaqGM:TCON), Bellicum Pharmaceuticals, Inc. (NasdaqGM:BLCM), Concert Pharmaceuticals, Inc. (NasdaqGM:CNCE), Lantheus Holdings, Inc. (NasdaqGM:LNTH), Neos Therapeutics, Inc. (NasdaqGM:NEOS), Applied Genetic Technologies Corporation (NasdaqGM:AGTC), Benefitfocus, Inc. (NasdaqGM:BNFT), Avadel Pharmaceuticals plc (NasdaqGM:AVDL), Intellia Therapeutics, Inc. (NasdaqGM:NTLA), Tabula Rasa HealthCare, Inc. (NasdaqGM:TRHC), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Cellectis S.A. (ENXTPA:ALCLS), Genfit SA (ENXTPA:GNFT), ALK-Abelló A/S (CPSE:ALK B), TransEnterix, Inc. (AMEX:TRXC), UDG Healthcare plc (LSE:UDG), Molecular Partners AG (SWX:MOLN), Novartis AG (SWX:NOVN), Celyad SA (ENXTBR:CYAD), Titan Medical Inc. (TSX:TMD), Array BioPharma Inc., Agiliti Health, Inc., Cambrex Corporation, Endocyte, Inc., Wells Fargo Securities, LLC, Mazor Robotics Ltd., Aprea Therapeutics AB, OncoMed Pharmaceuticals, Inc., OMNI life science, Inc., Alder BioPharmaceuticals, Inc., Corindus Vascular Robotics, Inc., VytronUS, Inc., Immune Design Corp., Tesaro, Inc., Nuvaira, Inc., Iteos Therapeutics S.A., Braeburn Inc., Neural Analytics, Inc., K2M Group Holdings, Inc., Outset Medical, Inc., Nouscom AG, Relay Therapeutics, Inc.Wells Fargo Securities, LLC, 2018 Wells Fargo Securities Healthcare Conference, Sep 05, 2018 through Sep 06, 2018. Venue: The Westin Copley Place, 10 Huntington Ave, Boston, Massachusetts, United States.
70
9/30/201818.09x47.41x51.48x85.27x82.21x$58,960$516.2915.88%Aug-1-2018Executive/Board Change - OtherIntuitive Surgical, Inc. Appoints Don Kania to the Board-The Board of Directors of Intuitive Surgical, Inc. appointed Don Kania, Ph.D. to the Board effective as of July 31, 2018. The Board also increased the authorized number of directors to ten (10) effective July 31, 2018. Kania, 63, has more than 25 years of experience in scientific research and development, global operations, and manufacturing. Most recently, Kania served as CEO and president of FEI Company until its 2016 acquisition by
Thermo Fisher Scientific Inc. Kania also held various positions at Veeco Instruments Inc., ultimately as chief operating officer.
71
9/30/201818.09x47.41x51.48x85.27x82.21x$59,016$516.7815.77%Jul-20-2018Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From April 1, 2018 to June 30, 2018, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 8,636,190 shares, representing 7.47% for $2,226.25 million under the buyback announced on February 2, 2015.
72
9/30/201818.09x47.41x51.48x85.27x82.21x$59,531$521.2914.77%Jul-19-2018Earnings CallIntuitive Surgical, Inc., Q2 2018 Earnings Call, Jul 19, 2018-Intuitive Surgical, Inc., Q2 2018 Earnings Call, Jul 19, 2018
73
9/30/201818.09x47.41x51.48x85.27x82.21x$59,531$521.2914.77%Jul-19-2018Corporate Guidance - New/Confirmed, Announcement of EarningsIntuitive Surgical, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018; Provides Gross Profit Margin and Income Tax Rate Guidance for the Year 2018-Intuitive Surgical, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2018. For the quarter, the company reported total revenue of $909.3 million against $758.8 million for the same period a year ago. Income from operations was $277.4 million against $259.9 million for the same period a year ago. Income before taxes was $295.6 million against $270.0 million for the same period a year ago. Net income was $254.6 million against $223.0 million for the same period a year ago. Net income attributable to the company was $255.3 million against $223.0 million for the same period a year ago. Net income per diluted share attributable to the company was $2.15 against $1.94 for the same period a year ago. Non-GAAP income from operations was $388.7 million against $314.9 million for the same period a year ago. Non-GAAP net income attributable to the company was $327.4 million against $229.9 million for the same period a year ago. Non-GAAP net income per share attributable to the company – diluted was $2.76 against $2.00 for the same period a year ago. Cash generated from operations was $220 million. The year-over-year revenue growth benefited by approximately 100 basis points from the weaker dollar.

For the six months, the company reported total revenue of $1,756.8 million against $1,438.4 million for the same period a year ago. Income from operations was $554.1 million against $453.3 million for the same period a year ago. Income before taxes was $585.5 million against $472.1 million for the same period a year ago. Net income was $541.9 million against $403.8 million for the same period a year ago. Net income attributable to the company was $542.9 million against $403.8 million a year ago. Net income per diluted share attributable to the company was $4.59 against $3.50 for the same period a year ago. Non-GAAP income from operations was $735.0 million against $580.7 million for the same period a year ago. Non-GAAP net income attributable to the company was $614.9 million against $426.9 million for the same period a year ago. Non-GAAP net income per share attributable to the company – diluted was $5.20 against $3.70 for the same period a year ago.

The4 company provided earnings guidance for the year 2018. For the year 2018, the company continues to expect pro forma gross profit margin to be within a range of between 70% and 71.5% of net revenue. The company forecasts 2018 pro forma income tax rate to be between 20% and 21% of pretax income. The company is now shifting estimates slightly lower to a range of between 19.5% and 20.5% of pretax income.
74
9/30/201818.09x47.41x51.48x85.27x82.21x$55,660$487.3922.75%Jul-05-2018Product-Related AnnouncementIntuitive Surgical Receives FDA Clearance for First 60mm Stapler-Intuitive Surgical, Inc. announced that the U.S. Food and Drug Administration granted clearance for the company’s fully wristed, 60mm stapler. SureForm 60™, a single-patient use 60mm stapler, offers 120 degrees of fully wristed articulation – an industry first. Surgeons control SureForm 60 through the da Vinci surgeon console, creating an immediate connection between clinical decision-making and instrument action. Combining da Vinci’s tremor filtration with SureForm 60’s tip stability and 120 degrees of articulation in all directions may help provide surgeons with precise stapler manipulation and placement. SureForm 60 uses SmartFire™ technology—integrated software that optimizes stapler and staple line performance. SmartFire measures tissue compression before and during staple firing, making automatic adjustments to the firing process as staples are formed and the transection is made. SmartFire makes more than 1,000 measurements per second, helping to ensure a more consistent staple line, while helping prevent tissue damage, across a range of tissue thicknesses.
75
6/30/201815.68x41.50x45.07x74.97x71.86x$55,766$490.4721.98%Jun-13-2018Company Conference PresentationIntuitive Surgical, Inc. Presents at Goldman Sachs 39th Annual Global Healthcare Conference, Jun-13-2018 08:00 AM-Intuitive Surgical, Inc. Presents at Goldman Sachs 39th Annual Global Healthcare Conference, Jun-13-2018 08:00 AM. Venue: Terranea Resort, 100 Terranea Way, Rancho Palos Verdes, California, United States. Speakers: David J. Rosa, Executive VP & Chief Commercial Officer.
76
6/30/201815.68x41.50x45.07x74.97x71.86x$56,272$494.9220.89%Jun-12-2018ConferenceThe Goldman Sachs Group, Inc., Goldman Sachs 39th Annual Global Healthcare Conference, Jun 12, 2018 through Jun 14, 2018Hologic, Inc. (NasdaqGS:HOLX), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), LivaNova PLC (NasdaqGS:LIVN), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), NuVasive, Inc. (NasdaqGS:NUVA), Mylan N.V. (NasdaqGS:MYL), Incyte Corporation (NasdaqGS:INCY), Henry Schein, Inc. (NasdaqGS:HSIC), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), Denali Therapeutics Inc. (NasdaqGS:DNLI), Unity Biotechnology, Inc. (NasdaqGS:UBX), Syneos Health, Inc. (NasdaqGS:SYNH), ICON Public Limited Company (NasdaqGS:ICLR), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Portola Pharmaceuticals, Inc. (NasdaqGS:PTLA), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), Seres Therapeutics, Inc. (NasdaqGS:MCRB), TherapeuticsMD, Inc. (NasdaqGS:TXMD), BeiGene, Ltd. (NasdaqGS:BGNE), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Blueprint Medicines Corporation (NasdaqGS:BPMC), Clovis Oncology, Inc. (NasdaqGS:CLVS), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), FibroGen, Inc. (NasdaqGS:FGEN), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), Illumina, Inc. (NasdaqGS:ILMN), Insmed Incorporated (NasdaqGS:INSM), Amgen Inc. (NasdaqGS:AMGN), Align Technology, Inc. (NasdaqGS:ALGN), Alkermes plc (NasdaqGS:ALKS), Exact Sciences Corporation (NasdaqCM:EXAS), GW Pharmaceuticals plc (NasdaqGM:GWPH), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Revance Therapeutics, Inc. (NasdaqGM:RVNC), Radius Health, Inc. (NasdaqGM:RDUS), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), CRISPR Therapeutics AG (NasdaqGM:CRSP), Zai Lab Limited (NasdaqGM:ZLAB), Surface Oncology, Inc. (NasdaqGM:SURF), Hill-Rom Holdings, Inc. (NYSE:HRC), AmerisourceBergen Corporation (NYSE:ABC), Humana Inc. (NYSE:HUM), Mallinckrodt plc (NYSE:MNK), Arcus Biosciences, Inc. (NYSE:RCUS), Inspire Medical Systems, Inc. (NYSE:INSP), Emergent BioSolutions Inc. (NYSE:EBS), Penumbra, Inc. (NYSE:PEN), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), AbbVie Inc. (NYSE:ABBV), Catalent, Inc. (NYSE:CTLT), The Goldman Sachs Group, Inc. (NYSE:GS), Edwards Lifesciences Corporation (NYSE:EW), Owens & Minor, Inc. (NYSE:OMI), Teleflex Incorporated (NYSE:TFX), West Pharmaceutical Services, Inc. (NYSE:WST), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Baxter International Inc. (NYSE:BAX), The Cooper Companies, Inc. (NYSE:COO), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Medtronic plc (NYSE:MDT), Mettler-Toledo International Inc. (NYSE:MTD), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), QIAGEN N.V. (NYSE:QGEN), STERIS plc (NYSE:STE), Universal Health Services, Inc. (NYSE:UHS), Becton, Dickinson and Company (NYSE:BDX), Tenet Healthcare Corporation (NYSE:THC), Johnson & Johnson (NYSE:JNJ), Agilent Technologies, Inc. (NYSE:A), Anthem, Inc. (NYSE:ANTM), Cigna Corporation (NYSE:CI), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Sanofi (ENXTPA:SAN), Cellectis S.A. (ENXTPA:ALCLS), DBV Technologies S.A. (ENXTPA:DBV), Genmab A/S (CPSE:GMAB), Coloplast A/S (CPSE:COLO B), Dr. Reddy's Laboratories Limited (BSE:500124), GlaxoSmithKline plc (LSE:GSK), AstraZeneca PLC (LSE:AZN), Koninklijke Philips N.V. (ENXTAM:PHIA), Novartis AG (SWX:NOVN), Foundation Medicine, Inc., Acorn Management Partners, LLC, Spark Therapeutics, Inc.The Goldman Sachs Group, Inc., Goldman Sachs 39th Annual Global Healthcare Conference, Jun 12, 2018 through Jun 14, 2018. Venue: Terranea Resort, 100 Terranea Way, Rancho Palos Verdes, California, United States.
77
6/30/201815.68x41.50x45.07x74.97x71.86x$56,272$494.9220.89%Jun-12-2018Private PlacementBroncus Medical, Inc. announced that it has received $15 million in funding from Intuitive Surgical, Inc.Broncus Medical, Inc.Broncus Medical, Inc. announced that it has received $15 million in its series A round of equity funding from new investor, Intuitive Surgical, Inc. (NasdaqGS:ISRG) on June 12, 2018.
78
6/30/201815.68x41.50x45.07x74.97x71.86x$55,183$485.3423.27%Jun-07-2018Shelf Registration FilingDex Liquidating Co. has closed its Shelf Registration dated December 15, 2010 in the amount of $5.03565 million.Dex Liquidating Co.Dex Liquidating Co. has closed its Shelf Registration dated December 15, 2010 in the amount of $5.03565 million.

Security Name: Common Stock
Securities Offered: 1,249,541
79
6/30/201815.68x41.50x45.07x74.97x71.86x$52,264$459.6730.16%May-31-2018Product-Related AnnouncementIntuitive Surgical, Inc. Announces New U.S. Food and Drug Administration Clearance for the da Vinci SP Surgical System-Intuitive Surgical, Inc. announced a new U.S. Food and Drug Administration (FDA) clearance for the da Vinci SP surgical system for urologic surgical procedures that are appropriate for a single port approach. The da Vinci SP system provides surgeons with robotic-assisted technology designed for deep and narrow access to tissue in the body. The ability to enter the body through a single, small incision helps surgeons perform more complex procedures. Intuitive anticipates pursuing further regulatory clearances for da Vinci SP, including transoral, transanal, and extraperitoneal applications, broadening the applicability of the SP platform over time. The da Vinci SP system includes three, multi-jointed, wristed instruments and the first da Vinci fully wristed 3D HD camera. The instruments and the camera all emerge through a single cannula and are properly triangulated around the target anatomy to avoid external instrument collisions that can occur in narrow surgical workspaces. The system enables flexible port placement and excellent internal and external range of motion (e.g., 360-degrees of anatomical access) through the single SP arm. Surgeons control the fully articulating instruments and the camera on the da Vinci SP system, which uses the same surgeon console as the da Vinci X and Xi systems. Since the initial U.S. FDA clearance in April 2014 for the da Vinci SP surgical system, Intuitive invested in important platform refinements. Intuitive plans to launch the da Vinci SP surgical system in the United States in a measured fashion, with customer shipments beginning in the third quarter of 2018.
80
6/30/201815.68x41.50x45.07x74.97x71.86x$52,263$459.6630.16%May-30-2018Business Expansion, Executive/Board Change - OtherIntuitive Surgical, Inc. Begins Direct Operations in India; Names Mandeep Singh Kumar as its General Manager in India-Intuitive Surgical, Inc. announced that it has begun direct operations in India, following seven years of doing business in the country through a distributor, Vattikuti Technologies Pvt. Ltd. Intuitive’s sixth international office will be headquartered in Bengaluru, where employees in sales, marketing, field service engineering, and business operations will be based to support customers throughout the country. More than 65 da Vinci surgical systems are currently in use in India, with surgeons performing robotic-assisted procedures in urology, gynecology, thoracic, and general surgery.


In support of the company’s commitment to India, Intuitive also named Mandeep Singh Kumar as its general manager. Mandeep will direct and implement Intuitive’s in-country strategy and commercial operations. He has more than 20 years of global business experience in health care, pharmaceuticals, medical devices, and advertising. Most recently, Mandeep served as the chief commercial officer for GE Healthcare, India and South Asia.
81
6/30/201815.68x41.50x45.07x74.97x71.86x$51,942$456.8330.97%May-15-2018Company Conference PresentationIntuitive Surgical, Inc. Presents at Bank of America Merrill Lynch 2018 Healthcare Conference, May-15-2018 04:20 PM-Intuitive Surgical, Inc. Presents at Bank of America Merrill Lynch 2018 Healthcare Conference, May-15-2018 04:20 PM. Venue: Encore at Wynn Hotel, Las Vegas, Nevada, United States. Speakers: Calvin Darling, Senior Director of IR.
82
6/30/201815.68x41.50x45.07x74.97x71.86x$51,942$456.8330.97%May-15-2018ConferenceBank of America Corporation, Bank of America Merrill Lynch 2018 Healthcare Conference, May 15, 2018 through May 17, 2018Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Seattle Genetics, Inc. (NasdaqGS:SGEN), Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), Pacira BioSciences, Inc. (NasdaqGS:PCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Myriad Genetics, Inc. (NasdaqGS:MYGN), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Illumina, Inc. (NasdaqGS:ILMN), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Alkermes plc (NasdaqGS:ALKS), Amgen Inc. (NasdaqGS:AMGN), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), Intrexon Corporation (NasdaqGS:XON), Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT), Nabriva Therapeutics plc (NasdaqGS:NBRV), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), AnaptysBio, Inc. (NasdaqGS:ANAB), Surgery Partners, Inc. (NasdaqGS:SGRY), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Premier, Inc. (NasdaqGS:PINC), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), LHC Group, Inc. (NasdaqGS:LHCG), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Aduro BioTech, Inc. (NasdaqGS:ADRO), Cardiovascular Systems, Inc. (NasdaqGS:CSII), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Merit Medical Systems, Inc. (NasdaqGS:MMSI), Hologic, Inc. (NasdaqGS:HOLX), CONMED Corporation (NasdaqGS:CNMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Amedisys, Inc. (NasdaqGS:AMED), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Magellan Health, Inc. (NasdaqGS:MGLN), Incyte Corporation (NasdaqGS:INCY), Henry Schein, Inc. (NasdaqGS:HSIC), Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), Healthcare Services Group, Inc. (NasdaqGS:HCSG), ICON Public Limited Company (NasdaqGS:ICLR), Diversified Healthcare Trust (NasdaqGS:DHC), Ascendis Pharma A/S (NasdaqGS:ASND), Savara Inc. (NasdaqGS:SVRA), Clovis Oncology, Inc. (NasdaqGS:CLVS), CytomX Therapeutics, Inc. (NasdaqGS:CTMX), Kala Pharmaceuticals, Inc. (NasdaqGS:KALA), Puma Biotechnology, Inc. (NasdaqGS:PBYI), REGENXBIO Inc. (NasdaqGS:RGNX), Aclaris Therapeutics, Inc. (NasdaqGS:ACRS), MyoKardia, Inc. (NasdaqGS:MYOK), Seres Therapeutics, Inc. (NasdaqGS:MCRB), NantHealth, Inc. (NasdaqGS:NH), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Spero Therapeutics, Inc. (NasdaqGS:SPRO), Editas Medicine, Inc. (NasdaqGS:EDIT), Homology Medicines, Inc. (NasdaqGS:FIXX), Varex Imaging Corporation (NasdaqGS:VREX), resTORbio, Inc. (NasdaqGS:TORC), Abaxis, Inc., Array BioPharma Inc., Celgene Corporation, Legacy LifePoint Health, Inc., Genomic Health, Inc., Alder BioPharmaceuticals, Inc., Synthetic Genomics, Inc., Civitas Solutions, Inc., Tesaro, Inc., Audentes Therapeutics, Inc., Berkeley Lights, Inc., Koninklijke Philips N.V. (ENXTAM:PHIA), VolitionRx Limited (AMEX:VNRX), Hutchison China MediTech Limited (AIM:HCM), DBV Technologies S.A. (ENXTPA:DBV), Evotec SE (XTRA:EVT), MiMedx Group, Inc. (OTCPK:MDXG), Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q), Bank of America Corporation (NYSE:BAC), Hill-Rom Holdings, Inc. (NYSE:HRC), Centene Corporation (NYSE:CNC), Encompass Health Corporation (NYSE:EHC), Humana Inc. (NYSE:HUM), Mettler-Toledo International Inc. (NYSE:MTD), QIAGEN N.V. (NYSE:QGEN), Universal Health Services, Inc. (NYSE:UHS), Allergan plc (NYSE:AGN), Charles River Laboratories International, Inc. (NYSE:CRL), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), Intersect ENT, Inc. (NasdaqGM:XENT), Tandem Diabetes Care, Inc. (NasdaqGM:TNDM), Adamas Pharmaceuticals, Inc. (NasdaqGM:ADMS), CRISPR Therapeutics AG (NasdaqGM:CRSP), Zai Lab Limited (NasdaqGM:ZLAB), Evolus, Inc. (NasdaqGM:EOLS), Theravance Biopharma, Inc. (NasdaqGM:TBPH), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Rhythm Pharmaceuticals, Inc. (NasdaqGM:RYTM), Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT), Zogenix, Inc. (NasdaqGM:ZGNX), NanoString Technologies, Inc. (NasdaqGM:NSTG), Radius Health, Inc. (NasdaqGM:RDUS), NewLink Genetics Corporation (NasdaqGM:NLNK), GW Pharmaceuticals plc (NasdaqGM:GWPH), Tactile Systems Technology, Inc. (NasdaqGM:TCMD), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Phibro Animal Health Corporation (NasdaqGM:PAHC), RadNet, Inc. (NasdaqGM:RDNT), Physicians Realty Trust (NYSE:DOC), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Danaher Corporation (NYSE:DHR), Capital Senior Living Corporation (NYSE:CSU), U.S. Physical Therapy, Inc. (NYSE:USPH), ResMed Inc. (NYSE:RMD), Bausch Health Companies Inc. (NYSE:BHC), MEDNAX, Inc. (NYSE:MD), Chemed Corporation (NYSE:CHE), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), Tenet Healthcare Corporation (NYSE:THC), Eli Lilly and Company (NYSE:LLY), Merck & Co., Inc. (NYSE:MRK), Owens & Minor, Inc. (NYSE:OMI), Service Corporation International (NYSE:SCI), Teleflex Incorporated (NYSE:TFX), West Pharmaceutical Services, Inc. (NYSE:WST), Boston Scientific Corporation (NYSE:BSX), Glaukos Corporation (NYSE:GKOS), Cigna Corporation (NYSE:CI), Genesis Healthcare, Inc. (NYSE:GEN), WellCare Health Plans, Inc. (NYSE:WCG), Nevro Corp. (NYSE:NVRO), Teladoc Health, Inc. (NYSE:TDOC), Brookdale Senior Living Inc. (NYSE:BKD), Quorum Health Corporation (NYSE:QHC), AbbVie Inc. (NYSE:ABBV), Invitae Corporation (NYSE:NVTA), Evolent Health, Inc. (NYSE:EVH), Penumbra, Inc. (NYSE:PEN), Catalent, Inc. (NYSE:CTLT), American Renal Associates Holdings, Inc. (NYSE:ARA), IQVIA Holdings Inc. (NYSE:IQV), Aileron Therapeutics, Inc. (NasdaqCM:ALRN), Exact Sciences Corporation (NasdaqCM:EXAS), Heron Therapeutics, Inc. (NasdaqCM:HRTX)Bank of America Corporation, Bank of America Merrill Lynch 2018 Healthcare Conference, May 15, 2018 through May 17, 2018. Venue: Encore at Wynn Hotel, Las Vegas, Nevada, United States.
83
6/30/201815.68x41.50x45.07x74.97x71.86x$52,610$462.7129.30%Apr-19-2018Annual General MeetingIntuitive Surgical, Inc., Annual General Meeting, Apr 19, 2018-Intuitive Surgical, Inc., Annual General Meeting, Apr 19, 2018, at 15:00 Pacific Standard Time. Location: 1020 Kifer Road Sunnyvale California United States Agenda: To elect nine members to the board of directors of the company to serve until the 2019 annual meeting of stockholders; to consider and approve, on an advisory basis, the compensation of the company's named executive officers as disclosed in the proxy statement; to ratify the appointment of Pricewaterhousecoopers LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2018; and to transact any other business which is properly brought before the annual meeting or adjournments or postponements thereof.
84
6/30/201815.68x41.50x45.07x74.97x71.86x$53,556$471.0327.02%Apr-18-2018Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From January 1, 2018 to March 31, 2018, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 8,636,190 shares, representing 7.47% for $2,226.25 million under the buyback announced on February 2, 2015.
85
6/30/201815.68x41.50x45.07x74.97x71.86x$49,511$435.4537.40%Apr-17-2018Earnings CallIntuitive Surgical, Inc., Q1 2018 Earnings Call, Apr 17, 2018-Intuitive Surgical, Inc., Q1 2018 Earnings Call, Apr 17, 2018
86
6/30/201815.68x41.50x45.07x74.97x71.86x$49,511$435.4537.40%Apr-17-2018Announcement of Earnings, Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2018; Provides Earnings Results Guidance for the Year 2018-Intuitive Surgical, Inc. reported earnings results for the first quarter ended March 31, 2018. For the quarter, the company reported total revenue of $847.5 million against $679.6 million a year ago. Income from operations was $276.7 million against $193.4 million a year ago. Net income was $287.3 million against $180.8 million a year ago. Income before taxes was $289.9 million against $202.1 million a year ago. Net income attributable to company was $287.6 million compared to $180.8 million a year ago. Diluted net income per share was $2.44 against $1.57 per share a year ago. Non-GAAP income from operations was $346.3 million against $265.8 million a year ago. Non-GAAP net income attributable to company was $287.5 million compared to $197.0 million a year ago. Non-GAAP diluted net income per share attributable to company was $2.44 compared to $1.71 a year ago.

The company provided earnings results guidance for the year 2018. The company forecast full year 2018 procedure growth within a range of 11% to 15%. The company refined the range and estimate full year 2018 procedure growth of 12% to 15%. The company forecast 2018 pro forma income tax rate to be between 20% and 22% of pretax income.
87
3/31/201814.29x38.06x41.41x68.48x60.25x$49,939$440.7735.74%Mar-14-2018Company Conference PresentationIntuitive Surgical, Inc. Presents at Barclays Global Healthcare Conference 2018, Mar-14-2018 10:45 AM-Intuitive Surgical, Inc. Presents at Barclays Global Healthcare Conference 2018, Mar-14-2018 10:45 AM. Venue: The Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Calvin Darling, Senior Director of IR, Jamie E. Samath, Principal Accounting Officer, Vice President and Corporate Controller.
88
3/31/201814.29x38.06x41.41x68.48x60.25x$49,877$440.2235.91%Mar-13-2018ConferenceBarclays Capital PLC, Barclays Global Healthcare Conference 2018, Mar 13, 2018 through Mar 15, 2018Exelixis, Inc. (NasdaqGS:EXEL), bluebird bio, Inc. (NasdaqGS:BLUE), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), Cross Country Healthcare, Inc. (NasdaqGS:CCRN), LivaNova PLC (NasdaqGS:LIVN), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Alkermes plc (NasdaqGS:ALKS), Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR), Mylan N.V. (NasdaqGS:MYL), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Achillion Pharmaceuticals, Inc. (NasdaqGS:ACHN), Mirati Therapeutics, Inc. (NasdaqGS:MRTX), Quidel Corporation (NasdaqGS:QDEL), Wright Medical Group N.V. (NasdaqGS:WMGI), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Seattle Genetics, Inc. (NasdaqGS:SGEN), Masimo Corporation (NasdaqGS:MASI), MeiraGTx Holdings plc (NasdaqGS:MGTX), Forty Seven, Inc. (NasdaqGS:FTSV), Syneos Health, Inc. (NasdaqGS:SYNH), Editas Medicine, Inc. (NasdaqGS:EDIT), Advaxis, Inc. (NasdaqGS:ADXS), Cardiovascular Systems, Inc. (NasdaqGS:CSII), Clovis Oncology, Inc. (NasdaqGS:CLVS), CytomX Therapeutics, Inc. (NasdaqGS:CTMX), Precision BioSciences, Inc. (NasdaqGS:DTIL), Moderna, Inc. (NasdaqGS:MRNA), BeiGene, Ltd. (NasdaqGS:BGNE), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), uniQure N.V. (NasdaqGS:QURE), REGENXBIO Inc. (NasdaqGS:RGNX), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Prothena Corporation plc (NasdaqGS:PRTA), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Henry Schein, Inc. (NasdaqGS:HSIC), ICON Public Limited Company (NasdaqGS:ICLR), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Merit Medical Systems, Inc. (NasdaqGS:MMSI), Magellan Health, Inc. (NasdaqGS:MGLN), Incyte Corporation (NasdaqGS:INCY), Cerner Corporation (NasdaqGS:CERN), Insulet Corporation (NasdaqGS:PODD), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), AngioDynamics, Inc. (NasdaqGS:ANGO), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Premier, Inc. (NasdaqGS:PINC), Barclays Capital PLC, Genoptix, Inc., Celgene Corporation, Impax Laboratories, Inc., Ortho-Clinical Diagnostics, Inc., Mazor Robotics Ltd., Civitas Solutions, Inc., Celtaxsys, Inc., Tesaro, Inc., Spark Therapeutics, Inc., AveXis, Inc., K2M Group Holdings, Inc., Oxford Nanopore Technologies, Inc., Cotiviti Holdings, Inc., Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), Koninklijke Philips N.V. (ENXTAM:PHIA), Pfenex Inc. (AMEX:PFNX), AstraZeneca PLC (LSE:AZN), UDG Healthcare plc (LSE:UDG), Exalenz Bioscience Ltd (TASE:EXEN), DiaSorin S.p.A. (BIT:DIA), EssilorLuxottica Société anonyme (ENXTPA:EL), DBV Technologies S.A. (ENXTPA:DBV), H. Lundbeck A/S (CPSE:LUN), Coloplast A/S (CPSE:COLO B), Novo Nordisk A/S (CPSE:NOVO B), QIAGEN N.V. (NYSE:QGEN), DaVita Inc. (NYSE:DVA), Universal Health Services, Inc. (NYSE:UHS), Allergan plc (NYSE:AGN), Integer Holdings Corporation (NYSE:ITGR), Becton, Dickinson and Company (NYSE:BDX), UnitedHealth Group Incorporated (NYSE:UNH), Tenet Healthcare Corporation (NYSE:THC), Charles River Laboratories International, Inc. (NYSE:CRL), Johnson & Johnson (NYSE:JNJ), Agilent Technologies, Inc. (NYSE:A), Anthem, Inc. (NYSE:ANTM), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), MAXIMUS, Inc. (NYSE:MMS), Abbott Laboratories (NYSE:ABT), Baxter International Inc. (NYSE:BAX), Bio-Rad Laboratories, Inc. (NYSE:BIO), HCA Healthcare, Inc. (NYSE:HCA), Eli Lilly and Company (NYSE:LLY), Merck & Co., Inc. (NYSE:MRK), Encompass Health Corporation (NYSE:EHC), Humana Inc. (NYSE:HUM), AmerisourceBergen Corporation (NYSE:ABC), Bayer Aktiengesellschaft (XTRA:BAYN), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Fresenius SE & Co. KGaA (XTRA:FRE), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), Laboratory Corporation of America Holdings (NYSE:LH), Medtronic plc (NYSE:MDT), Hill-Rom Holdings, Inc. (NYSE:HRC), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN), Avanos Medical, Inc. (NYSE:AVNS), Mallinckrodt plc (NYSE:MNK), AbbVie Inc. (NYSE:ABBV), Zymeworks Inc. (NYSE:ZYME), WellCare Health Plans, Inc. (NYSE:WCG), Genesis Healthcare, Inc. (NYSE:GEN), Brookdale Senior Living Inc. (NYSE:BKD), Globus Medical, Inc. (NYSE:GMED), Diplomat Pharmacy, Inc. (NYSE:DPLO), Bausch Health Companies Inc. (NYSE:BHC), Teleflex Incorporated (NYSE:TFX), Varian Medical Systems, Inc. (NYSE:VAR), Boston Scientific Corporation (NYSE:BSX), Perrigo Company plc (NYSE:PRGO), Myovant Sciences Ltd. (NYSE:MYOV), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), Ligand Pharmaceuticals Incorporated (NasdaqGM:LGND), CRISPR Therapeutics AG (NasdaqGM:CRSP), Intellia Therapeutics, Inc. (NasdaqGM:NTLA), Foamix Pharmaceuticals Ltd. (NasdaqGM:FOMX), LeMaitre Vascular, Inc. (NasdaqGM:LMAT), Revance Therapeutics, Inc. (NasdaqGM:RVNC), Marinus Pharmaceuticals, Inc. (NasdaqGM:MRNS), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Oxford Immunotec Global PLC (NasdaqGM:OXFD), Acceleron Pharma Inc. (NasdaqGM:XLRN), Leap Therapeutics, Inc. (NasdaqGM:LPTX), Protagonist Therapeutics, Inc. (NasdaqGM:PTGX), Retrophin, Inc. (NasdaqGM:RTRX), Coherus BioSciences, Inc. (NasdaqGM:CHRS), Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), Exact Sciences Corporation (NasdaqCM:EXAS), Abeona Therapeutics Inc. (NasdaqCM:ABEO), aTyr Pharma, Inc. (NasdaqCM:LIFE), Intec Pharma Ltd. (NasdaqCM:NTEC), ReWalk Robotics Ltd. (NasdaqCM:RWLK)Barclays Capital PLC, Barclays Global Healthcare Conference 2018, Mar 13, 2018 through Mar 15, 2018. Venue: The Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States.
89
3/31/201814.29x38.06x41.41x68.48x60.25x$48,322$426.5040.28%Mar-06-2018Company Conference PresentationIntuitive Surgical, Inc. Presents at Raymond James 39th Annual Institutional Investors Conference, Mar-06-2018 09:15 AM-Intuitive Surgical, Inc. Presents at Raymond James 39th Annual Institutional Investors Conference, Mar-06-2018 09:15 AM. Venue: J.W. Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, Florida, United States.
90
3/31/201814.29x38.06x41.41x68.48x60.25x$48,068$424.2541.02%Mar-5-2018Executive/Board Change - OtherIntuitive Surgical Name Phil Bradshaw as First General Manager in the United Kingdom and Ireland-Intuitive Surgical has named Phil Bradshaw as its first General Manager in the United Kingdom and Ireland (UK&I). Mr. Bradshaw will direct business strategy and operations for the company in these countries. Mr. Bradshaw brings nearly three decades of experience in the medical device field working for market-leading companies, and more than eight years of general management experience in the UK and European markets. Before joining Intuitive Surgical, Mr. Bradshaw worked at Medtronic as Strategic Alliance Director for EMEA within the Integrated Health Solutions Division.
91
3/31/201814.29x38.06x41.41x68.48x60.25x$0Mar-04-2018ConferenceRaymond James & Associates, Inc., Raymond James 39th Annual Institutional Investors Conference, Mar 04, 2018 through Mar 07, 2018Teligent, Inc. (NasdaqGS:TLGT), Wintrust Financial Corporation (NasdaqGS:WTFC), Cogent Communications Holdings, Inc. (NasdaqGS:CCOI), Ruth's Hospitality Group, Inc. (NasdaqGS:RUTH), Masimo Corporation (NasdaqGS:MASI), Natus Medical Incorporated (NasdaqGS:NTUS), SS&C Technologies Holdings, Inc. (NasdaqGS:SSNC), Stericycle, Inc. (NasdaqGS:SRCL), Qorvo, Inc. (NasdaqGS:QRVO), SBA Communications Corporation (NasdaqGS:SBAC), E*TRADE Financial Corporation (NasdaqGS:ETFC), Herman Miller, Inc. (NasdaqGS:MLHR), IDEXX Laboratories, Inc. (NasdaqGS:IDXX), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Internap Corporation (NasdaqGS:INAP), Citrix Systems, Inc. (NasdaqGS:CTXS), Cognex Corporation (NasdaqGS:CGNX), CommScope Holding Company, Inc. (NasdaqGS:COMM), NCS Multistage Holdings, Inc. (NasdaqGS:NCSM), Alarm.com Holdings, Inc. (NasdaqGS:ALRM), Gogo Inc. (NasdaqGS:GOGO), CyrusOne Inc. (NasdaqGS:CONE), Atlassian Corporation Plc (NasdaqGS:TEAM), Paylocity Holding Corporation (NasdaqGS:PCTY), ORBCOMM Inc. (NasdaqGS:ORBC), PRA Group, Inc. (NasdaqGS:PRAA), Beacon Roofing Supply, Inc. (NasdaqGS:BECN), Preferred Bank (NasdaqGS:PFBC), Iridium Communications Inc. (NasdaqGS:IRDM), Premier, Inc. (NasdaqGS:PINC), Nasdaq, Inc. (NasdaqGS:NDAQ), Allegiant Travel Company (NasdaqGS:ALGT), IPG Photonics Corporation (NasdaqGS:IPGP), OraSure Technologies, Inc. (NasdaqGS:OSUR), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), Adaptimmune Therapeutics plc (NasdaqGS:ADAP), Uniti Group Inc. (NasdaqGS:UNIT), BlackRock TCP Capital Corp. (NasdaqGS:TCPC), Carrols Restaurant Group, Inc. (NasdaqGS:TAST), Ares Capital Corporation (NasdaqGS:ARCC), Home Bancshares, Inc. (Conway, AR) (NasdaqGS:HOMB), LKQ Corporation (NasdaqGS:LKQ), HealthEquity, Inc. (NasdaqGS:HQY), SunPower Corporation (NasdaqGS:SPWR), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), Trimble Inc. (NasdaqGS:TRMB), Quidel Corporation (NasdaqGS:QDEL), ACI Worldwide, Inc. (NasdaqGS:ACIW), Willis Towers Watson Public Limited Company (NasdaqGS:WLTW), Hologic, Inc. (NasdaqGS:HOLX), DexCom, Inc. (NasdaqGS:DXCM), Avnet, Inc. (NasdaqGS:AVT), PotlatchDeltic Corporation (NasdaqGS:PCH), SEI Investments Company (NasdaqGS:SEIC), Seacoast Banking Corporation of Florida (NasdaqGS:SBCF), Mylan N.V. (NasdaqGS:MYL), Dawson Geophysical Company (NasdaqGS:DWSN), Fastenal Company (NasdaqGS:FAST), Red Robin Gourmet Burgers, Inc. (NasdaqGS:RRGB), TripAdvisor, Inc. (NasdaqGS:TRIP), Texas Capital Bancshares, Inc. (NasdaqGS:TCBI), FLIR Systems, Inc. (NasdaqGS:FLIR), Tractor Supply Company (NasdaqGS:TSCO), ATN International, Inc. (NasdaqGS:ATNI), The Cheesecake Factory Incorporated (NasdaqGS:CAKE), Merit Medical Systems, Inc. (NasdaqGS:MMSI), ICU Medical, Inc. (NasdaqGS:ICUI), Hancock Whitney Corporation (NasdaqGS:HWC), Patterson-UTI Energy, Inc. (NasdaqGS:PTEN), ScanSource, Inc. (NasdaqGS:SCSC), TD Ameritrade Holding Corporation (NasdaqGS:AMTD), Viasat, Inc. (NasdaqGS:VSAT), Atlantic Union Bankshares Corporation (NasdaqGS:AUB), CDW Corporation (NasdaqGS:CDW), United Bankshares, Inc. (NasdaqGS:UBSI), Bank OZK (NasdaqGS:OZK), Pacific Premier Bancorp, Inc. (NasdaqGS:PPBI), Cboe Global Markets, Inc. (BATS:CBOE), Viveve Medical, Inc. (NasdaqCM:VIVE), Antares Pharma, Inc. (NasdaqCM:ATRS), TG Therapeutics, Inc. (NasdaqCM:TGTX), The Habit Restaurants, Inc. (NasdaqGM:HABT), Adverum Biotechnologies, Inc. (NasdaqGM:ADVM), TPI Composites, Inc. (NasdaqGM:TPIC), ADMA Biologics, Inc. (NasdaqGM:ADMA), Flexion Therapeutics, Inc. (NasdaqGM:FLXN), First Foundation Inc. (NasdaqGM:FFWM), Everbridge, Inc. (NasdaqGM:EVBG), Malibu Boats, Inc. (NasdaqGM:MBUU), Rapid7, Inc. (NasdaqGM:RPD), Newtek Business Services Corp. (NasdaqGM:NEWT), Applied Optoelectronics, Inc. (NasdaqGM:AAOI), ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP), The Allstate Corporation (NYSE:ALL), S&P Global Inc. (NYSE:SPGI), Raymond James Financial, Inc. (NYSE:RJF), Roper Technologies, Inc. (NYSE:ROP), Alliance Data Systems Corporation (NYSE:ADS), American Tower Corporation (REIT) (NYSE:AMT), AutoZone, Inc. (NYSE:AZO), Ethan Allen Interiors Inc. (NYSE:ETH), FleetCor Technologies, Inc. (NYSE:FLT), Concho Resources Inc. (NYSE:CXO), Crown Castle International Corp. (REIT) (NYSE:CCI), Dine Brands Global, Inc. (NYSE:DIN), Kansas City Southern (NYSE:KSU), Laboratory Corporation of America Holdings (NYSE:LH), Leggett & Platt, Incorporated (NYSE:LEG), WEX Inc. (NYSE:WEX), Charles River Laboratories International, Inc. (NYSE:CRL), Superior Energy Services, Inc. (NYSE:SPN), Helix Energy Solutions Group, Inc. (NYSE:HLX), CACI International Inc (NYSE:CACI), Oil States International, Inc. (NYSE:OIS), Fortive Corporation (NYSE:FTV), AAC Holdings, Inc. (OTCPK:AACH), Vocera Communications, Inc. (NYSE:VCRA), Tempur Sealy International, Inc. (NYSE:TPX), American Equity Investment Life Holding Company (NYSE:AEL), Whiting Petroleum Corporation (NYSE:WLL), Spirit Airlines, Inc. (NYSE:SAVE), Broadridge Financial Solutions, Inc. (NYSE:BR), QEP Resources, Inc. (NYSE:QEP), Lannett Company, Inc. (NYSE:LCI), Moody's Corporation (NYSE:MCO), Enterprise Products Partners L.P. (NYSE:EPD), WESCO International, Inc. (NYSE:WCC), Cadence Bancorporation (NYSE:CADE), Main Street Capital Corporation (NYSE:MAIN), Cable One, Inc. (NYSE:CABO), CatchMark Timber Trust, Inc. (NYSE:CTT), Palo Alto Networks, Inc. (NYSE:PANW), Delek US Holdings, Inc. (NYSE:DK), Prestige Consumer Healthcare Inc. (NYSE:PBH), Digital Realty Trust, Inc. (NYSE:DLR), MSCI Inc. (NYSE:MSCI), Alteryx, Inc. (NYSE:AYX), WellCare Health Plans, Inc. (NYSE:WCG), Catalent, Inc. (NYSE:CTLT), Envestnet, Inc. (NYSE:ENV), Switch, Inc. (NYSE:SWCH), Chegg, Inc. (NYSE:CHGG), Wayfair Inc. (NYSE:W), Q2 Holdings, Inc. (NYSE:QTWO), New Relic, Inc. (NYSE:NEWR), MRC Global Inc. (NYSE:MRC), Steelcase Inc. (NYSE:SCS), Waste Connections, Inc. (NYSE:WCN), Republic Services, Inc. (NYSE:RSG), Quest Diagnostics Incorporated (NYSE:DGX), Toll Brothers, Inc. (NYSE:TOL), Rayonier Inc. (NYSE:RYN), New York Community Bancorp, Inc. (NYSE:NYCB), Teleflex Incorporated (NYSE:TFX), Service Corporation International (NYSE:SCI), Stanley Black & Decker, Inc. (NYSE:SWK), Union Pacific Corporation (NYSE:UNP), Valero Energy Corporation (NYSE:VLO), Walmart Inc. (NYSE:WMT), Covanta Holding Corporation (NYSE:CVA), Ryman Hospitality Properties, Inc. (NYSE:RHP), ProAssurance Corporation (NYSE:PRA), Baxter International Inc. (NYSE:BAX), HCA Healthcare, Inc. (NYSE:HCA), Cubic Corporation (NYSE:CUB), First Republic Bank (NYSE:FRC), W.W. Grainger, Inc. (NYSE:GWW), HNI Corporation (NYSE:HNI), The Home Depot, Inc. (NYSE:HD), La-Z-Boy Incorporated (NYSE:LZB), Pioneer Natural Resources Company (NYSE:PXD), Polaris Inc. (NYSE:PII), Booz Allen Hamilton Holding Corporation (NYSE:BAH), Brunswick Corporation (NYSE:BC), Cardinal Health, Inc. (NYSE:CAH), Masco Corporation (NYSE:MAS), Waste Management, Inc. (NYSE:WM), Unit Corporation (NYSE:UNT), United Parcel Service, Inc. (NYSE:UPS), Agnico Eagle Mines Limited (NYSE:AEM), Aflac Incorporated (NYSE:AFL), Argo Group International Holdings, Ltd. (NYSE:ARGO), Arrow Electronics, Inc. (NYSE:ARW), Becton, Dickinson and Company (NYSE:BDX), D.R. Horton, Inc. (NYSE:DHI), Weyerhaeuser Company (NYSE:WY), TETRA Technologies, Inc. (NYSE:TTI), salesforce.com, inc. (NYSE:CRM), Instructure, Inc. (NYSE:INST), Parsley Energy, Inc. (NYSE:PE), Pebblebrook Hotel Trust (NYSE:PEB), California Resources Corporation (NYSE:CRC), Zayo Group Holdings, Inc. (NYSE:ZAYO), Foundation Building Materials, Inc. (NYSE:FBM), Mallinckrodt plc (NYSE:MNK), Murphy USA Inc. (NYSE:MUSA), Physicians Realty Trust (NYSE:DOC), NOW Inc. (NYSE:DNOW), EnLink Midstream, LLC (NYSE:ENLC), Avanos Medical, Inc. (NYSE:AVNS), Fortress Transportation and Infrastructure Investors LLC (NYSE:FTAI), AquaVenture Holdings Limited (NYSE:WAAS), Jernigan Capital, Inc. (NYSE:JCAP), Safehold Inc. (NYSE:SAFE), Abaxis, Inc., Spectrum Brands Legacy, Inc., ARRIS International Limited, Oclaro, Inc., SunTrust Banks, Inc., Andeavor, Carrizo Oil & Gas, Inc., Genesee & Wyoming Inc., Envision Healthcare Corporation, Raymond James & Associates, Inc., EnLink Midstream Partners, LP, J.B. Hunt Transport, Inc., Vital Therapies, Inc., Control4 Corporation, Civitas Solutions, Inc., SRC Energy Inc., Cotiviti Holdings, Inc., Senseonics Holdings, Inc. (AMEX:SENS), Lineage Cell Therapeutics, Inc. (AMEX:LCTX), MiX Telematics Limited (JSE:MIX), Norbord Inc. (TSX:OSB), Algonquin Power & Utilities Corp. (TSX:AQN), Gildan Activewear Inc. (TSX:GIL)Raymond James & Associates, Inc., Raymond James 39th Annual Institutional Investors Conference, Mar 04, 2018 through Mar 07, 2018. Venue: J.W. Marriott Grande Lakes, 4040 Central Florida Parkway, Orlando, Florida, United States.
92
3/31/201814.29x38.06x41.41x68.48x60.25x$47,242$416.9643.49%Feb-2-2018Buyback Tranche UpdateTranche Update on Intuitive Surgical, Inc. (NasdaqGS:ISRG)'s Equity Buyback Plan announced on February 2, 2015.-From October 1, 2017 to December 31, 2017, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 8,636,190 shares, representing 7.47% for $2,226.25 million under the buyback announced on February 2, 2015.
93
3/31/201814.29x38.06x41.41x68.48x60.25x$50,963$449.8133.01%Jan-25-2018Earnings CallIntuitive Surgical, Inc., Q4 2017 Earnings Call, Jan 25, 2018-Intuitive Surgical, Inc., Q4 2017 Earnings Call, Jan 25, 2018
94
3/31/201814.29x38.06x41.41x68.48x60.25x$50,963$449.8133.01%Jan-25-2018Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Provides Earnings Guidance for the Year 2018-Intuitive Surgical, Inc. provided earnings guidance for the year 2018. For the year, the company expects pro forma gross profit margin to be within a range of between 70% and 71.5% net revenue. The company is projecting a modestly lower gross profit margin in 2018, reflecting higher costs associated with new products. The company expects pro forma income tax rate to be between 20% and 22% of pretax income. The company announced that will continue to make substantive investments in several strategic areas that are poised to benefit the company over the long run. As a result, the company expects to grow 2018 pro forma operating expenses between 16% and 18% above 2017 levels and expects other income, which is comprised mostly of interest income, to total between $45 million and $55 million in 2018.
95
3/31/201814.29x38.06x41.41x68.48x60.25x$50,963$449.8133.01%Jan-25-2018Announcement of EarningsIntuitive Surgical, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended Dec. 31, 2017-Intuitive Surgical, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended Dec. 31, 2017. For the quarter, the company’s total revenue was $892.4 million compared with $756.9 million a year ago. Income from operations was $327.0 million compared with $264.4 million a year ago. Income before taxes was $339.3 million compared with $276.1 million a year ago. Net loss was $38.8 million compared with net income of $204.0 million a year ago. Diluted net loss per share was $0.35 compared with income of $1.71 a year ago. Non-GAAP income from operations was $384.1 million compared with $319.7 million a year ago. Non-GAAP net income was $297.7 million compared with $242.3 million a year ago. Diluted non-GAAP net income per share was $2.54 compared with $2.03 a year ago. Higher fourth quarter revenue was driven by increased procedures and systems placements. Fourth quarter 2017 GAAP net loss reflected $318 million, or $2.83 per diluted share, of income tax expense as a result of the Tax Cuts and Jobs Act (2017 Tax Act") enacted on December 22, 2017. This amount primarily relates to a one-time deemed repatriation tax on undistributed foreign earnings and revaluation of deferred taxes due to a reduction of the U.S. corporate income tax rate.


For the full year, the company reported total revenue was $3,128.9 million compared with $2,704.4 million a year ago. Income from operations was $1,054.6 million compared with $945.2 million a year ago. Income before taxes was $1,096.5 million compared with $980.8 million a year ago. Net income was $660.0 million compared with $735.9 million a year ago. Diluted net income per share was $5.67 compared with $6.24 a year ago. Non-GAAP income from operations was $1,307.6 million compared with $1,153.5 million a year ago. Non-GAAP net income was $1,045.9 million compared with $878.7 million a year ago. Diluted non-GAAP net income per share was $8.99 compared with $7.45 a year ago.
96
3/31/201814.29x38.06x41.41x68.48x60.25x$47,741$421.3741.99%Jan-11-2018Company Conference PresentationIntuitive Surgical, Inc. Presents at 36th Annual J.P. Morgan Healthcare Conference, Jan-11-2018 09:00 AM-Intuitive Surgical, Inc. Presents at 36th Annual J.P. Morgan Healthcare Conference, Jan-11-2018 09:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Gary S. Guthart, CEO, President & Director.
97
3/31/201814.29x38.06x41.41x68.48x60.25x$48,012$423.7641.19%Jan-10-2018Corporate Guidance - New/ConfirmedIntuitive Surgical, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year of 2017-Intuitive Surgical, Inc. provided unaudited revenue guidance for the fourth quarter and full year of 2017. The company expects revenue for the fourth quarter of 2017 of approximately $892 million, an increase of approximately 18% compared with $757 million for the fourth quarter of 2016.

The company expects 2017 revenue of approximately $3.1 billion, an increase of approximately 16% compared with $2.7 billion for 2016.
98
3/31/201814.29x38.06x41.41x68.48x60.25x$44,398$391.8652.68%Jan-8-2018ConferenceJPMorgan Chase & Co., 36th Annual J.P. Morgan Healthcare Conference, Jan 08, 2018 through Jan 11, 2018Microsoft Corporation (NasdaqGS:MSFT), Acorda Therapeutics, Inc. (NasdaqGS:ACOR), Alnylam Pharmaceuticals, Inc. (NasdaqGS:ALNY), Aduro BioTech, Inc. (NasdaqGS:ADRO), ChemoCentryx, Inc. (NasdaqGS:CCXI), Mersana Therapeutics, Inc. (NasdaqGS:MRSN), Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI), PTC Therapeutics, Inc. (NasdaqGS:PTCT), Jazz Pharmaceuticals plc (NasdaqGS:JAZZ), Momenta Pharmaceuticals, Inc. (NasdaqGS:MNTA), LHC Group, Inc. (NasdaqGS:LHCG), AngioDynamics, Inc. (NasdaqGS:ANGO), Five Prime Therapeutics, Inc. (NasdaqGS:FPRX), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), ICON Public Limited Company (NasdaqGS:ICLR), Luminex Corporation (NasdaqGS:LMNX), Sangamo Therapeutics, Inc. (NasdaqGS:SGMO), Sarepta Therapeutics, Inc. (NasdaqGS:SRPT), Enanta Pharmaceuticals, Inc. (NasdaqGS:ENTA), Amedisys, Inc. (NasdaqGS:AMED), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), Endologix, Inc. (NasdaqGS:ELGX), Patterson Companies, Inc. (NasdaqGS:PDCO), Incyte Corporation (NasdaqGS:INCY), Henry Schein, Inc. (NasdaqGS:HSIC), ICU Medical, Inc. (NasdaqGS:ICUI), Mylan N.V. (NasdaqGS:MYL), Premier, Inc. (NasdaqGS:PINC), Accuray Incorporated (NasdaqGS:ARAY), OraSure Technologies, Inc. (NasdaqGS:OSUR), Bruker Corporation (NasdaqGS:BRKR), MacroGenics, Inc. (NasdaqGS:MGNX), Insulet Corporation (NasdaqGS:PODD), ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), Cerner Corporation (NasdaqGS:CERN), CONMED Corporation (NasdaqGS:CNMD), Abiomed, Inc. (NasdaqGS:ABMD), AMAG Pharmaceuticals, Inc. (NasdaqGS:AMAG), Quidel Corporation (NasdaqGS:QDEL), NextGen Healthcare, Inc. (NasdaqGS:NXGN), Bio-Techne Corporation (NasdaqGS:TECH), Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR), CymaBay Therapeutics, Inc. (NasdaqGS:CBAY), Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN), Repligen Corporation (NasdaqGS:RGEN), Rigel Pharmaceuticals, Inc. (NasdaqGS:RIGL), Seattle Genetics, Inc. (NasdaqGS:SGEN), United Therapeutics Corporation (NasdaqGS:UTHR), Wright Medical Group N.V. (NasdaqGS:WMGI), Vertex Pharmaceuticals Incorporated (NasdaqGS:VRTX), Walgreens Boots Alliance, Inc. (NasdaqGS:WBA), Teligent, Inc. (NasdaqGS:TLGT), DexCom, Inc. (NasdaqGS:DXCM), Hologic, Inc. (NasdaqGS:HOLX), bluebird bio, Inc. (NasdaqGS:BLUE), Gilead Sciences, Inc. (NasdaqGS:GILD), HMS Holdings Corp. (NasdaqGS:HMSY), Lexicon Pharmaceuticals, Inc. (NasdaqGS:LXRX), Masimo Corporation (NasdaqGS:MASI), BioCryst Pharmaceuticals, Inc. (NasdaqGS:BCRX), BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), Ironwood Pharmaceuticals, Inc. (NasdaqGS:IRWD), Myriad Genetics, Inc. (NasdaqGS:MYGN), Natus Medical Incorporated (NasdaqGS:NTUS), Neurocrine Biosciences, Inc. (NasdaqGS:NBIX), NuVasive, Inc. (NasdaqGS:NUVA), Omnicell, Inc. (NasdaqGS:OMCL), Orthofix Medical Inc. (NasdaqGS:OFIX), Alkermes plc (NasdaqGS:ALKS), Tivity Health, Inc. (NasdaqGS:TVTY), Amgen Inc. (NasdaqGS:AMGN), Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA), Cross Country Healthcare, Inc. (NasdaqGS:CCRN), DENTSPLY SIRONA Inc. (NasdaqGS:XRAY), Pacira BioSciences, Inc. (NasdaqGS:PCRX), Endo International plc (NasdaqGS:ENDP), Biogen Inc. (NasdaqGS:BIIB), IDEXX Laboratories, Inc. (NasdaqGS:IDXX), Illumina, Inc. (NasdaqGS:ILMN), ImmunoGen, Inc. (NasdaqGS:IMGN), Nektar Therapeutics (NasdaqGS:NKTR), Integra LifeSciences Holdings Corporation (NasdaqGS:IART), Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS), Vir Biotechnology, Inc. (NasdaqGS:VIR), Eidos Therapeutics, Inc. (NasdaqGS:EIDX), Orchard Therapeutics plc (NasdaqGS:ORTX), Aptinyx Inc. (NasdaqGS:APTX), Rubius Therapeutics, Inc. (NasdaqGS:RUBY), Varex Imaging Corporation (NasdaqGS:VREX), Aimmune Therapeutics, Inc. (NasdaqGS:AIMT), Twist Bioscience Corporation (NasdaqGS:TWST), ObsEva SA (NasdaqGS:OBSV), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), Editas Medicine, Inc. (NasdaqGS:EDIT), Tricida, Inc. (NasdaqGS:TCDA), Guardant Health, Inc. (NasdaqGS:GH), Global Blood Therapeutics, Inc. (NasdaqGS:GBT), Prothena Corporation plc (NasdaqGS:PRTA), 10x Genomics, Inc. (NasdaqGS:TXG), MyoKardia, Inc. (NasdaqGS:MYOK), Seres Therapeutics, Inc. (NasdaqGS:MCRB), Jounce Therapeutics, Inc. (NasdaqGS:JNCE), Syros Pharmaceuticals, Inc. (NasdaqGS:SYRS), Crinetics Pharmaceuticals, Inc. (NasdaqGS:CRNX), Syneos Health, Inc. (NasdaqGS:SYNH), Livongo Health, Inc. (NasdaqGS:LVGO), TCR2 Therapeutics Inc. (NasdaqGS:TCRR), Kaleido BioSciences, Inc. (NasdaqGS:KLDO), Axovant Gene Therapies Ltd. (NasdaqGS:AXGT), Denali Therapeutics Inc. (NasdaqGS:DNLI), Kezar Life Sciences, Inc. (NasdaqGS:KZR), Forty Seven, Inc. (NasdaqGS:FTSV), IDEAYA Biosciences, Inc. (NasdaqGS:IDYA), Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO), InflaRx N.V. (NasdaqGS:IFRX), Inovalon Holdings, Inc. (NasdaqGS:INOV), Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST), Clovis Oncology, Inc. (NasdaqGS:CLVS), BioNTech SE (NasdaqGS:BNTX), Otonomy, Inc. (NasdaqGS:OTIC), NovoCure Limited (NasdaqGS:NVCR), Apellis Pharmaceuticals, Inc. (NasdaqGS:APLS), Assembly Biosciences, Inc. (NasdaqGS:ASMB), Adaptive Biotechnologies Corporation (NasdaqGS:ADPT), Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP), TherapeuticsMD, Inc. (NasdaqGS:TXMD), Progyny, Inc. (NasdaqGS:PGNY), Kala Pharmaceuticals, Inc. (NasdaqGS:KALA), Moderna, Inc. (NasdaqGS:MRNA), Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE), Karyopharm Therapeutics Inc. (NasdaqGS:KPTI), G1 Therapeutics, Inc. (NasdaqGS:GTHX), iRhythm Technologies, Inc. (NasdaqGS:IRTC), Ascendis Pharma A/S (NasdaqGS:ASND), IVERIC bio, Inc. (NasdaqGS:ISEE), Conformis, Inc. (NasdaqGS:CFMS), Intrexon Corporation (NasdaqGS:XON), Acadia Healthcare Company, Inc. (NasdaqGS:ACHC), R1 RCM Inc. (NasdaqGS:RCM), Natera, Inc. (NasdaqGS:NTRA), China Biologic Products Holdings, Inc. (NasdaqGS:CBPO), AnaptysBio, Inc. (NasdaqGS:ANAB), HealthEquity, Inc. (NasdaqGS:HQY), Pacific Biosciences of California, Inc. (NasdaqGS:PACB), Intra-Cellular Therapies, Inc. (NasdaqGS:ITCI), Halozyme Therapeutics, Inc. (NasdaqGS:HALO), Inogen, Inc. (NasdaqGS:INGN), Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH), Race Oncology Limited (ASX:RAC), Mesoblast Limited (ASX:MSB), Immutep Limited (ASX:IMM), Benitec Biopharma Limited (ASX:BLT), CSL Limited (ASX:CSL), Biocartis Group NV (ENXTBR:BCART), UCB SA (ENXTBR:UCB), Qualicorp Consultoria e Corretora de Seguros S.A. (BOVESPA:QUAL3), Instituto Hermes Pardini S.A. (BOVESPA:PARD3), Fleury S.A. (BOVESPA:FLRY3), Ouro Fino Saúde Animal Participações S.A. (BOVESPA:OFSA3), Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079), Raia Drogasil S.A. (BOVESPA:RADL3), Medivir AB (publ) (OM:MVIR B), Swedish Orphan Biovitrum AB (publ) (OM:SOBI), Hanmi Pharm. Co., Ltd. (KOSE:A128940), Samsung Biologics Co.,Ltd. (KOSE:A207940), Celltrion, Inc. (KOSE:A068270), LG Chem, Ltd. (KOSE:A051910), Isofol Medical AB (publ) (OM:ISOFOL), Moberg Pharma AB (publ) (OM:MOB), Molecular Partners AG (SWX:MOLN), Kiadis Pharma N.V. (ENXTAM:KDS), Koninklijke Philips N.V. (ENXTAM:PHIA), Curetis N.V. (ENXTAM:CURE), Daiichi Sankyo Company, Limited (TSE:4568), Otsuka Holdings Co., Ltd. (TSE:4578), SanBio Company Limited (TSE:4592), Healios K.K. (TSE:4593), IHH Healthcare Berhad (KLSE:IHH), Abcam plc (AIM:ABC), TransEnterix, Inc. (AMEX:TRXC), Hikma Pharmaceuticals PLC (LSE:HIK), NMC Health Plc (LSE:NMC), Indivior PLC (LSE:INDV), Basilea Pharmaceutica AG (SWX:BSLN), Tecan Group Ltd. (SWX:TECN), Vifor Pharma AG (SWX:VIFN), Roche Holding AG (SWX:ROG), Lonza Group Ltd (SWX:LONN), Novartis AG (SWX:NOVN), UDG Healthcare plc (LSE:UDG), Mediclinic International plc (LSE:MDC), Vectura Group plc (LSE:VEC), GlaxoSmithKline plc (LSE:GSK), Innate Pharma S.A. (ENXTPA:IPH), Sanofi (ENXTPA:SAN), Transgene SA (ENXTPA:TNG), Cellectis S.A. (ENXTPA:ALCLS), DBV Technologies S.A. (ENXTPA:DBV), Onxeo SA (ENXTPA:ONXEO), Ipsen S.A. (ENXTPA:IPN), ERYTECH Pharma S.A. (ENXTPA:ERYP), Valbiotis SA (ENXTPA:ALVAL), GN Store Nord A/S (CPSE:GN), Ambu A/S (CPSE:AMBU B), Genmab A/S (CPSE:GMAB), H. Lundbeck A/S (CPSE:LUN), Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294), DiaSorin S.p.A. (BIT:DIA), Konica Minolta, Inc. (TSE:4902), Takeda Pharmaceutical Company Limited (TSE:4502), Astellas Pharma Inc. (TSE:4503), NanoCarrier Co., Ltd. (TSE:4571), Sosei Group Corporation (TSE:4565), Santen Pharmaceutical Co., Ltd. (TSE:4536), Lupin Limited (BSE:500257), Sino Biopharmaceutical Limited (SEHK:1177), Dr. Reddy's Laboratories Limited (BSE:500124), 3SBio Inc. (SEHK:1530), Lee's Pharmaceutical Holdings Limited (SEHK:950), Innovent Biologics, Inc. (SEHK:1801), Hua Medicine (Shanghai) Ltd. (SEHK:2552), VR Adviser, LLC, Abaxis, Inc., Array BioPharma Inc., The Medicines Company, Agiliti Health, Inc., Temasek Holdings (Private) Limited, athenahealth, Inc., BTG Limited, Intas Pharmaceuticals Limited, Ascension Health, Inc., CommonSpirit Health, Dignity Health, Analogic Corporation, Celgene Corporation, Express Scripts Holding Company, Legacy LifePoint Health, Inc., Apricus Biosciences, Inc., Impax Laboratories, Inc., Shire plc, Keryx Biopharmaceuticals, Inc., The MicroBio Group Limited, Aetna Inc., Ortho-Clinical Diagnostics, Inc., Advocate Health Care, Inc., PHC Corporation, AdventHealth, Blue Cross and Blue Shield of Florida, Inc., Baylor Scott & White Health LLC, Cable News Network, Inc., Medidata Solutions, Inc., Cogentix Medical, Inc., InTouch Technologies, Inc., Genomic Health, Inc., Prospect Medical Holdings, Inc., Ablynx NV, Johns Hopkins University, Partners HealthCare System, Inc., Bill & Melinda Gates Foundation, Henry Ford Health System, Intermountain Healthcare, Inc., Northwell Health, Inc., Steward Health Care System, LLC, Parkview Health System, Inc., WakeMed Health & Hospitals, Inc., Aurora Health Care, Inc., FOX News Network, LLC, Phoenix Children's Hospital, Inc., Pharmaceutical Research and Manufacturers of America, Northwestern Memorial Healthcare Corporation, Cincinnati Children's Hospital Medical Center, Boehringer Ingelheim GmbH, American Specialty Health Incorporated, LTS Lohmann Therapie-Systeme AG, ABILITY Network Inc., Straith Hospital For Special Surgery Inc, Indiana University School of Medicine, Capitol Street Corporation, Centers for Medicare & Medicaid Services, Fresenius Medical Care Groupe France SAS, Stanford University School of Medicine, U.S. Food and Drug Administration, GenScript Corporation, Selexis SA, TxCell S.A., MedDay SA, CureVac AG, Alder BioPharmaceuticals, Inc., Prolong Pharmaceuticals, LLC, Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, Orchid Orthopedic Solutions LLC, EUSA Pharma, Inc., Envigo International Holdings, Inc., PatientsLikeMe, Inc., 23andMe, Inc., Amplyx Pharmaceuticals, Inc., Grupo Farmaceutico Biotoscana S.A., Inspire Medical, Inc., Vascular Therapies, Inc., Femasys Inc., RCCH HealthCare Partners, Augmenix, Inc., DNAnexus, Inc., TraceLink, Inc., Ascentage Pharma Group Corporation, Ltd., Mitra Biotech Pvt Ltd, Foundation Medicine, Inc., HeartFlow, Inc., Sharecare Inc., Arrail Dental International Group Co. Ltd., Prognos Health Inc., Welltok, Inc., Nuvaira, Inc., Springstone, Inc., Genalyte, Inc., Direct Vet Marketing, Inc., Ascletis, Inc., One Medical Group, Inc., Fountain Biopharma Inc., SK Biopharmaceuticals Co., Ltd., Columbia Pacific Healthcare Sdn Bhd, Geisinger Health System, OvaScience, Inc., Ignyta, Inc., Hookipa Biotech AG, NantWorks, LLC, Abide Therapeutics Inc., H3 Biomedicine Inc., Cartiva, Inc., HealthLoop, Inc., GoodRx, Inc., NuMedii, Inc., Practo Technologies Private Limited, NeuClone Pty. Limited, Audentes Therapeutics, Inc., Oscar Insurance Corporation, MedAvail Technologies Inc., Spark Therapeutics, Inc., Juno Therapeutics, Inc., Centrexion Therapeutics Corporation, Agilis Biotherapeutics, LLC, Clementia Pharmaceuticals Inc., Guang Dong No.1 Pharmacy Chains Co. Ltd., K2M Group Holdings, Inc., Maravai Life Sciences Inc., Pear Therapeutics, Inc., Notre Dame Intermédica Saúde S.A., University Wisconsin Health, Centogene AG, Big3Bio, WuXi Nextcode Genomics, Inc., Outset Medical, Inc., Caris Life Sciences, Inc., Carbon, Inc., China Pharmaceutical Innovation and Research Development Association, Ping An Health Cloud Company Limited, Codiak BioSciences, Inc., Verily Life Sciences LLC, NeuroRx, Inc., Mercy Health, Smart Labs, LLC, iCarbonx, IBM Watson Health, Inc., Luye Medical Group Co., Ltd, Cotiviti Holdings, Inc., Virtual Frameworks, Inc., Bioventus LLC, CStone Pharmaceuticals (Suzhou) Co., Ltd., Bioverativ Inc., Dova Pharmaceuticals, Inc., Kiniksa Pharmaceuticals Corp., BenevolentAI Limited, PepVax, Inc, General Catalyst LLC, MOBE LLC, Froedtert & the Medical College of Wisconsin, Three Lakes Partners, Ginkgo, SpringWorks Therapeutics, LLC, Prestige Bio Pharmaceuticals Co. Ltd., Pneuma Respiratory, Inc., BGI Group Limited, Grace Therapeutics, LLC, Glenmark Pharmaceuticals Limited (NSEI:GLENMARK), Aurobindo Pharma Limited (NSEI:AUROPHARMA), Wockhardt Limited (NSEI:WOCKPHARMA), Cipla Limited (NSEI:CIPLA), Melinta Therapeutics, Inc. (OTCPK:MLNT.Q), Medizone International, Inc. (OTCPK:MZEI.Q), Achaogen, Inc. (OTCPK:AKAO.Q), GeoVax Labs, Inc. (OTCPK:GOVX), MiMedx Group, Inc. (OTCPK:MDXG), INSYS Therapeutics, Inc. (OTCPK:INSY.Q), Propanc Biopharma, Inc. (OTCPK:PPCB), Sienna Biopharmaceuticals, Inc. (OTCPK:SNNA.Q), MorphoSys AG (XTRA:MOR), Medigene AG (XTRA:MDG1), Bayer Aktiengesellschaft (XTRA:BAYN), MERCK Kommanditgesellschaft auf Aktien (XTRA:MRK), Evotec SE (XTRA:EVT), Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Seegene, Inc. (KOSDAQ:A096530), Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Diplomat Pharmacy, Inc. (NYSE:DPLO), Veeva Systems Inc. (NYSE:VEEV), Nevro Corp. (NYSE:NVRO), Penumbra, Inc. (NYSE:PEN), Select Medical Holdings Corporation (NYSE:SEM), Teladoc Health, Inc. (NYSE:TDOC), WellCare Health Plans, Inc. (NYSE:WCG), Emergent BioSolutions Inc. (NYSE:EBS), Catalent, Inc. (NYSE:CTLT), AbbVie Inc. (NYSE:ABBV), Castlight Health, Inc. (NYSE:CSLT), Avanos Medical, Inc. (NYSE:AVNS), Evolent Health, Inc. (NYSE:EVH), Zoetis Inc. (NYSE:ZTS), Invitae Corporation (NYSE:NVTA), Myovant Sciences Ltd. (NYSE:MYOV), Mallinckrodt plc (NYSE:MNK), Esperion Therapeutics, Inc. (NasdaqGM:ESPR), Supernus Pharmaceuticals, Inc. (NasdaqGM:SUPN), Amarin Corporation plc (NasdaqGM:AMRN), Immunomedics, Inc. (NasdaqGM:IMMU), Eagle Pharmaceuticals, Inc. (NasdaqGM:EGRX), Chimerix, Inc. (NasdaqGM:CMRX), AtriCure, Inc. (NasdaqGM:ATRC), Merrimack Pharmaceuticals, Inc. (NasdaqGM:MACK), GenMark Diagnostics, Inc. (NasdaqGM:GNMK), Magenta Therapeutics, Inc. (NasdaqGM:MGTA), Quotient Limited (NasdaqGM:QTNT), Zai Lab Limited (NasdaqGM:ZLAB), Verrica Pharmaceuticals Inc. (NasdaqGM:VRCA), Coherus BioSciences, Inc. (NasdaqGM:CHRS), UroGen Pharma Ltd. (NasdaqGM:URGN), Quanterix Corporation (NasdaqGM:QTRX), Ardelyx, Inc. (NasdaqGM:ARDX), Retrophin, Inc. (NasdaqGM:RTRX), Clearside Biomedical, Inc. (NasdaqGM:CLSD), Sage Therapeutics, Inc. (NasdaqGM:SAGE), Axcella Health Inc. (NasdaqGM:AXLA), NanoString Technologies, Inc. (NasdaqGM:NSTG), Radius Health, Inc. (NasdaqGM:RDUS), Lantheus Holdings, Inc. (NasdaqGM:LNTH), Acceleron Pharma Inc. (NasdaqGM:XLRN), Oxford Immunotec Global PLC (NasdaqGM:OXFD), NewLink Genetics Corporation (NasdaqGM:NLNK), Amicus Therapeutics, Inc. (NasdaqGM:FOLD), Merus N.V. (NasdaqGM:MRUS), Intersect ENT, Inc. (NasdaqGM:XENT), Glaukos Corporation (NYSE:GKOS), Vocera Communications, Inc. (NYSE:VCRA), Molina Healthcare, Inc. (NYSE:MOH), Genesis Healthcare, Inc. (NYSE:GEN), Invacare Corporation (NYSE:IVC), Eli Lilly and Company (NYSE:LLY), McKesson Corporation (NYSE:MCK), Merck & Co., Inc. (NYSE:MRK), 3M Company (NYSE:MMM), Owens & Minor, Inc. (NYSE:OMI), Teleflex Incorporated (NYSE:TFX), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Varian Medical Systems, Inc. (NYSE:VAR), West Pharmaceutical Services, Inc. (NYSE:WST), Perrigo Company plc (NYSE:PRGO), Bausch Health Companies Inc. (NYSE:BHC), Edwards Lifesciences Corporation (NYSE:EW), Boston Scientific Corporation (NYSE:BSX), ResMed Inc. (NYSE:RMD), Quest Diagnostics Incorporated (NYSE:DGX), Alexandria Real Estate Equities, Inc. (NYSE:ARE), JPMorgan Chase & Co. (NYSE:JPM), JPMorgan Chase & Co. (NYSE:JPM), Laboratory Corporation of America Holdings (NYSE:LH), Mettler-Toledo International Inc. (NYSE:MTD), AmerisourceBergen Corporation (NYSE:ABC), Bristol-Myers Squibb Company (NYSE:BMY), Centene Corporation (NYSE:CNC), Community Health Systems, Inc. (NYSE:CYH), Encompass Health Corporation (NYSE:EHC), Humana Inc. (NYSE:HUM), Hill-Rom Holdings, Inc. (NYSE:HRC), Rite Aid Corporation (NYSE:RAD), Haemonetics Corporation (NYSE:HAE), Stryker Corporation (NYSE:SYK), Thermo Fisher Scientific Inc. (NYSE:TMO), International Business Machines Corporation (NYSE:IBM), Tenet Healthcare Corporation (NYSE:THC), Charles River Laboratories International, Inc. (NYSE:CRL), Becton, Dickinson and Company (NYSE:BDX), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), DaVita Inc. (NYSE:DVA), STERIS plc (NYSE:STE), Universal Health Services, Inc. (NYSE:UHS), Medtronic plc (NYSE:MDT), QIAGEN N.V. (NYSE:QGEN), Welltower Inc. (NYSE:WELL), Danaher Corporation (NYSE:DHR), PerkinElmer, Inc. (NYSE:PKI), The Cooper Companies, Inc. (NYSE:COO), Zimmer Biomet Holdings, Inc. (NYSE:ZBH), Agilent Technologies, Inc. (NYSE:A), Abbott Laboratories (NYSE:ABT), Baxter International Inc. (NYSE:BAX), Bio-Rad Laboratories, Inc. (NYSE:BIO), Cantel Medical Corp. (NYSE:CMD), Johnson & Johnson (NYSE:JNJ), Model N, Inc. (NYSE:MODN), Pfizer Inc. (NYSE:PFE), Cardinal Health, Inc. (NYSE:CAH), Cigna Corporation (NYSE:CI), General Electric Company (NYSE:GE), Idera Pharmaceuticals, Inc. (NasdaqCM:IDRA), Heron Therapeutics, Inc. (NasdaqCM:HRTX), Exact Sciences Corporation (NasdaqCM:EXAS), La Jolla Pharmaceutical Company (NasdaqCM:LJPC), Plus Therapeutics, Inc. (NasdaqCM:PSTV), Tyme Technologies, Inc. (NasdaqCM:TYME), Millendo Therapeutics, Inc. (NasdaqCM:MLND), TG Therapeutics, Inc. (NasdaqCM:TGTX), DelMar Pharmaceuticals, Inc. (NasdaqCM:DMPI), aTyr Pharma, Inc. (NasdaqCM:LIFE), ZIOPHARM Oncology, Inc. (NasdaqCM:ZIOP), Stemline Therapeutics, Inc. (NasdaqCM:STML), Accelerate Diagnostics, Inc. (NasdaqCM:AXDX), Dynavax Technologies Corporation (NasdaqCM:DVAX), AVEO Pharmaceuticals, Inc. (NasdaqCM:AVEO), VistaGen Therapeutics, Inc. (NasdaqCM:VTGN), Microbio Co., Ltd. (GTSM:4128), OBI Pharma, Inc. (GTSM:4174), Oneness Biotech Co., Ltd. (GTSM:4743), Taiwan Liposome Company, Ltd. (GTSM:4152), JHL Biotech, Inc. (GTSM:6540), ASLAN Pharmaceuticals Limited (GTSM:6497)JPMorgan Chase & Co., 36th Annual J.P. Morgan Healthcare Conference, Jan 08, 2018 through Jan 11, 2018. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States.
99
12/31/201712.94x34.71x37.84x63.92x51.24x$43,098$383.7855.89%Dec-07-2017Company Conference PresentationIntuitive Surgical, Inc. Presents at Citi Global Healthcare Conference, Dec-07-2017 10:15 AM-Intuitive Surgical, Inc. Presents at Citi Global Healthcare Conference, Dec-07-2017 10:15 AM. Venue: Lotte New York Palace, New York, New York, United States. Speakers: Calvin Darling, Senior Director, IR, Marshall L. Mohr, Senior VP & CFO.
100
12/31/201712.94x34.71x37.84x63.92x51.24x$42,566$379.0457.84%Dec-6-2017Company Conference PresentationIntuitive Surgical, Inc. Presents at Embedded Systems Conference & Expo 2017, Dec-06-2017 03:00 PM-Intuitive Surgical, Inc. Presents at Embedded Systems Conference & Expo 2017, Dec-06-2017 03:00 PM. Venue: San Jose Convention Center, San Jose, California, United States. Speakers: Jonathan Sorger.
101
12/31/201712.94x34.71x37.84x63.92x51.24x$42,566$379.0457.84%Dec-06-2017ConferenceCitigroup Inc., Citi Global Healthcare Conference, Dec 06, 2017 through Dec 07, 2017Aclaris Therapeutics, Inc. (NasdaqGS:ACRS), Atara Biotherapeutics, Inc. (NasdaqGS:ATRA), Allscripts Healthcare Solutions, Inc. (NasdaqGS:MDRX), Alexion Pharmaceuticals, Inc. (NasdaqGS:ALXN), MacroGenics, Inc. (NasdaqGS:MGNX), Illumina, Inc. (NasdaqGS:ILMN), Inovio Pharmaceuticals, Inc. (NasdaqGS:INO), Bavarian Nordic A/S (CPSE:BAVA), Zealand Pharma A/S (CPSE:ZEAL), Genmab A/S (CPSE:GMAB), Novo Nordisk A/S (CPSE:NOVO B), Innate Pharma S.A. (ENXTPA:IPH), DBV Technologies S.A. (ENXTPA:DBV), Roche Holding AG (SWX:ROG), Novartis AG (SWX:NOVN), Legacy LifePoint Health, Inc., Tesaro, Inc., Cotiviti Holdings, Inc., Fresenius Medical Care AG & Co. KGaA (XTRA:FME), Humana Inc. (NYSE:HUM), Bristol-Myers Squibb Company (NYSE:BMY), Community Health Systems, Inc. (NYSE:CYH), Medtronic plc (NYSE:MDT), Mettler-Toledo International Inc. (NYSE:MTD), Universal Health Services, Inc. (NYSE:UHS), Waters Corporation (NYSE:WAT), Allergan plc (NYSE:AGN), Johnson & Johnson (NYSE:JNJ), MEDNAX, Inc. (NYSE:MD), HCA Healthcare, Inc. (NYSE:HCA), PerkinElmer, Inc. (NYSE:PKI), Merck & Co., Inc. (NYSE:MRK), Varian Medical Systems, Inc. (NYSE:VAR), Boston Scientific Corporation (NYSE:BSX), Citigroup Inc. (NYSE:C), CRISPR Therapeutics AG (NasdaqGM:CRSP), OBI Pharma, Inc. (GTSM:4174), PharmaEssentia Corporation (GTSM:6446)Citigroup Inc., Citi Global Healthcare Conference, Dec 06, 2017 through Dec 07, 2017. Venue: Lotte New York Palace, New York, New York, United States.
Loading...